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ABSTRACT 
Programmed cell death (PCD), an active process that leads to cell suicide, is a 
critical mechanism in eukaryotes and prokaryotes. In eukaryotes, apoptosis, a well-
characterized form of PCD, is a gene-directed program that can be inhibited by some 
oncogenic mutations, resulting in the development of cancer. Toxin-antitoxin (TA) is one 
example of an intracellular death program that is present in almost all bacteria and 
comprises a stable toxin and a labile antitoxin that blocks the lethal function of the toxin. 
MazEF, one of the best studied bacterial PCD systems, includes a toxin, namely, MazF that 
cleaves mRNAs at ACA sequences leading to the inhibition of protein synthesis. Although 
the exact mechanism remains unknown, it seems the MazF-mediated apoptosis depends on 
the presence of BAK, a pro-apoptotic protein in mammalian cells. Since cancer is a 
heterogeneous group of diseases with various sensitivities to different treatments, we 
examined the impact of MazF proteins on the growth and viability of three cancer cell 
lines: MCF7, HT29, and AGS. These cells lines were transfected with ACA-less mazF 
mRNAs, and the cells were evaluated for development of MazF-mediated cell death. Our 
data illustrated that expression of MazF proteins in the aforementioned cells leads to 
significant reductions in cell viability. In order to confirm the occurrence of apoptosis, the 
activation of caspase-3 and -7 and the presence of caspase-3’s substrate were evaluated in 
transfected cells. Our observations suggested that in the presence of MazF, the levels of 
activated caspase-3 and -7 were significantly elevated in transfected cells. In addition, the 
inhibition of protein synthesis by MazF in MCF7 and AGS cell lines were examined via 
quantifying mRNA translation on a single-cell basis. Our data confirmed that the 
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expression of MazF causes a significant drop in the levels of protein translation in the 
examined cell lines. Recently, it has been reported that the DNA delivery system does not 
seem to be a suitable approach to transfer mazF in tumors due to the lack of continuous 
expression of MazF, degradation, and the incidence of mutations in mazF gene. To address 
these challenges, we developed an mRNA delivery system to transfer ACA-less mazF 
mRNA exclusively into cancer cells. To examine the expression and stability of mazF 
mRNA in cells, we synthesized mazF and GFP mRNA for IRES- or cap- dependent 
translation. Our results suggest that cap/IRES-dependency, poly-A tails, and 
modified/unmodified nucleotides played important roles in efficient expression of MazF 
proteins in transfected cell lines but is dependent on the cell line. 
MazF is a nonspecific ribonuclease that can induce death in both normal and cancer 
cells. Thus, the application of MazF is dependent on efficient expression and delivery 
system to transfer MazF into tumors. We developed a listerial bi-vector expression and 
delivery system to transfer mazF mRNA into specific HER2-positive SKBR3 human breast 
cancer cells. Our results showed that following the infection of cells by functionalized 
bacterial vectors, caspase activities elevated in SKBR3 cells 48 hours post-transfection. In 
this research, this expression and delivery system for the delivery of mazF mRNA as a 
potential therapeutic mRNA in cancer cells was reported for the first time. 
 
 iv 
DEDICATION 
 
 
I dedicate this work to my beloved Parents, my adorable Sister and my wonderful 
Brother-in-Law for their endless supports, scarifies and encouragement. 
 v 
ACKNOWLEDGMENTS 
First and most, I would like to express my deepest gratitude to Dr. Tzuen-Rong 
Tzeng for giving me an opportunity in pursuing PhD and allowing me to work on this 
project. This dissertation would not have been completed without his superb guidance, 
wisdom, persistent support, involvement, motivation and patience. Under his supervision, 
I successfully overcame many obstacles and acquired a lot of knowledge. His unflinching 
courage, optimism, and enthusiasm has always inspired me to become a better person. I 
am sincerely grateful to him and will be truly indebted to him throughout my lifetime.  
I am extremely thankful to my committee members, Dr. Min Cao for her valuable 
feedbacks, Dr. Wen Chen for his constructive suggestions and Dr. Yanzhang Wei for his 
constant help and insightful advice throughout my research. 
I would like to acknowledge Dr. Zhicheng Dou for providing me with the requisite 
materials in this project.  
I would like to extend my appreciation to all the administrative staff of the 
Department of Biological Sciences for all their services. 
My sincere thanks to Dr. Guohui Huang for training me in cell culturing, instructing 
me to design experiments and providing me with cells throughout this project.  
I would like to express my gratitude to John Abercrombie for his patience, constant 
help and his resourcefulness throughout this project and my teaching assignments.  
 vi 
Big thanks to Aaron Brown for being an extraordinary resource for molecular 
techniques during my PhD. 
I am grateful to all the past and current lab mates and IGEM members for their 
support and help throughout this endeavor. 
I would like to extend my gratitude to Mr. Alen Izadpanah for his encouragement 
and supports during my PhD. 
I am extremely grateful to my exceptional friends, Mrs. Shahnaz Taghavi, Dr. 
Pallavi Vedantam, Dr. Yash Raval, Dr. Maryam Hamidpour, Dr. Sepideh Yazdekhasti, Dr. 
Zahra Ronaghi, Dr. Parishad Rahbari, Dr. Sukhpreet Kaur, Dr. Ojas Natarajan, Amy 
Bergmann, Hui Ding and Harrison Taylor who have always inspired me throughout this 
endeavor.  
   
 vii 
TABLE OF CONTENTS 
ABSTRACT .................................................................................................................................................... ii 
DEDICATION............................................................................................................................................... iv 
ACKNOWLEDGMENTS ............................................................................................................................. v 
LIST OF TABLES ......................................................................................................................................... x 
LIST OF FIGURES ...................................................................................................................................... xi 
CHAPTER ONE ............................................................................................................................................ 1 
1. Literature Review ...................................................................................................................................... 1 
Hallmark Traits of Cancer and Their Roles in Tumor Growth and Metastasis ..................... 1 
Apoptosis: Events and Pathways in Normal Cells ...................................................................... 6 
Apoptosis Inhibitors in Tumors ................................................................................................. 10 
Programmed Cell Death in Bacteria .......................................................................................... 11 
MazEF: Type II Toxin-Antitoxin ............................................................................................. 13 
The Application of MazF in Biotechnology ............................................................................... 14 
Bacterial Delivery Systems.......................................................................................................... 16 
Bacteria and Tumor Microenvironments .................................................................................. 17 
Bacterial Cancer Therapies ........................................................................................................ 18 
Bactofection and Alternative Gene Therapy ............................................................................. 21 
Listeria monocytogenes: A Versatile Vector in Gene Therapy ............................................... 23 
Objective ....................................................................................................................................... 25 
CHAPTER TWO ......................................................................................................................................... 27 
2. Overexpression of ACA-less mazF in Escherichia coli Cells ................................................................ 27 
Introduction.................................................................................................................................. 27 
Experimental Section................................................................................................................... 30 
General Molecular Techniques ................................................................................................ 30 
Construction of ACA-less mazF in E. coli Cells...................................................................... 31 
Overexpression of MazF Proteins in E. coli Cells ................................................................... 34 
Results ........................................................................................................................................... 34 
Discussion ..................................................................................................................................... 39 
CHAPTER THREE ..................................................................................................................................... 40 
3. MazF: A Potential Apoptotic Inducer in Various Cancer Lines ......................................................... 40 
Introduction.................................................................................................................................. 40 
Cancer and Ribonucleases ........................................................................................................ 40 
 viii 
Table of Contents (Continued) 
 
mRNA-Based Therapies........................................................................................................... 42 
Experimental Section................................................................................................................... 54 
General Molecular Techniques: ............................................................................................... 54 
Plasmid Construction ............................................................................................................... 55 
In Vitro mRNA Synthesis......................................................................................................... 56 
Cell Culture .............................................................................................................................. 58 
Transfection .............................................................................................................................. 58 
Cell Viability Assay ................................................................................................................. 59 
Cell Proliferation Assay ........................................................................................................... 59 
Immunofluorescent Microscopy............................................................................................... 59 
Caspase Activity Assay ............................................................................................................ 60 
Western Blot Analysis .............................................................................................................. 60 
Nascent Protein Synthesis Assay ............................................................................................. 61 
Statistical Analysis ................................................................................................................... 61 
Results ........................................................................................................................................... 62 
mazF mRNA Structure ............................................................................................................. 62 
MazF-Mediated Death in Cancer Cells .................................................................................... 71 
MazF-Mediated Apoptosis in Cancer Cells ............................................................................. 79 
MazF-Mediated Inhibition of Protein Synthesis in Cancer Cells............................................. 84 
Discussion ..................................................................................................................................... 87 
CHAPTER FOUR ........................................................................................................................................ 93 
4. Listeria monocytogenes-Mediated Delivery of mazF mRNA into Cancer Cells ................................. 93 
Introduction.................................................................................................................................. 93 
Gene Delivery and Vectors ...................................................................................................... 93 
Experimental Section................................................................................................................. 101 
General Microbiology Technique .......................................................................................... 101 
Construction of a T7 Expression System for mazF mRNA ................................................... 102 
Functionalization of Bacterial Cells with Anti-HER Antibodies ........................................... 106 
Eukaryotic Cell Culture .......................................................................................................... 107 
Immunofluorescence Staining ................................................................................................ 107 
Delivery of mazF mRNAs into HER-Positive Cells by Lm Cells ......................................... 108 
Results ......................................................................................................................................... 110 
Construction of a T7 Transcription System for mazF mRNA in L. monocytogenes ............. 110 
Interaction of Protein A with Anti-HER Antibodies for Bacterial Coating ........................... 114 
Immunolabeling of SKBR3 Cells with Anti-HER Antibodies .............................................. 115 
Internalization of Anti-HER Functionalized Lm Cells into Eukaryotic Cells in Vitro .......... 116 
Internalization of functionalized Lm into SKBR3 and 4T1 Cell Lines ................................. 119 
Toxicity of the Bacterial Vectors in SKBR3 Cells................................................................. 122 
Bacterial-Mediated Delivery of mazF mRNA into SKBR3 ................................................... 123 
Discussion ................................................................................................................................... 128 
5. Conclusion .............................................................................................................................................. 135 
6. References ............................................................................................................................................... 141 
 ix 
Table of Contents (Continued) 
 
Appendix...................................................................................................................................... 155 
Rights and Permissions .......................................................................................................... 155 
 
 x 
LIST OF TABLES 
 
 
Table                                                                                                                        Page 
 
2.1.   Designed primers for construction of pGEM-Z ......................................................32 
3.1.   List of primers for construction of pcDNA3.3-mazF and pcDNA3.1 (+) IRES-
mazF and preparation of templates for in vitro transcription purposes ...................57 
3.2.   The in vitro transcription reaction ...........................................................................58 
4.1.   List of primers for insertion of mazF fragment in pCNB1 ....................................103 
4.2.   Q5® High-Fidelity DNA Polymerase PCR reaction assembly .............................103 
4.3.   Q5® High-Fidelity DNA Polymerase PCR protocol ............................................103 
4.4.   HIFI DNA assembly instruction ............................................................................103 
4.5.   List of primers for insertion of Kan fragments in pCNB1-mazF ..........................104 
 
 xi 
LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
1.1.   Motile bacteria can travel throughout tumors. ........................................................19 
1.2.   Bacteria: Smart vectors to identify tumors ..............................................................20 
1.3.   Bactofection process. ...............................................................................................22 
2.1.   pBAD vector map ....................................................................................................33 
2.2.   pBAD-mazF map ....................................................................................................35 
2.3.   The effect of overproduction of MazF on E. coli LMG 194 ...................................37 
2.4.   The percentage of bacterial survivors after mazF induction. ..................................38 
2.1.   a-e.DNA temples used for in vitro transcription purposes. .....................................68 
3.2.   The impact of mRNA structural elements on MazF translation..............................70 
3.3.   a-f. The expression of GFP mRNA in cancer cells 24 hours post-transfection ......73 
3.4.   a-f. The morphological changes in cancer cells after transfection of cells with 
mazF mRNA ............................................................................................................75 
3.5.   a-c. The expression of MazF results in significant reduction of cell viability in 
transfected cells .......................................................................................................78 
3.6.   a-d. The activation of caspase-3 and -7 in cancer cell lines ....................................80 
3.7.   a-c. The induction of MazF results in the activation of caspase in                          
(a) MC7 (b) AGS and (c) HT29 ..............................................................................83 
3.8.   The presence of cleaved-PARP in transformed cell lysates ....................................84 
3.9.   a-b. MazF blocked protein translation in (a) MCF7 and (b) AGS. .........................86 
3.10.  MazF is able to cleave mRNA at ACA sequences .................................................87 
 xii 
List of Figures (Continued)  
4.1.   pCSA1 map ...........................................................................................................111 
4.2.   pCNB-mz-kn .........................................................................................................113 
4.3.   The functionalized Lm-spa+ and Lm-spa- with human ErbB2/Her2 ....................115 
4.4.   Immunofluorescence staining of SKBR3 cells with an anti-HER antibody .........116 
4.5.   Infection of SKBR3 cells with various concentrations of functionalized         
bacteria. .................................................................................................................119 
4.6.   The infection of SKBR3 with Lm cells coated with Human ErbB2/Her2. ...........121 
4.7.   The infection of HER-positive and -negative cell lines with Lm-spa+ .................122 
4.8.   The influence of coated bacteria on cell viability .................................................123 
4.9.   The induction of death in SKBR3 cells by mazF mRNA .....................................124 
4.10.  The impact of delivered mazF on SKBR3 and T4 cells .......................................126 
4.11.   Detection of caspase-3 and -7 activity in infected cells with Lm-spa+                   
and Lm-spa- ...........................................................................................................128 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
CHAPTER ONE 
1. Literature Review 
Hallmark Traits of Cancer and Their Roles in Tumor Growth and 
Metastasis 
Cancer, as the plague of the current centuries, arises from the abnormal 
proliferation of a group of cells that bypass the strict cell division rules. Unlike cancer cells, 
normal cells do not have an autonomy to divide, differentiate, or die, and their behaviors 
and destinies are dictated by molecular networks and signals. Once mutations or alterations 
occur in these stern networks, the balance between cell division and quiescence is 
interrupted, and cells are liable to develop a neoplastic state [1].  
Cancer is described as a multi-gene, multistep disease stemming from the domino 
effect of mutations in cell genomes, promoting the formation of a tumor mass [2]. 
Consecutively, a series of mutations causes tumor expansion and progression, and 
ultimately, tumors disrupt the surrounding tissues of the basal membrane barrier and 
metastasize to other tissues or organs [2]. 
Tumors are complex tissues and contain multiple distinct cells interacting with one 
another and with the tumor microenvironments. These cells share several cancerous 
biological traits, enabling them to develop tumorigenic and metastatic natures. The 
sustainment of proliferative signals, evasion of growth suppressors, resistance to cell death, 
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replicative immortality, induction of angiogenesis, activation of invasion and metastasis, 
energy metabolism, evasion of immune destruction, genome instability and mutation, and 
tumor-promoting inflammation are hallmarks of cancer [3].  
The architectures and functions of normal tissues are maintained through the 
molecular signaling networks that strictly control the production and availability of growth-
promoting signals, while cancer cells have biological capabilities to preserve mitogenic 
signaling, resulting in growth and progression of tumors. These capabilities include the 
overexpression of growth factor ligands displaying on the surfaces of cancer cells, 
stimulation of normal cells to provide various growth factors for cancer cells, and the 
induction of independency to growth factors [3].  
In addition to stimulating cell proliferation, cancer cells also have the ability to 
overcome negative regulation of cell proliferation circumstances. These abilities arise from 
the lost or nonfunctional suppressor genes in tumors. The two prototypical tumor 
suppressors encoding the RB (retinoblastoma-associated) and TP53 proteins mainly 
regulate the balance of cell proliferation or death in normal tissues. In cancer cells, the 
nonfunctional RB are unable to critically monitor the cell-cycle progression, which causes 
continued cell proliferation in tumors. The TP53 protein senses abnormal intracellular 
signals, such as excessive damage to the genome, efficiency of glucose, oxygenation, or 
nucleotide pools. Consequently, TP53 temporary blocks the cell-cycle progression during 
these abnormal conditions. In addition, this protein can recognize the overwhelming or 
irreparable damages to cellular systems and induce apoptosis in normal cells. However, 
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cancer cells with nonfunctional TP53 genes are unable to receive intercellular signals and 
suppress cell proliferation [3].  
Resistance to cell death is another hallmark of cancer cells. Apoptosis, as a form of 
programmed cell death, serves as the main barrier to uncontrolled cell proliferation in 
normal cells. The occurrence of apoptosis is regulated by counterbalancing pro- and anti-
apoptotic members of the Bcl-2 family. In cancer cells, this balance is disturbed, and 
proapoptotic proteins stimulate the hyperproliferation in tumors [4].  
Normal cell proliferation is limited and is governed by two distinct phases: 
senescence, the state of cells being non-proliferative but viable, and crisis, the cell death 
state. Subsequent to repeated cycles of division, cells enter a senescence phase during 
which the proliferation of live cells is halted, and then death is induced in the majority of 
cells. However, cancer cells develop an immortal nature in which cells escape either 
senescence or crisis and continuously proliferate. The immortality ability might stem from 
the telomeres protecting the ends of chromosomes in cells. In normal cells, telomerase, 
hexanucleotide repeats, protect the ends of the chromosomes to enhance the stability of 
chromosomal DNA but shorten progressively during cell divisions. Thus, cell division is 
tightly linked to the length of telomeric DNA, and once these telomeres are eliminated, the 
crisis phase is triggered. In contrast to normal cells, cancer cells overexpress telomerase, 
the specialized DNA polymerase adding telomere repeat segments to the ends of telomeric 
DNA, and stabilize their chromosomal DNA, leading to the development of resistance to 
both senescence and crisis/apoptosis [3]. 
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One of the important hallmarks of cancer tumors is their abilities to promote 
angiogenesis. Both normal tissues and tumors need to have access to nutrients and oxygen 
and clear their wastes and carbon dioxide. Angiogenesis is defined as the development and 
remodeling of new blood vessels to supply oxygen and nutrients and evacuate metabolic 
wastes from tissue environments. In normal tissues, normal vasculature is quiescent, but in 
adults, during physiological processes, angiogenesis can be transiently activated and 
induce formation of new vessels. However, this pathway continuously generates and 
remodels blood vessels in cancer cells [5]. In normal cells, vasculature contains organized 
and differentiated networks of arteries, arterioles, capillaries, venules, and veins. In tumors, 
vasculature systems are remodeled and consist of irregular, abnormal, and large blood 
vessels which cannot supply sufficient nutrients or oxygen for tumors. This system is also 
deficient in evacuating carbon dioxide and other metabolites, leading to the creation of an 
acidic tumor microenvironment. The vasculature systems also play an important role in the 
formation of metabolic insufficiency, ischemia, and necrotic zones in each tumor. 
Hyperpermeability, another trait of tumor vasculature systems, causes the occurrence of 
local edema and extravascular clotting of plasma in tumors and affects the gene expression 
patterns in fibroblasts and endothelial cells [2].  
In cancer cells, angiogenesis pathways are regulated by several signals, such as the 
secretion of growth factors and cytokines from tumors and the tumor microenvironment 
[2]. For example, vascular endothelial growth factor-A (VEGF-A) and thrombo-spondin-
1 (TSP-1) are cell surface receptors that regulate the stimulation and inhibition of 
neovascularization, respectively [3]. In cancer cells, various factors, such as activation of 
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oncogenes, loss of tumor suppressor genes, hormones, and other cytokines are involved in 
the overexpression of VEGF-A in tumor cells [2] . 
One of the most notable hallmarks of cancer tumors is their ability to invade and 
metastasize to other sites. The local spread of highly pathological epithelial cells is referred 
to as cancer invasion, while distant migration of cancer cells is called metastasis, which is 
the most common reason for mortality in cancer patients. Generally, it has been observed 
that cancer cells involved in invasion or metastasis processes lose E-cadherin cell-to-cell 
adhesion molecules which affect the attachment of cancer cells to other epithelial cells and 
to the extracellular matrix (ECM). Cancer cells usually downregulate the expression of E-
cadherin or possess a mutant and nonfunctional form of this protein. In addition to E-
cadherin, the gene expression of other adhesion molecules is also downregulated, but other 
molecules involved in cell migration, such as N-cadherin, are upregulated in cancer [3].  
Invasion and metastasis are known as the multistage processes and invasion 
abilities that some of the cells develop to attack the regional sites. These cells then invade 
nearby blood and lymphatic vessels and transfer to the parenchyma of distant tissues. The 
migrated cells colonize and establish small nodules (micrometastases) in the new sites. 
Eventually, the micrometastases expand and form macroscopic tumors. However, the exact 
mechanisms of invasion and metastasis remain to be discovered [6].  
The heterogenic nature of cancer has been the main barrier to fighting cancer. The 
hallmark traits of tumors led to the advent of hallmark-targeting cancer drugs in cancer 
therapy. These targeting therapeutics can block one or more capabilities of tumors at 
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molecular levels and hinder tumor proliferation and expansion. The target specificity and 
safety profiles of these drugs have been attractive enough to lead to the development of 
experimental and clinical trials in exploiting cancer hallmarks to destroy tumors. However, 
several challenges, such as the development of adaptive resistance through mutation, 
epigenetic reprogramming, remodeling of the stromal microenvironment, and the presence 
of parallel signaling pathways for each capability, have minimized the advantages of the 
treatments [3]. 
Apoptosis: Events and Pathways in Normal Cells   
Programmed cell death (PCD) is defined as the occurrence of cell death by an 
intracellular mechanism [7]. According to the Nomenclature Committee on Cell Death 
(NCCD), PCD can be categorized into different distinct modalities based on changes on 
cell morphology (apoptosis, necrosis, or autophagy), enzymological activities (activation 
or inactivation of nucleases or proteases, such as caspases, calpains, cathepsins, and 
transglutaminases), functional criteria (programmed or accidental, physiological or 
pathological), or immunological features (immunogenic or nonimmunogenic) [8]. 
The term apoptosis was coined by Kerr, Wyllie, and Currie in 1972 to describe the 
morphological events involved in a type of cell death [8]. Apoptosis is a tightly regulated, 
multistep programmed cell death that secure embryogenesis and tissue homeostasis and 
eliminate damaged or infected cells. Cells undergoing apoptosis develop several 
morphological and biological changes such as cell shrinkage, DNA fragmentation 
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(karyorrhexis), chromatin condensation, phosphatidylserine externalization, 
encompassment of the cell contents in small vesicles, and then the separation of vesicles 
from the adjacent or extracellular matrix. The formed vesicles will be eventually engulfed 
by other cells. Apoptotic cells share several biochemical alterations such as protein 
cleavage, protein cross-linking, DNA breakdown, mitochondrial-membrane 
permeabilization (MMP) and/or massive caspase activation [4].  
Apoptosis is a sophisticated process which occurs through two main pathways: the 
extrinsic (or death-receptor) pathway and the intrinsic (mitochondrial) pathway. In both 
pathways, a family of endoproteases, caspases, provide critical links in cell regulatory 
networks and cell death [9]. However, the two pathways are not synchronized. Caspases 
are a group of proteinases that degrade proteins at aspartic acid residues and promote the 
irreversible death in apoptotic cells. Based on their activities, these proteinases are 
classified into three groups: initiators (caspase 2, 8, 9, and 10), effectors or executioners 
(caspase 3, 6 and 7), and inflammatory caspases (caspase 1, 4, and 5). Also, there are other 
caspases present in cells that are active at certain conditions, such as caspase 11, which 
induces apoptosis during septic shock; caspase 12, which involved in endoplasmic-specific 
apoptosis and cytotoxicity by amyloid-β; caspase 13, which is a bovine gene; and caspase 
14, which participates in embryonic tissues [10].  
In the extrinsic pathway, the activated plasma-membrane receptors, as members of 
the tumor necrosis factor (TNF) receptor superfamily, transmit a death signal from the cell 
surface to the intracellular signaling pathways that lead to the activation of caspase 8 and 
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trigger the execution phase of apoptosis [9]. TNF receptors possess two domains, the 
cysteine-rich extracellular and the cytoplasmic (death domain, DD) domains, which are 
common among all the dead receptors. The cytoplasmic domains are responsible for 
delivering the external signals to intracellular signaling pathways and triggering apoptosis. 
The extrinsic pathways are generally activated through the interaction of ligands and 
receptors. FasL/FasR, TNF-α/TNFR1, Apo3L/DR3, Apo2L/DR4, and Apo2L/DR5 are 
well-known examples of ligand-receptor reactions involved in apoptosis. In this pathway, 
once ligands bind to their cognate receptors, cytoplasmic adapter proteins in cells bind to 
the cytoplasmic domains of receptors and activate caspase 8 inside cells [10].  
In comparison to the extrinsic pathway, the highly complex intrinsic (stress) 
pathway is involved in mitochondrial-initiated events, which comprise various sets of non-
receptor-mediated stimuli and intracellular signals [9]. In this pathway, the proapoptotic 
members of the Bcl2-family, BAX and BAK, influence the permeabilization of 
mitochondria by creating pores in the outer mitochondrial membrane (OMM) and release 
two groups of potentially lethal proteins. The first group contains cytochrome c, 
Smac/DIABLO, and the serine protease HtrA2/Omi. These proteins are involved in 
caspase-dependent pathways. The release of cytochrome c in the cytosol leads to the 
activation of the caspase adaptor Apaf-1 and procaspase-9, which together form a 
holoenzyme complex named the apoptosome. Caspase 9 possesses holoenzymes that 
activate caspase 3 and caspase 8 and eventually induces apoptosis in cells [11]. 
Smac/DIABLO and HtrA2/Omi have affinities to interact with IAP (inhibitors of apoptosis 
proteins) activity and stimulate apoptosis [12]. AIF, endonuclease G, and CAD are the 
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second group of proteins released from mitochondria. These proteins translocate to the 
nucleus and mediate DNA fragmentation, condensation of peripheral nuclear chromatin, 
and production of oligonucleosomal DNA fragments in the nucleus [13]. AIF and 
endonuclease G activities are caspase-independent, while CAD cleaves the DNA fragments 
generated by caspase 3 and provokes more chromatin condensation in nuclei [14].  
The Bcl-2 family plays vital roles in regulation of intrinsic pathways. Bcl-2 proteins 
are categorized into 3 groups: the anti-apoptotic subfamily (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, 
A1, and also Bcl-B in humans), the apoptotic family, and BH3-only proteins (BID, BIM, 
PUMA). The anti-apoptotic proteins have homology in (BH) 1, 2, 3, or 4 domains, while 
pro-apoptotic BH3-only proteins possess homology in the BH3 domain. Based on their 
functions, the apoptotic proteins can also be classified into two groups: activator BH3-only 
proteins (BID, BIM, PUMA) and effectors (BAX and/or BAK proteins). The interaction 
between these two groups of proteins leads to the formation of pores in mitochondrial 
membranes, which triggers apoptosis cascades. Anti-apoptotic Bcl-2 family members 
block the interaction of activators and effectors (BAX and BAK) or directly bind to 
activated BAX and BAK and halt the apoptosis incidence. On the other hand, “sensitizer” 
BH3 proteins (e.g., BAD, NOXA, etc.) can shift the balance toward apoptosis by binding 
to anti-apoptotic proteins and release activators. Overall, the pro- and anti-apoptotic Bcl-2 
proteins tightly regulate the mitochondrial apoptotic response based on the stage of cell 
growth and the necessity of cell eliminations [15].  
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Apoptosis Inhibitors in Tumors  
Apoptosis, a gene-directed program, can be inhibited by some oncogenic 
mutations. Also, these mutations can promote tumor initiation. For example, the Fac/DC95 
receptor regulates cell numbers by inducing apoptosis in the extrinsic pathway; disruption 
of this pathway can cause lymphoproliferative disorders and even cancer [16].  
The Bcl-2 family is known as the key regulator of the intrinsic pathway. Bcl-2, as 
an anti-apoptotic protein, is over-expressed in many types of cancer cells, such as renal, 
stomach, and brain cancer. In cancer cells, various alterations and mutations, such as 
chromosomal translocations, gene amplification, increased gene transcription, altered post-
translational processing, transcriptional activation by NF-B signaling, or promoter hypo-
methylation, might provoke the overexpression of Bcl-2 proteins [15]. The overproduced 
Bcl-2 proteins play important roles in multiple processes, such as tumor progression, 
invasion, and tumor adaptations to chemotherapeutic drugs and radiation therapy [17, 18]. 
Numerous studies on transgenic mice have exhibited that the overexpression of Bcl-2, Bcl-
xL, or Mcl-1 proteins determine the expansion, maintenance, and survival of cells in 
established tumors [19], while the deletion of Bcl-2 proteins on a transgenic mouse 
leukemia model was reported to abolish leukemic cells in surviving mice [20]. Another 
anti-apoptotic protein, XIAP, is a caspase inhibitor overexpressed in breast, colon, and 
pancreatic cancers. The downregulation of XIAP can promote the execution phase of 
apoptosis in cancer cells [21].  
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Downregulation of proapoptotic Bcl-2 proteins is another factor that stimulates 
tumor formation and progression. Animal model studies have revealed that suppressed, 
post-translational modifications or deficient BH3-only proteins have a permissive 
influence in the tumorigenesis process. In addition, BAD and BIM deficient also facilitate 
the development of lymphoma in transgenic mice [22].  
In normal cells, the tumor suppressor p53 is one of the key proteins that reacts to 
apoptotic stimuli and triggers apoptosis through upregulation of pro-apoptotic genes, 
including PUMA, NOXA, BID, and BAX. The elimination of p53 or the presence of TP53, 
a mutant form of p53, disturbs the balance of apoptotic and anti-apoptotic proteins, which 
leads to the inhibition of apoptosis, promotion of cell proliferation, and stimulation of 
tumor progression [22]. 
Overall, the inhibition of apoptosis pathways plays a vital role in the initiation, 
growth, and invasion of cancer tumors. Recognition of apoptosis stimuli and inhibitors 
could be the key to innovative therapeutic approaches. 
Programmed Cell Death in Bacteria 
Programmed cell death is not limited to eukaryotic cells. Bacteria are usually 
exposed to harsh conditions such as amino-acid starvation, antibiotics treatment, 
temperature change, DNA damage, and phage contamination. Hence, regulation of cell 
growth and death is crucial for bacterial populations [23]. As mentioned above, 
programmed cell death (PCD) is defined as any form of death caused by an intracellular 
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death program [23]. Toxin-antitoxin (TA) is one example of an intracellular death program 
that is present in almost all bacteria and comprises unsensational bicistronic operons 
containing toxins and antitoxin [24]. In TA systems, toxins target several processes such 
as DNA replication, mRNA stability, protein synthesis, and ATP synthesis, while their 
cognate antitoxins prevent toxin activities during the normal condition [25].  
In all TA systems, toxins are seen as small stable proteins, while antitoxins are 
labile and have different structures. Based on the nature and functions of the antitoxin, TA 
systems have been categorized into five groups (I-V) [26]: The Type I TA system includes 
antisense sRNAs as antitoxins, which are located at the upstream of toxin genes with the 
reverse orientation. In this system, the antitoxin binds to the toxin mRNA and impedes the 
translation of the toxin [26]. In turn, the unleashed toxin creates a pore in the bacterial inner 
membrane and disturbs ATP synthesis [25]. 
In a Type II system, both antitoxins and toxins are small proteins encoded on the 
same operon. At normal conditions, the antitoxin binds to the toxin and precludes toxin 
functions. Under stressful environmental conditions, the toxin is released from the stable 
antitoxin-toxin complex, and the antitoxin is degraded by ATP-dependent proteases [25].  
The Type III system was initially reported from Erwinia carotovora sub-species 
atrosepticum (Pectobacterium carotovoum). In this system, an sRNA, as the antitoxin, 
interacts with the toxin protein and blocks its functions [25].  
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Recently, two other TA systems have been discovered in E. coli [25]. The Type IV 
TA system was named yeeU/yeeV (ctbA/ctbB), wherein the antitoxin, yeeU, does not bind 
to the toxin, but instead hampers the toxin’s function by stabilizing the toxin’s targets. In 
this system, the toxin binds to two important cytoskeleton proteins, MreB and FtsZ, and 
inhibits the cytoskeleton assembly process and cell division [27].  
The Type V system has been classified as the ghoS/ghoT TA system, which 
involves GhoS, which digests the toxin mRNA, blocking its translation [28]. 
MazEF: Type II Toxin-Antitoxin 
MazEF is a well-studied TA system that possesses all the common features of the 
Type II system. In this system, an unstable antitoxin protein (MazE) antagonizes the stable 
toxin’s (MazF) function under normal conditions. Both MazF and MazE are co-expressed 
proteins and located downstream of the relA gene [29]. MazE autoregulates the 
transcription of the TA operon [30].  
The MazEF system is present on chromosomes of many bacteria, such as E. coli, 
Myxococcus xanthus [31], and Bacillus subtilis [32]. However, the toxin recognizes 
different cleavage sites on mRNA in various bacteria. For example, E. coli MazF cleaves 
^ACA, while M. xanthus MazF digests GU^UGC [25]. 
MazEF, a stress-induced death-mediated system [33], is triggered by several harsh 
conditions, such as extreme amino acid starvation, blocked transcription or translation by 
 
 14 
antibiotics (e.g., rifampin, chloramphenicol, and spectinomycin), high temperature, DNA 
damage caused by thymine starvation, mitomycin C, nalidixic acid, and UV irradiation 
[34]. 
One of the most interesting aspects of the mazEF system is the mode of action. 
Several investigations have indicated that ectopic overexpression of MazF blocks protein 
translation in bacteria but does not affect DNA or RNA synthesis. The MazF protein has 
several targets, including specific sites in single-stranded mRNAs, tmRNA, tRNA-mRNA 
hybrids that bind to the A site of ribosomes, and 16S rRNA in bacteria [23, 29, 35, 36]. 
Zhang et al. shed light on the MazF enzymatic function by studying DNA-RNA chimeric 
substrates containing an XACA sequence. Their research has revealed that MazF cleaves 
RNAs at either the 5´or 3´ of the first A residue of the ACA sequences. MazF cleaves 
phosphodiester bonds at the 5´ side, leading to the formation of a free 5´-OH group on the 
3´-end cleavage product and a 2´, 3´-cyclic phosphate on the 5´-end product. The OH group 
at the cleavage site is important for MazF function, making it comparable to the function 
of RNase A in the cleavage of RNA. Thus, because of its function, MazF is known as an 
RNA restriction enzyme [37]. 
 
The Application of MazF in Biotechnology  
The ribonuclease activity of MazF has opened new doors for many applications in 
biotechnology. The single protein production (SPP) that utilizes MazF is particularly 
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valuable in protein structure biology. With the SPP technique, the gene of interest is 
engineered to be an ACA-less sequence without altering the amino-acid sequence. While 
MazF proceeds to cleave almost all of the bacterial mRNA, the protein of interest is 
produced in the cells. In other words, overexpression of MazF turns E. coli cells into “a 
single protein production” factory [38]. 
Shimazue and colleagues have shown that MazF is capable of impeding protein 
synthesis and inducing Bak-dependent apoptosis in mammalian cells [39]. This finding has 
brought about an intriguing application for the use of MazF against human viruses such as 
HIV. This virus requires the Tat protein (transactivator of transcription) and TAR 
(transactivation response) to induce the transcription of the HIV-1 genome. Chono et al. 
developed a Tat-dependent production of a MazF construct to eliminate cells harbouring 
HIV [40]. In this system, mazF is inserted downstream of HIV-1 U3-TAR and is solely 
induced in infected cells. Therefore, the MazF protein cleaves the viral mRNA from HIV-
1 IIIB to completely inhibit viral proliferation in the cells [40]. The Hepatitis C virus (HCV) 
is another virus that could be eliminated by MazF. This virus requires NS3 serine protease 
in order to replicate inside the host cells. Shapira et al. designed an interesting construct 
that includes mazF linked with mazE via an NS3-cleavable linker. The MazF proteins 
produced by the construct will be unleashed and thus induce apoptosis in infected cells at 
low levels of NS3 [41]. Based on this previous research, we hypothesized that mazF gene 
could be a useful candidate for induction of apoptosis in cancer cells. Moreover, one 
objective was to employ bacteria as smart vectors in order to limit MazF protein toxicity 
to cancer cells but not to healthy cells.  
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Bacterial Delivery Systems 
The idea of recruiting bacteria against tumors was conceived over 200 years ago 
when Dr. Busch demonstrated that Streptococcus pyrogenes can colonize the late stage of 
sarcoma tumors and cause primary tumors and lymph node shrinkages within a week. 
However, the lethal impacts of the bacterial infection prevented bacterial-based treatment 
from being further pursued. Thirty years later in 1891, Dr. Coley observed that the 
inoculation of several inoperable tumors with Streptococcus pyrogenes was not completely 
effective to stop tumor regression. Thus, Coley developed a toxin containing heat-killed 
microorganisms – S. pyogenes and Serratia marcescens –against lymphoma and sarcosma 
and named it Coley’s toxin [42]. In 1976, for the first time, a bacterial toxin was used in 
clinical trials against cancer. Morales, Eidinger, and Bruce showed that the Bacillus 
Calmette-Guérin (BCG) vaccine has an immunotherapeutic effect on urinary bladder 
cancer. The vaccine is still applied for treatment of high-risk urinary bladder tumors [43]. 
Over the past decades, accumulated knowledge and technological advances have led to 
overcoming obstacles with bacterial therapy, such as low efficiency but high toxicities, and 
development of various applications utilizing bacteria for the treatment of bacteria against 
cancer.  
The preference of bacteria to colonize and replicate in tumors has prompted the 
emerging interests of utilizing bacteria in cancer therapy. Although the exact mechanism 
of colonization remains to be discovered, the natural ability of bacteria to sense a tumor 
environment might stem from some tumor features such as abundant of secreted nutrients 
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in the microenvironment, the presence of hypoxia, and the leaky vascular systems in tumors 
[44]. This preferential tumor accumulation has been reported for various bacteria genera 
such as Salmonella, Escherichia, Clostridium, Bifiobacterium, Listeria, Shigella, Vibro, 
and Staphylococcus [45]. 
Bacteria and Tumor Microenvironments 
The current knowledge in cancer therapy has revealed that the heterogenic nature 
of tumors and their microenvironments contribute to progression, invasion, and metastasis 
and determine the success of treatments to defeat tumor growth. Aggressive tumors have 
extraordinarily high proliferation abilities, which leads to creating unorganized vascular 
systems and regions with a low concentration of oxygen in contents but are highly acidic 
in nature and possess accumulated waste metabolites. These regions develop an 
immunological self-tolerance area. These environments are ideal for abnormal tumor cells 
and cause them to be more resistant to radiation, anticancer chemotherapy, or normal 
apoptotic mechanisms [44]. Hypoxia, the area with low oxygen concentration, is one of the 
main obstacles in the usage of traditional therapies such as chemotherapy and radiotherapy. 
Hypoxia can provoke the induction of various transcription factors such as the hypoxia 
inducible factor 1(HIF1), resulting in the induction of the vascular endothelial growth 
factor (VEGF) and stimulating the angiogenesis process in tumors [44, 46]. Therefore, 
hypoxia has always been an attractive target to attack in tumors. Due to the lack of a low 
concentration of oxygen, necrotic zones and hypoxia are desired areas for various 
anaerobic and facultative bacteria to colonize or escape from immune systems [44, 47].  
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In addition to hypoxia, the secretion of chemotaxins and nutrients, e.g., purines, 
and the permeable nature of tumor vascular systems are other attractive elements to direct 
bacteria toward tumors. Ye et al. reported that bacterial tumor colonization is a dose-
dependent process, with a threshold of 104 and 105 cells to prevent the clearance of bacteria 
by the immune system. In addition, there is no correlation observed between bacterial 
tumor colonization and some bacterial features such as gram morphology and 
pathogenicity or tumor characters, e.g. tumor growth rate or tumor volume. In contrast, the 
stages of tumor development and the presence of necrotic areas stimulate bacterial 
colonization in tumors [44]. In addition, the immune-privileged nature of tumors and the 
presence of nutrients in microenvironments are other factors that make solid tumors and 
metastases a desired place for bacterial replication [48].  
Together, the nature of tumors, coupled with the ability of bacteria to colonize 
tumors, has provided valuable knowledge and tools for targeting cancers. 
Bacterial Cancer Therapies 
Due to the limitations and side effects of traditional cancer therapies, the advent of 
innovated approaches with high specificity has been prioritized over the past decades. In 
cancer therapy, the ideal treatments are illustrated with various characteristics such as being 
nonpathogenic, nonimmunogenic agents, cost-effective, easy to generate, having high 
preferences in targeting tumors and metastasis, and their abilities to deliver or express 
therapeutic genes or proteins in tumors. Bacteria, due to their unique capabilities to 
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colonize tumors, seem to be a suitable agent in cancer therapy [44, 49-52]. Bacteria are 
inclined to localize in tumor microenvironments. For instance, the abundance of aspartate 
and ribose in tumor microenvironment makes tumors a preferential home for Salmonella 
typhimurium [51]. These tendencies of bacteria to migrate toward tumors have made 
bacteria a versatile agent with high safety profiles against tumors. In addition, the motility 
of bacteria allows them to travel to various regions of tumors that remain inaccessible for 
other treatments. Beyond the natural features, the ease of genetic modifications for many 
applications make bacteria good candidates to be superior agents in cancer therapy (Figure 
1.1). 
 
Figure 1.1. Motile bacteria can travel throughout tumors [53]. Reproduced with permission from Springer 
Nature and Copyright Clearance Center. 
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Figure 1.2. Bacteria: Smart vectors to identify tumors [51]. Reproduced with permission from Springer 
Nature and Copyright Clearance Center. 
Over the past decades, bacteria have been recruited for multiple purposes in cancer 
therapies. It has been reported that the Clostridium spores are promising treatments to grow 
in and destroy hypoxia, and bacterial toxins can stimulate apoptosis in apoptosis-resistant 
tumors [51, 54]. Live, attenuated, and nonpathogenic bacteria can also be utilized to 
replicate in tumors and destroy them. Lactobacillus sp., Bifidobacterium sp., and 
Streptococcus, as probiotic bacteria, can cure or prevent the regression of bladder cancer 
with no side effects on normal cells [55, 56]. Salmonella, facultative bacteria, tend to dwell 
in tumors of different sizes. This preference stems from the presence of two promoters 
(pflE and ansB promoter regions) in Salmonella’s genome, which, once activated in 
hypoxia, facilitate bacterial reproduction in tumors [57]. The S. typhimurium strain 
VNP20009 is a well-known bacteria in cancer therapy and is a purine axotrophic mutant 
with truncated lipopolysaccharides (LPS) due to the deletion of purI and msbB, 
respectively [58]. This strain exclusively colonizes tumors but not normal cells. 
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Another exciting application of bacteria in cancer therapy is to exploit them as a 
vector for gene therapy. In contrast to virus and non-viral vehicles, bacteria can deliver 
genetical elements of various sizes. Therefore, the size of the therapeutic payload is not a 
limitation in this delivery system. Bacteria can be used to deliver DNAs, mRNAs, small 
interfering RNAs, and proteins into cells [51, 59]. In addition, bacterial vectors can be 
systematically administrated through intravenous (iv) or intraperitoneal (ip) methods into 
the host. Bacteria have abilities to deliver genes into both solid tumors, e.g. melanoma, 
lung, colon, breast, renal, and hepatic, and metastatic cancers [56, 59]. Bacteria can also be 
recruited to be involved in gene-directed enzyme prodrug therapy (GDEPT). In this 
approach, vectors deliver the construct encoding enzymes such as cytosine deaminase and 
purine nucleoside phosphorylase into tumors. These enzymes are able to convert the non-
toxic prodrugs into toxic drugs inside tumors. Several bacterial strains, e.g. Listeria and 
Bifobacterium, have been reported to deliver conversion enzymes into cancer cells [60]. 
Bactofection and Alternative Gene Therapy  
Generally, bacterial delivery systems consist of two strategies: bactofection and 
alternative gene therapy (AGT). The term bactofection was coined for the application of 
bacteria as a vehicle to deliver genetic information into phagocytic and nonphagocytic 
mammalian cells. In this approach, bacteria enter the target cells carrying a suicide gene, 
lyse inside the cells or vacuoles, and a plasmid encoding a therapeutic gene is released 
(Figure 1.3) [61]. 
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Figure 1.3. Bactofection process.  
A) Bacterium enters cancer cells. B) Bacterium can replicate inside the cells. C) Plasmid releases 
from lysed bacteria into cytosol. D) Plasmid enters nucleus randomly [61].  
In bactofection, based on the nature of vectors, bacteria localize in the cytoplasm 
(e.g. Listeria and Shigella), in vacuoles (e.g. Salmonella and Yersinia), or in extracellular 
space (e.g. Agrobacterium) [62]. The advances in molecular technologies have engendered 
the development of various modified bacterial vectors for gene delivery purposes. For 
instance, an engineered E. coli strain that carried inv, encoding for invasion, from Y. 
pseudotuberculosis and hly from Listeria monocytogenes, expressing Listeriolysin O, was 
able to attack the target cells, enter, and deliver a plasmid to cell cytosols [62].  
Bactofection, despite advantages like simplicity and specificity, encounters several 
drawbacks and limitations. One of the limitations of this approach is the elimination of 
vectors by immune systems prior to interacting with cancer cells. Another concern with the 
usage of bactofections for therapeutic purposes is that attenuated bacteria might regain their 
pathogenicity [62]. 
Alternative gene therapy (AGT) is another strategy in bacterial therapy. In AGT, 
unlike bactofection, bacteria are converted to a factory for synthesizing the therapeutic 
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agents inside tumors. AGT is a nucleus-independent approach which reduces the risk of 
tumor adaptation compared to other gene therapy strategies [49]. In comparison to classical 
gene therapy approaches, AGT can be easily shut down by using antibiotics or by applying 
inducible promoters or suicide genes [49]. Several studies suggested that Clostridia, 
Bifidobacteria, Salmonella, or Listeria are suitable candidates for AGT purposes. Listeria 
has been reported to be able to survive and produce therapeutic proteins directly in the 
cytoplasm of target cells [63].  
Listeria monocytogenes: A Versatile Vector in Gene Therapy  
L. monocytogenes is an intracellular pathogen that can cross three tight barriers in 
the human body, i.e., the intestinal, the blood-brain, and the fetoplacental barriers [64].  
Listeria is a suitable vector for the delivery of DNA or RNA into target cells. This 
ability comes from its life cycle in mammalian cells, which includes a series of consecutive 
events: 1) contact with the cells via membrane proteins, 2) entering into the phagocytic 
vacuole, 3) lysing the vacuole, 4) replicating inside the cytosol, and 5) spreading from cell 
to cell [64]. 
Listeria is able to enter inside phagocytic (e.g. macrophage or neutrophils) and non-
phagocytic cells (hepatocytes and endothelial cells) [64]. However, internalization of this 
bacterium occurs as a result of the active interaction between the bacterium and the host 
cells. Listeria has two surface proteins, i.e., internalin A (InlA) and internalin B (InlB), that 
are involved in listerial entry into different cell lines [63]. E-cadherin, the receptor for InlA, 
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and the hepatocyte growth factor (HGF) receptor Met, the receptor for InlB, are located on 
the surface of the host cell [65]. Once Listeria enters a cell, it lyses the phagosome by 
producing a pore-forming bacterial toxin, listeriolysin-O (LLO), encoded by the hly gene. 
Listeria can also secrete phosphatidylcholine phospholipase C (plcB) to escape from a 
secondary vacuole [63, 64]. In the cytosol, the bacteria replicate and subsequently express 
the ActA protein, which triggers actin polymerization around the bacteria and facilities 
several processes such as bacterial movement in the cytosol, the formation of protrusions 
at the host cell surface, and bacterial cell-to-cell spread. In addition, ActA is involved in 
some other bacterial functions, including entry into the cell, escape from phagosomes, 
avoidance of autophagy, and the formation of biofilms [66]. 
 Listeria, a gram positive organism, does not have the lipopolysaccharides (LPS), 
bacterial endotoxins that induce inflammation in hosts [67]. However, its pathogenicity 
casts a shadow upon its application in gene therapy. Thus, attenuation of its virulence is 
required for safety considerations [68]. Today, several attenuated Listeria strains have been 
introduced by several research groups. Dietrich et al. developed an attenuated self-
destructing L. monocytogenes to transfer DNA into the host cell macrophage cytosol. This 
attenuated bacterium produces a PactA-dependent Listeria-specific phage lysin to initiate 
suicide once inside the target cells [69]. Schoen et al. demonstrated the usage of self-
destructing L. monocytogenes carrying the lysin gene from phage A118 (ply 118) to deliver 
eGFP mRNA into the cytosol of epithelial cells, macrophages, and human dendritic cells 
[62]. Tangency and co-workers produced a highly ampicillin-sensitive host strain L. 
monocytogenes that grows in solid tumors and subsequently could be killed after ampicillin 
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administration [70]. Yang et al. genetically engineered a replication-deficient strain of L. 
monocytogenes (Lmdd) to express and secrete human CD24 protein in cancer stem cells 
(CSCs). This attenuated bacterium is deficient for alanine racemase (dal) and D-amino acid 
aminotransferase (dat), which are essential for the synthesis of D-alanine. Bacteria lacking 
these genes are not able to make the mucopeptide component of the bacterial cell wall, 
which is essential for replication, and depend only on the availability of exogenous D-
alanine. This bacterium has been shown to be a safe and effective cancer vaccine in 
preventing HCC chemoresistance, metastasis, and recurrence [68]. Heisig et al. generated 
an internalin A and B (InlAB)-deficient L. monocytogenes strain (Lm-spa+) that expresses 
protein A of Staphylococcus aureus (SPA) and anchors SPA in the correct orientation on 
the bacterial cell surface. This bacterium can bind to antibodies and be specifically directed 
to the target recognized by the antibody [71]. 
In this project, we intend to increase the safety of the attenuated L. monocytogenes 
strain with deleted internalin A and B (Inl AB)-expressing SPA [71] by transferring a 
plasmid carrying the self-destructing L. monocytogenes lysin gene from phage A118 (ply 
118), which induces listerial suicide once inside the cancer cells. 
Objective  
Apoptosis, as a regulated cellular mechanism, is essential for various processes, 
including normal cell turnover, proper development and functioning of the immune system, 
hormone-dependent atrophy, embryonic development, and chemical-induced cell death. 
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Inappropriate apoptosis, an important factor in the development of many types of cancer, 
occurs due to the disrupted balance of pro-apoptotic and anti-apoptotic proteins, impaired 
death receptor signaling, or reduced caspase function. Therefore, any drugs or treatment 
strategies that are able to direct the apoptotic signaling pathways towards normality have 
the potential to eliminate cancer. The main goal of this dissertation was to introduce a 
proof-of-concept application for MazF protein as a potential apoptotic inducer against 
cancer. The first aim deals with evaluating the expression of ACA-less mazF mRNA in E. 
coli cells. The second aim is to investigate the ability of MazF to inhibit protein synthesis 
and eventually trigger death in various cancer cell lines. The third aim explores the 
feasibility of using a Listeria delivery system to generate and transfer mazF mRNA into 
cancer cells. Data collected in this research would facilitate the development of new cancer 
treatment options that target only cancer cells but not healthy cells. Furthermore, such 
treatment approaches, based on using bacteria to deliver mRNA to target cells, offer more 
advantages, e.g. inexpensiveness, target tissue specificity, and easy and safe delivery, in 
comparison to other gene therapy vectors or direct protein administration. 
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CHAPTER TWO 
2. Overexpression of ACA-less mazF in Escherichia coli Cells  
Introduction 
Bacteria are usually exposed to various stressful conditions such as amino-acid 
starvation, antibiotics treatment, temperature change, DNA damage, and phage 
contamination. Hence, regulation of cell growth and death is crucial for bacterial 
populations. Similar to eukaryotes, bacterial cells face programmed cell death (PCD) in 
their lifetime. As mentioned above, PCD is defined as any form of death caused by an 
intracellular death program [23]. PCD occurs in bacterial cells through various pathways. 
Toxin-antitoxin (TA) is one example of an intracellular death program that is present in 
almost all bacteria and comprises bicistronic operons containing toxins and antitoxins [36]. 
MazF is one of the well-known toxins involved in bacterial programmed cell death. 
This small endoribonuclease, with a molecular weight of 12 kDa, cleaves mRNA at ACA 
sequences in a ribosome-independent manner and restrains bacterial growth during 
stressful conditions [36]. MazF is one of the toxins present in the TA Type II system. In 
this system, the antitoxin binds to the toxin and precludes toxin functions at normal 
conditions. However, under stressful environmental conditions, the toxin is released from 
the stable antitoxin-toxin complex, and the antitoxin is degraded by ATP-dependent 
proteases [25].  
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Engelberg-Kulka et al. studied the influence of the mazEF locus on triggering 
programed cell death in bacteria during stressful conditions. According to their results, 
once bacteria encounter harsh conditions, such as extreme amino acid starvation, inhibition 
of transcription and/or translation by antibiotics, lethal action of toxic phage products and 
DNA damage caused by thymine starvation, UV irradiation, oxidative stress, and DNA 
damaging agents, the expression of both MazF and MazE is halted. In this situation, MazE, 
as the corresponding antitoxin to MazF, is degraded by the ATP-dependent serine protease 
clpPA, while MazF is released to digest mRNAs in cells. Hazan et al. found that E. coli 
ΔmazEF are more resistant to high temperatures (50ºC) and DNA damage by nalidixic acid 
(at concentrations of 2 mg/ml and lower) and mitomycin C (at concentrations of 1.5 µg/ml 
and lower) [73]. During stress, the MazEF operon is downregulated, and the concentration 
of MazE, due to its unstable nature, drastically drops, while  MazF proteins are unleashed 
and function in cells [29]. The MazEF system also serves as a defense mechanism against 
phage spread. It has been shown that E. coli ΔmazF is susceptible to infection and being 
completely killed by P1phage, while in the wild-type (WT), infected cells are killed by the 
MazEF system, as opposed to the phage. The WT culture survives and grows normally, but 
phage spread is restricted. In other words, MazEF saves the whole population by 
eliminating the individual infected cells [29].  
Recently, two genetically distinct programmed cell death pathways, apoptotic-like 
death (ALD) and the MazEF pathway, have been described for E. coli populations. ALD 
shares some similarity in morphological changes (such as membrane depolarization and 
DNA fragmentation) with eukaryotic apoptosis. ALD is the recA-dependent cell death 
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pathway and is triggered exclusively by DNA damage [74]. Erental and colleagues have 
shown that mazEF is a recA-independent pathway, which prevents the activation of the 
ALD pathway, either by cleaving mRNAs of recA or by inhibiting recA transcription. 
According to their model, mazEF rescues the small bacterial population that is resistant to 
various stressful conditions. Whereas, ALD allows the survival of those individual cells 
that either escape from or repair DNA damage [74]. 
MazF is known as an RNA restriction enzyme [37]. It has been reported that 
RNA/DNA or RNA/RNA duplexes or single stranded DNA are resistant to MazF action. 
In addition, several mRNAs have been found to be resistant to MazF. One example of these 
mRNAs unsusceptible to MazF is lpp mRNA, which possesses four ACA triplets in its 
sequence. Zhang et al. showed that the secondary structure of RNA caused three ACA 
sequences of this mRNA to be inaccessible to MazF proteins, and only one of the ACA 
sets is removed from mRNA, which does not affect the expression of lipoprotein, one of 
the abundant proteins in E. coli cells [37].  
The presence of ACA codons in the mazF sequence enables this ribonuclease to 
degrade its own mazF mRNAs, leading to inhibition of protein synthesis in cells [37]. To 
avoid the elimination of mazF mRNA by itself, the application of an ACA-less mazF gene 
was used in this research. To validate the expression and function of an ACA-less mazF in 
E. coli cells, this construct was placed under the control of a stringent promoter, and the 
bacterial viability was monitored.  
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Experimental Section 
General Molecular Techniques 
Gel electrophoresis: DNA, due to its phosphate residues in the backbone, is 
negatively charged. These electrical charges direct DNA toward the positive pole in a 
constant electrical field, which makes it possible to separate DNA in a size manner on 
agarose gel.  
The concentration of the agarose gels was prepared based on the size of DNA 
plasmids or fragments in 1X TAE buffer. The DNA samples were mixed with 1X loading 
dye and loaded in gel wells. Gels were post-stained with 1X Gel RED, and DNA bands 
were visualized under UV-light. 
Plasmid extraction: Plasmid extraction was conducted using commercial Qiagen 
Kits (Qiagen, USA). Plasmids were extracted from 100 ml of bacterial culture 
supplemented with appropriate antibiotics. All procedures were carried out according to 
the manufacture’s protocol. 
Gel purification: Gel purification was performed by using QIAquick Gel 
Extraction Kit (Qiagen, USA). First, samples were loaded into wells of a low-melting-point 
(LMP) agarose gel. Since UV has a mutagenic effect on DNA, the gel was stained with 
Gelgreen stain (Biotium, USA) and visualized under a blue light transilluminator. Samples 
were excised from the gel and mixed with Buffer QG (Qiagen, USA). To melt the gel, the 
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mixture was incubated at 50ºC and subsequently subjected to further purification according 
to Qiagen’s protocol. 
DNA restriction: In this project, restriction enzymes were used for assembly and 
also validation purposes. The restriction enzymes were type II endonucleases, which were 
selected based on the presence of their restriction sites on DNA. For digestion reactions, 2-
5µg of DNA was used in a 50µl volume with 5-10 units of restriction enzymes. The 
digestion buffers were selected according to the manufacture’s recommendations. The 
reactions were incubated overnight at 37ºC. The heat-sensitive enzymes were deactivated 
at the recommended temperatures for 10-20 minutes. 
Ligation: Ligation is defined as linking the sugar-phosphate backbones of two or 
more double-stranded DNAs by ligase enzymes. The purity and the concentration of DNA 
and the presence of ATP in ligase buffers are the most important elements in a ligase 
reaction. The ligation reactions were prepared in vector:insert ratios between 1:1 to 1:3, 
although the ratio was optimized for each reaction separately. T4 DNA ligase (New 
England biolabs, USA) was used for the ligation purpose, and reactions were incubated at 
16ºC or 4ºC overnight. 
Construction of ACA-less mazF in E. coli Cells 
The ACA-less mazF is a toxin-encoding gene that can kill transformed bacteria at 
the early stage of growth. Thus, the presence of a stringent promoter is required to express 
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mazF gene at the exact expected time. mazF gene was placed under the control of a pBAD 
promoter, which is induced by arabinose.  
The synthesized ACA-less mazF is 336 bp and does not carry the ribosome binding 
site. To amplify the ACA-less mazF fragment, a set of primers were designed: Forward 
(X-mz-F) and Reverse (H-mz-R) primers (Table 2.1). The forward and reverse primers 
contain XhoI and HindIII restriction sites, respectively. Because the mazF fragment is 
short, the digestion process did not occur properly. Hence, the amplicons were first 
appended with poly-A at both end sites and then directly ligated to the linearized pGEM®-
T Easy vector. This vector contains the α-peptide coding region of the enzyme β-
galactosidase, enabling blue/white screening of clones containing the insert. Plasmid 
pGEM®-T containing mazF was electroporated into E. coli DH10B. Following the 
purification of the transformed bacteria, the vector was isolated using QIAprep Spin 
Miniprep Kit and sequenced. Plasmid pGEM®-T harbouring the right insert was digested 
using XhoI and HindIII restriction enzymes, and ACA-less mazF was extracted using 
QIAquick Gel Extraction Kit. 
Table 2.1. Designed primers for construction of pGEM-Z 
Primers Sequences  Applications  
X-mz-F ACTATACTCGAGATGGTAAGCCGATACG Amplification of mazF fragment for pGEM-mazF 
construction  H-mz-R GTTAGCCTCCCCCAAGCTTTCACCC 
The pBAD-His vector was purchased from Invitrogen. The optimized ribosome 
binding site, araBAD promoter (PBAD), N-terminal polyhistidine tag, and araC gene are 
some of the features of the pBAD-His vector (Figure 2.1). The vector was digested with 
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XhoI and HindIII restriction enzymes and purified using QIAquick Gel Extraction Kit. The 
XhoI-HindIII digested ACA-less mazF fragment was inserted into the digested pBAD-His. 
E. coli DH10B was the host of the construct. The construct was stored at -20ºC.  
 
Figure 2.1. pBAD vector map 
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Overexpression of MazF Proteins in E. coli Cells 
In order to express the low basal level of MazF without induction, the above 
construct was electroporated into E. coli LMG 194, which was purchased from Invitrogen. 
The genotype of this strain is F- ΔlacX74 galE thi rpsL ΔphoA (Pvu II) Δara714 leu::Tn10.  
The transformed bacteria were grown overnight on M9 minimal medium supplied 
with 0.1% glucose and 10% casamino acid. The bacterial culture was diluted in fresh M9 
medium, and the OD was measured at 600 nm every 30 minutes. As the bacteria reached 
their mid-logarithmic phase (OD600 = 0.5), the culture was split into two flasks: one flask 
with 0.2% arabinose and the other one as a control. Both flasks were incubated at 37ºC 
without shaking, and after 20 minutes, 1 ml from each sample was withdrawn and used for 
further dilution in PBS. One hundred microliters of diluted samples was spread on M9-
ampicilin plates and recorded as time 0. Then, samples were collected at various time 
points: 20 min, 40 min, 1 hour, 2 hours, 4 hours, and 6 hours in the same manner. 
Results 
MazF is a bacterial toxin that can cleave 90% of mRNA at ACA sequences and 
induce death in E. coli cells [73]. To monitor the effect of MazF proteins on bacterial cells, 
ACA-less mazF was inserted downstream of an inducer promoter, pBAD (Figure 2.2). This 
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promoter is a tightly regulated promoter of the arabinose operon and induced by the 
presence of arabinose as the carbon source in the bacterial medium.   
 
Figure 2.2. pBAD-mazF map 
To analyze the effect of MazF on bacterial viability, the pBAD construct was 
electroporated into E. coli LMG 194. The transformed bacterial cells were grown in M9 
minimal medium to mid-logarithmic phase. The expression of MazF protein was induced 
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by the addition of arabinose in the culture medium. The bacterial samples were then 
cultured on M9 medium, and the CFU/ml was calculated for each time point.  
The result showed that overexpression of mazF led to drastically decreased colony 
sizes and also caused a 6-log reduction in bacterial viability during a period of 6 hours 
(Figure 2.3 and Figure 2.4). Our result was consistent with other studies, which used 
unmodified mazF sequences in bacterial cells [75]. 
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Figure 2.3. The effect of overproduced MazF protein on E. coli LMG 194 
The top plates: the mazF gene was induced by addition of arabinose at 20 minutes and 40 minutes. 
As shown, the number and size of bacterial colonies reduced severely compared to controls. The 
below plates: MazF protein was not induced in bacterial cells (controls for the same time point). 
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Figure 2.4. The percentage of bacterial survivors after mazF induction. The blue line is related to the 
percentage of cells in which mazF was not induced (control). 
 
 
 
 
 
 
 
 39 
Discussion 
MazF protein is one of the bacterial toxins that plays an important role in the 
regulation of bacterial populations during stationary phases. This protein can block protein 
synthesis and eventually arrest bacterial growth during harsh conditions. MazF proteins are 
described as a bacterial ribonuclease that digests mRNAs at ACA sequences. This protein 
is also able to cleave its own mRNA due to the presence of ACA codons in its sequence. 
This might be one of the reasons that the expression of MazF and MazE is inhibited during 
harsh conditions [76]. In this research, we investigated the effect of overexpressed ACA-
less mazF on bacterial cells.  
To examine the lethal ability of the overexpressed MazF protein, ACA-less mazF 
was inserted under the control of the PBAD promoter, and the construct was transferred into 
E. coli cells. The transformed bacteria were used to validate the expression of MazF 
protein. Our results showed that significant reduction occurred in bacterial viability shortly 
after the induction of the PBAD promoters. In addition, the surviving bacteria generated 
smaller colonies compared to the control strain. Also, our result recorded approximately 6-
log reductions in bacterial viability 6 hours post induction. Therefore, these data confirmed 
that MazF was overproduced in bacterial cells, and MazE proteins were unable to 
neutralize the function of MazF in bacterial cells. Our result was in agreement with findings 
reported by Amitai et al. [76], indicating that overexpression of MazF proteins can mediate 
death in bacterial cells.  
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CHAPTER THREE 
3. MazF: A Potential Apoptotic Inducer in Various Cancer Lines  
Introduction 
Cancer and Ribonucleases 
Despite recent advances in treatment and diagnostic measures, cancer continues to 
plague the medical community. The second leading cause of mortality and morbidity 
worldwide, cancer is a group of diseases sharing limited common characteristics that arise 
from various mutations [77]. This heterogeneity has been a major challenge for cancer 
therapy, since these mutations often compromise the success of treatment. Traditionally, 
the battle against cancer has been led by surgery, chemotherapy, and radiotherapy. 
However, these treatment methods suffer from various limitations (e.g., the lack of 
specificity in the traditional strategies) and side effects, including both temporary (e.g., 
diarrhea, nausea, loss of hair, reduced resistance to infection) and long-term effects (e.g., 
decreased heart, lung, and kidney health). In an attempt to avoid these drawbacks, recent 
treatment efforts have focused on introducing certain drugs or small toxins with mild 
toxicities and tolerable immunogenicity [78].  
Ribonucleases have been a promising route in cancer therapy at gene expression 
levels [79]. Ribonucleases, or RNases, are defined as small basic proteins, 10-15 kDa, that 
degrade RNA molecules. Based on their activity, sequence, and structure, these proteins 
are classified into two main groups: endoribonucleases and exoribonucleases [79]. The 
actions of RNases have diverse effects on cellular events. RNases have the ability to 
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function as angiogenic, neurotoxic, antitumor, or immunosuppressive agents [80]. 
Paradigm onconase from the northern leopard frog (Rana pipiens) is a well-known example 
of an RNase that could serve as a potential treatment against a variety of malignancies [80]. 
In addition, several endeavors have been made to design RNases with high toxicity and 
specificity against cancer tumors [81, 82].  
Ribonucleases naturally occur in prokaryotic and eukaryotic cells, and are not 
limited to fungi, plants, and animals. RNases have been harvested from several mushroom 
species for therapeutic uses, including Cordyceps sinensis, C. militaris, Coriolus 
versicolor, Ganoderma lucidum, Grifola frondosa, and Hericium erinaceus. The 
mushroom Calvatia caelata produces a ubiquitin-like 8-kDa peptide that has been shown 
to suppress breast cancer proliferation. This mushroom also contains the RNase calcaelin, 
which has antimitogenic activity in mouse splenocytes and a lethal effect on breast cancer 
cells [82].  
RNases also are present in many plant organelles, including chloroplasts, vacuoles, 
nuclei, and mitochondria [83]. These RNases are involved in a series of biological activities 
such as self-incompatibility, programmed cell death, response to phosphate starvation, 
plant defense, and plant development. The Japanese pear (Pyrus pyrifolia), Arabidopsis, 
tomato plants, and wild almonds (Prunus webbii) are all known to produce RNases. The 
ginseng plant is known to generate various anti-cancer and anti-HIV-RT RNases. It has 
also been reported that RNases extracted from wheat leaf, mung bean, black pine pollen, 
tomato, and hop will prevent the proliferation of cancer cells [79, 84, 85]. 
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Animal cells contain various RNases such as onconase, ranpirnase (commercial 
name), or P30 (initial name) that have been tested in phase III trials against mesothelioma 
[86]. Onconase is extracted from the embryos and unfertilized oocytes of northern leopard 
frogs and belongs to the RNase A superfamily [86, 87]. These proteins, due to their 
stability, low catalytic activity, and low immunogenicity have been nominated as a 
potential treatment against cancer. Other examples of animal-derived RNases that show 
therapeutic activity against cancer and HIV include bovine pancreatic RNase A (BP-
RNase), bovine seminal RNase (BS-RNase), and human pancreatic RNase (HP-RNase) 
[87]. 
Bacteria also generate diverse groups of RNase proteins with different cytotoxic 
abilities. Extracted from Bacillus intermedius and a member of the bacterial T1 RNase 
family, Binase specifically inhibits proliferation of and induces apoptosis in human 
myelogenic erythroleukemia K562 cells, human lung carcinoma A549 cells, and human 
peripheral blood mononuclear cells [88]. RNase Sa3, another member of the bacterial T1 
family of RNases, is isolated from Streptomyces aureofaciens (strain CCM 3239). This 
protein selectively targets human erythroleukemia K562 cells in culture at a low 
concentration [89].  
mRNA-Based Therapies 
Nucleic acid-encoded drugs have opened a window to battling various life-
threatening diseases. These drugs traditionally have been employed to modify gene 
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expression or edit genes within the genome [90]. Wolff et al., as the pioneer of developing 
these new treatments, showed that the direct injection of DNA and RNA into murine 
skeletal muscle initiates the encoded protein expression in the same muscle [91]. At the 
time, pDNA and viral DNA-based approaches attracted the highest attention against 
various diseases, while mRNA-based drugs, owing to the labile structure of mRNA, 
remained unpursued for a long time. Although mRNA was discovered in 1961, its 
structure, stability, function, and metabolic relevance were, until recently, the main focuses 
of mRNA studies [92]. Since the 1990s, various strategies have been described for the 
application and improvement of in vitro transcribed mRNA (IVT mRNA) limitations, e.g. 
their short half-life, and immunogenicity against cancer and infectious diseases [92-94].  
Unlike other nucleic acid-based therapies, IVT-mRNA-based therapy offers 
exceptional advantages in the medical field. IVT mRNA does not seek access to the nucleus 
but is instead functional in the cytoplasm. Thus, mRNA can be translated in both dividing 
and non-dividing cells. In contrast to plasmid DNA and viral vectors, IVT mRNA bears no 
risk of genomic integration and insertional mutagenesis. Unlike DNA, IVT mRNA does 
not need to possess a strong promoter or a terminator to be expressed inside the cells [90, 
92]. Moreover, mRNA can be applied to encode nucleases, e.g. zinc finger motifs (ZFN), 
TALEN–transcription activator-like effector nucleases (TALEN), and CRISPR Cas9, for 
gene editing purposes [90]. Another advantage of mRNA over pDNA is the lack of 
immunogenic CpG motifs, which enhances the transfection efficiency and safety profile of 
mRNA-based treatments. Both bacterial and certain viral DNA carry unmethylated CpG 
(cytosine–phosphate–guanine) motifs that make them vulnerable to the immune system. 
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The bacterial DNA containing CpG motifs activates B cells, monocytes, dendritic cells, 
macrophages, and the lytic activity of natural killer cells that subsequently leads to failed 
gene deliveries in vivo [95]. 
In general, IVT mRNA has been utilized in two therapeutic applications. One 
application delivers mRNA into the patient’s cells ex vivo for genome engineering, genetic 
reprogramming, T cell- and dendritic cell (DC)-based immunotherapies against cancer and 
infectious diseases, and certain protein-replacement approaches [92]. The second 
application transfers mRNA to cells in a variety of ways for vaccination, oncology, 
infectious disease, tolerization regimens to battle allergies, and for other protein-
replacement therapies [92].  
To function as a pharmacologically active drug, IVT mRNA exploits cells’ 
translational machinery in order to be expressed inside cells. IVT mRNA shares similar 
structures with naturally mature mRNAs and undergoes translation in the cytoplasm [92]. 
IVT mRNA is a single-stranded molecule containing a 5´ cap (m7GpppN or m7Gp3N (N 
–any nucleotide)), a 5′- untranslated region (5′-UTR) and a protein-encoding open reading 
frame (ORF), a 3′-untranslated region (3′-UTR), and a 100-250 adenosine-containing 
region (3′- poly(A)-tail) [90, 92].  
The mRNA usually possesses a long string of nucleotides that causes chemically-
automated mRNA synthesis to be impracticable, but in this case, mRNA synthesis is solely 
linked to in vitro enzymatic synthesis or cell-free systems. In cell-free systems, a linearized 
plasmid or PCR product serves as a template to encode all structural elements of mRNA, 
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with the exception of the 5´ cap. The template DNA contains either the T7 or SP6 promoter, 
to be paired with the corresponding RNA polymerase in vitro transcriptional reactions. The 
polymerases utilize nucleotides to generate and elongate mRNAs. Consequently, the cap 
is incorporated into the mRNA through an enzymatic reaction. The template DNA is then 
eliminated by DNases, and the synthesized mRNA is purified [92].  
In order to be translated, IVT mRNA must be transported from extracellular space 
to its final destination, the cytoplasm. Both the activity of ubiquitous RNases in 
extracellular space and the cell membrane determine the fate and cytoplasmic 
bioavailability of IVT mRNA. Hence, transfection approaches should be designed to 
protect the mRNAs from destruction by RNases and enhance their cellular uptakes [92].  
When placed in the cytoplasm, stability and translation of IVT and native mRNAs 
are controlled by identical complex cellular mechanisms. The IVT mRNA is then translated 
to a protein product which functions as a bioactive compound [92]. 
The success of mRNA-based therapeutics depends on many factors such as the 
quantity of in vitro transcription products, intracellular stability of IVT mRNA, and its 
translational efficiency. In general, mRNA-based therapies, in spite of their advantages, 
have faced skepticism rooted in the instability and short half-life of mRNAs. mRNA has a 
hydroxyl group on the second carbon of its sugar moiety that inhibits the formation of 
stable double-ß-helix structures and facilitates mRNA hydrolytic destruction [95]. 
Recently, several modifications in various mRNA structural elements such as 5´ caps, 5´ 
and 3´- UTRs, coding regions, and Poly-A tails have been established to improve IVT 
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mRNA stability, translocation, and translation in cells. These modifications eventually 
enhance the synthesis of the encoded protein in transformed cells [90, 92].  
The 5´ cap is a key structural element in mRNA stability, transport, and translation. 
Eukaryotic mRNA possesses a 7-methylguanosine (m7G) cap linked to the first transcribed 
mRNA nucleotide via a 5ʹ-5ʹ-triphosphate bridge (ppp) (m7GpppN structure) [90, 95]. In 
the nucleus, a cap-binding protein (CBP) heterodimer, CBP80-CBP20, interacts with caps 
and ushers mRNAs to the cytoplasm. This complex is also responsible for eliminating 
prematurely translated mRNAs through nonsense-mediated mRNA decay (NMD). The cap 
structure prevents degradation of mRNA against Xrn1 in the cytoplasm and Xrn2 in the 
nucleus [96]. Facilitation of mRNA translation is another important role of the 5’ cap. Caps 
bind to the CBP complex and the eukaryotic initiation factor 4F (eIF4F) before directing 
the 40S ribosomal subunit to the mRNAs in order to enhance the translational process 
[97].  
During in vitro transcription, the capping process is accomplished via two different 
approaches. In one procedure, the synthesized mRNAs are capped with the recombinant 
vaccinia virus-derived capping enzymes, while the second approach is to supplement the 
IVT reactions with cap analogs in a single step. However, due to the competition between 
GTP and the cap analog, both approaches unfortunately result in the appearance of 
uncapped and translationally inactive mRNAs [90, 92, 95]. Moreover, m7GppG can be 
linked in two orientations, Gpppm7GpN and m7GpppGpN, which causes half of the IVT 
products to remain unrecognizable to ribosomes inside of cells [90, 92, 95]. Recently, 
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various cap-analogs have been commercially introduced to prevent reverse bindings and 
enhance the translational efficiency of IVT mRNAs. Phosphorothioate-containing ARCA 
cap analogs and asymmetric cap-analogs carrying methylated guanosine residues at their 
N7 atoms [90] or anti-reverse cap analogs (ARCAs, m2
7,3ʹ−OGpppG) have been designed 
to boost the translation and stability of IVT mRNAs [90, 92]. Tavernier et al. compared 
the impact of a regular (mCAP) with an anti-reverse analog (mARCA) on the expression 
of luciferase in Hela cells. Their results showed that an ARCA in mRNA structures 
prolongs expression of the luciferase to 5-7 days post transfection [95]. Kuhn et al. reported 
that the IVT mRNAs capped by a phosphorothioate-modified cap result in a higher stability 
profile when compared to the transcript capped with a mCAP. However, the success of 
IVT mRNA bioavailability and translational efficiency depends on multiple parameters 
including cell type, cell differentiation state, and delivery system [98]. 
In eukaryotic cells, protein translation is a strictly regulated process that begins with 
the recognition of a 5´modified nucleotide cap of mRNA via several initiation factor (eIF) 
proteins and is followed by ribosomes scanning mRNA nucleotides to identify the start 
codon. Hence, the 5´ cap plays a crucial role in the canonical pathway of translation 
initiation. However, several eukaryotic and viral mRNAs have been found to be cap-less 
and bypass the canonical pathways. These mRNAs contain specific RNA sequences in 
untranslated regions (UTR) called internal ribosome-entry sites (IRESs) that facilitate the 
interaction of the 40S ribosome to the adjoining sequences of the initiation codon [99]. 
Poliovirus (PV) and encephalomyocarditis virus (EMCV) are well-studied examples of 
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cap-independent and end-independent RNAs where their IRES sequences protect and boost 
the translation of the viral mRNAs in mammalian cytosols [100].  
The viral IRESs are categorized in four groups based on the following criteria: 
involvement of initiation factors, secondary structure of the IRESs, vicinity of the start 
codon to the IRES, and ability of the IRES to function in rabbit reticulocyte extract with or 
without supplementation [99, 100]. Group one contains IRES RNAs that directly bind to 
ribosomes. This group is eIF- and initiator methionyl-tRNAi-independent and includes 
Cricket paralysis virus (CrPV) and Plautia stali intestine virus (PSIV) [101].  
In the second group, IRES RNAs interact with the 40S subunit and engage a subset 
of canonical eIFs (eIF3, eIF2) and Met-tRNAi. HCV, classical swine fever virus (CSFV, a 
pestivirus) and porcine teschovirus (PTV-1, a picornavirus) are members of this second 
group [101, 102].  
Translation in group three initiates through the association of IRES RNAs with 
canonical eIFs, Met-tRNAi, and additional proteins called IRES trans-activating factors 
(ITAFs). These mRNAs can be translated in rabbit reticulocyte lysates and the AUG codon 
placed at the 3´ ends of IRES. Group 3 includes EMCV, FMDV, and Theiler’s Murine 
Encephalomyelitis virus (TMEV) [103-105].  
In contrast to group three, group four IRES RNAs are only translated in 
supplemented rabbit reticulocyte lysates with other cell type extracts with the start codon 
located relatively downstream of the IRES. Despite the involvement of viral mRNA, the 
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diverse sequences and the unpredictable secondary structures of cellular mRNAs are the 
largest obstacles to the classification of mammalian IRESs [105-107]. 
The discovery of IRES in 1988 shed light on the enigmatic translation of the RNAs 
of human pathogens but also offered a versatile tool for gene therapy. The development of 
vectors with the ability to transfer and introduce multiple genes has been a notable 
challenge for gene therapy. Complex disorders such as cancer and certain infectious 
diseases, e.g. HIV-1 (human immunodeficiency virus), require use of multiple genes and 
may also attack various targets within the cells. The availability of a selectable marker 
for the purposes of gene detection is yet another desired feature of gene therapy vectors 
[108]. Thus, the introduction of co-expressed multiple gene systems is highly valued in 
designing gene therapy vectors. IRES provides the means to design polycistronic 
constructs carrying two or more separated genes under the control of a single promoter. 
Morgan et al. (1992) designed an IRES retroviral vector co-expressing a drug-selectable 
marker and a reporter gene [109]. Felipe and Izquierdo (2000) developed tricistronic and 
tetracistronic vectors for multigene therapy. These retroviral vectors carry genes 
downstream of the internal ribosome entry sites (IRESs) of the encephalomyocarditis virus 
(ECMV) [110].  
IRES has been utilized in various therapeutic strategies against cancer and complex 
diseases. In one strategy, IRES is incorporated upstream of a selectable marker or a reporter 
gene which detects stable expression of the therapeutic gene in cells. IRES can also be used 
to co-express various subunits of multimeric proteins [111]. Another IRES strategy is to 
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co-express a suicide gene and an immunomodulating gene in cancer cells [112, 113]. In 
addition, IRES can be implemented to deliver drug resistance genes into hematopoietic 
progenitor cells. This approach can reduce the chance of myelosuppression caused by high-
dose chemotherapy [114]. 
Eukaryotic mRNAs possess a poly-A tail at their 3´ ends that enhances the mRNAs’ 
stability and translational efficiency [92]. The presence of a poly-A tail is also crucial for 
the transport of mature mRNAs to the cytoplasm [115]. Polyadenylation of IVT mRNA is 
conducted either through the presence of poly-T in the template vector or by an enzymatic 
two-step reaction in which recombinant poly-A polymerase incorporates modified 
nucleotides to the poly-A tail. A key limitation of enzymatic polyadenylation is the 
resulting mixture of RNAs with varying lengths of poly-A tails. However, the IVT mRNAs 
rooted in a co-transcriptional fashion have a defined poly-A tail length. The optimal length 
of the poly-A tail to decrease the immunogenicity of mRNA has been reported to be 
between 120 and 150 nucleotides [90, 92, 115]. 
The translation and stability of IVT mRNAs can also be enhanced by incorporating 
5ʹ- and 3ʹ-UTRs carrying regulatory sequence elements [92]. UTRs are also involved in the 
transport of mRNAs into the cytosol as well as subcellular localization. UTRs govern these 
functions through the interaction of nucleotide patterns or motifs located in 5' UTRs and 3' 
UTRs with specific RNA-binding proteins, an association of sequence elements placed in 
the UTRs with specific complementary non-coding RNAs, or the interaction between 
repetitive elements and binding proteins [116]. The sequence of UTRs is believed to 
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contribute to the stability of mRNA. The 3′-UTR carrying adenosine/uridine-rich 
sequences produces unstable mRNAs in cells, while the replacement of the AU-rich 
regions with the sequence from a durable UTR extends the half-life of the mRNAs [90]. 
The translational efficiency can also be influenced by codon composition and any 
adjacent nucleotides which might stimulate overexpression or downregulation of the gene 
of interest [92, 117]. Cannarozzi et al. revealed that the usage of the same codon for a 
particular amino acid and same tRNAs accelerate the translation process [117]. Hence, the 
optimization of the codon content may be another factor to augment protein expression. 
Van Gulck et al. demonstrated that the codon-optimized IVT mRNAs could be potentially 
applied as a vaccine against HIV [118].  
However, the usage of optimized codons can give rise to some concerns for 
improper folding of proteins in high speed translations and vaccine failure in induction of 
modified ORFs [90]. Optimized codons may also increase the chance of cryptic T cell 
epitope formations [90].  
Another approach to improve stability and immunogenicity is the implementation 
of modified nucleotides in IVT mRNAs. These nucleotides escape the recognition of 
exogenous mRNAs by Toll-like receptors (TLRs) and also reduce the toxicity of mRNAs 
[90]. In human cells, TLR3, TLR7, and TLR8 are responsible for tracking foreign mRNA 
in cells. TLR7 and TLR3 activate with uridine-rich single-stranded RNAs and double-
stranded RNAs, respectively, and both receptors interact with hairpin secondary structures, 
double-stranded regions of mRNA [90]. Modified nucleotides such as 2′-
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Omethylnucleosides, 5-methylcytidine (m5C), N6-methyladenosine (m6A), 5-
methyluridine (m5U), pseudouridine, and 2-thiouridine assist mRNAs in evading detection 
by TLR3, TLR7, TLR8, and RIG-I receptors. It has been reported that the incorporation of 
pseudouridine, a natural nucleotide, in IVT mRNAs boosts the translational efficiency, 
stabilization of primary and secondary structures of mRNAs, and lessens its 
immunogenicity. The incorporations of pseudouridine and 2-thiouridine in IVT mRNA 
structures conceal the mRNA to be recognized by RIG-I and protein kinases (PKR). 
However, the usage of specific modified nucleotides, e.g. N 6 -methyladenine, stimulates 
the degradation of IVT mRNA by YTH family proteins [90, 92].  
RNA therapy has been hailed as an attractive therapeutic approach to battle a broad 
range of diseases and disorders. The application of IVT mRNAs has been explored in 
immunotherapeutics, protein-replacement therapies, and regenerative medicine 
applications. In cancer, IVT mRNAs have been subjected to several preclinical and clinical 
trials that have led to the introduction of effective vaccines against cancer [92]. One of the 
exciting applications of mRNA is the improvement of cancer immunizations. This idea was 
influenced by the ability of exogenous mRNA to stimulate the release of proinflammatory 
cytokines such as TNF-α, IL-1β, IL-12, IL-6, and IL-8; the secretion of type I interferons 
(IFN-α and IFN-β); chemokines GRO, MCP-1, RANTES, and MDC; and the maturation 
of antigen-presenting cells, which trigger both innate and adaptive immune cells [90]. 
Boczkowski et al. showed that immunization of mice carrying tumors with DCs pulsed 
with RNA encoding specific antigens stimulates T cell immune responses and stops the 
growth of small tumors [119]. The result of this research and other investigations have 
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opened doors to the development of ex vivo IVT mRNA vaccines for cancer patients. These 
vaccines have been used against melanoma, prostate cancer, hematological malignancies, 
ovarian cancer, lymphoma, leukemia, and mesothelioma [92]. Since 1993, the design of 
IVT mRNA against infectious diseases has attracted high amounts of attention in the 
medical fields. Recently, three types of IVT mRNA–based vaccines have been presented 
in pharmaceutical markets. DCs carrying IVT mRNA encoding HIV proteins have been 
shown to immunize HIV patients against the virus [120]. The safety and ability of this 
vaccine to stimulate antigen-specific CD8+ and CD4+ T cell responses have been 
demonstrated in Phase I/II clinical trials [121]. The other types of IVT vaccines are the 
injection of adjuvant and naked IVT mRNA encoded to express influenza haemagglutinin 
antigen alone and the injection of influenza IVT mRNA with neuraminidase-encoding IVT 
mRNA [92]. Other IVT mRNA vaccines have been used for immunization against 
flavivirus, RSV, influenza and parainfluenza virus infection [122, 123]. The strong 
capacity of mRNAs to stimulate the immune system, together with the short half-life of 
mRNAs, has suggested a new application for IVT mRNA: allergy vaccines [92]. This 
vaccine, due to the unstable nature of mRNAs, has a higher safety profile and lower risk 
of anaphylactic side effects than DNA-based allergy vaccines [90, 92]. It has been shown 
that IVT mRNA encoding for Vascular Endothelial Growth Factor (VEGF) can be utilized 
for vessel regeneration in cardiovascular diseases [124]. Interestingly, The IVT mRNA-
based methods have been promising approaches in various fields, including 
reprogramming fibroblast differentiation [125], induction of pluripotent stem cells [125], 
and genome editing (ZFN, TALEN, CRISPR-Cas9) [90, 92]. 
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In this research, we used the IVT mRNA technique to synthesize mazF mRNAs 
and deliver the developed mRNAs into cancer cells. The expression of the IVT mazF 
mRNA and the effects of MazF proteins on cancer cells are discussed in detail.  
Experimental Section 
General Molecular Techniques: 
Bacterial culture: For all genetic modifications, Escherichia coli DH10B was used 
as the host. This strain was cultured in Lysogeny broth (LB) or LB agar media at 37°C. 
The overnight cultures originated from a single colony. To maintain plasmids, appropriate 
antibiotics were added to growth cultures. 
Electrocompetent cells: Since E. coli cells are not intrinsically competent to 
acquire plasmids, it is necessary to prepare competent cells prior to transformation. 
Transformation of E. coli cells can be performed via several physical approaches. Overall, 
it seems that electroporation is the most efficient transformation method. Hence, competent 
cells were prepared to be suitable for this method. The electrocompetent cells were 
prepared based on Samsbrug et al.’s protocol. A single colony of E. coli was used to 
inoculate 50 ml of LB medium, and cells were incubated overnight at 37°C with vigorous 
aeration (250 rpm in a rotary shaker). The overnight culture was obtained to inoculate 
prewarmed LB medium in separate 2-liter flasks. The flasks were incubated at 37°C until 
OD600 reached 0.4. The flasks were then placed on ice for 15-30 minutes. The cells were 
harvested by centrifugation at 1000 ×g (2500 rpm) for 20 minutes at 4°C. The cells were 
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resuspended in ice-cold deionized water, followed by another centrifugation for 20 minutes 
at 4°C.  The cells were then washed three times with ice-cold 10% glycerol. Eventually, 
the cells were resuspended in GYT (0.125% (w/v) yeast extract and 10% (v/v) glycerol). 
The competent cells were aliquoted into centrifuge tubes which were then exposed to liquid 
nitrogen. The frozen tubes were maintained at -80°C. 
Plasmid Construction 
pcDNA3.3-mazF vector was generated by replacing GFP with ACA-less mazF in 
pcDNA3.3_eGFP (Addgne, cat# 26822, USA), which contains the T7 promoter. ACA-less 
mazF was amplified from pBApo-mazF (kindly provided by Takara) by using the forward 
(mz-3.3F) and reverse (mz-3.3R): 5’- primers-3’ primers. The linearized pcDNA3.3_eGFP 
was generated with forward (3.3VF) and reverse (3.3VR) primers. The pcDNA 3.1-IRES-
mazF vector was developed by substituting GFP with ACA-less mazF in pcDNA3.1(+) 
IRES (purchased from Addgene, cat#51406, USA) by overlapping PCR. To this end, the 
ACA-less mazF fragment was generated by applying the forward (3.1mzF) and reverse 
(3.1mzR), and pcDNA3.1(+) IRES was linearized by using the forward (3.1VF) and 
reverse (3.1VR) primers. 
The ACA-less mazF fragment and the linear corresponding plasmids were ligated 
by using the NEBbuilder HIFI DNA assembly kit (New England Biolabs Inc., USA),  
according to the manufacturer’s instructions. pT7-IRES-EMCV was purchased from 
Oxford genetics Lab, UK. The pT7-IRES-mazF vector was designed by placing the ACA-
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less mazF fragment between NcoI and XbaI digestion sites in pT7-IRES-EMCV. 
Eventually, the ligated products were electro-transfected into Escherichia coli Dh10B. 
In Vitro mRNA Synthesis 
T7-mazF and T7-GFP were amplified from pcDNA3.3-mazF and 
pcDNA3.3_eGFP, respectively, with the forward (G-in-F) and reverse (G-in-R) primers 
[126]. pcDNA3.1(+) IRES and pcDNA 3.1-IRES-mazF were used as the DNA templates 
for T7-IRES-GFP and T7-IRES-mazF amplicons by the forward (IZ-in-F) and the reverse 
(IZ-in-R). To eliminate the plasmid templates, the PCR reaction was degraded by DNPI 
(New England Biolabs Inc., USA). The PCR products were then purified by using 
QIAquick PCR purification kit (Qiagen, USA), and the purified fragments were used to 
generate mRNAs via MEGAscript T7 kit (Life Technologies, USA). In vitro transcription 
(IVT) reactions contained ATP, CTP, and GTP from MEGAscript T7 kit, Pseudo-UTP () 
and Anti-Reverse Cap Analog, 3´-O-Me-m7G(5') ppp (5')G (from TriLink 
BioTechnologies, USA), and mazF PCR products and T7 Polymerase (from MEGAscript 
T7 kit). The IVT reactions were incubated at 37ºC overnight. To destroy the DNA template 
and exclude the 5’ triphosphates, the IVT reactions were cured with Turbo DNase (from 
MEGAscript T7 kit) and Antarctic phosphatase (New England Biolabs Inc., USA), 
respectively, which was followed by purification of IVT with RNeasy Mini Kit (Qiagen, 
USA). The quality of RNA samples was analyzed by formaldehyde agarose gel 
electrophoreses. The synthesized mRNAs were stored at -80ºC.  
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Table 3.1. List of primers used in this research for construction of pcDNA3.3-mazF and pcDNA3.1 (+) IRES-mazF and preparation of DNA templates 
for in vitro transcription purposes. 
Primer Sequence Application 
mz3.3F 5’ATGATAATATGGCCACAACCATGGTAAGCCGATACGT3’ Amplification of mazF for construction 
of pcDNA3.3-mazF  
mz3.3R 5’GATAATTCTTAATTAATTCATCACCCAATCAGTACGTTAATTTTGGC3’ 
3.3 VF 5’TTAACGTACTGATTGGGTGATGAATTAATTAAGAATTATCACCGCTTCTATTCAGC3’ Amplification of pcDNA3.3 for 
construction of pcDNA3.3-mazF 3.3VR 5’GGTACGTATCGGCTTACCATGGTTGTGGCCATATTATCA3’ 
3.1 mF ATGATAATATGGCCACAACCATGGTAAGCCGATACGT-3’ Amplification of mazF for construction 
of pcDNA 3.1-IRES-mazF 3.1mzR 5’GATAATTCTTAATTAATTCATCACCCAATCAGTACGTTAATTTTGGC-3, 
3.1VF 5’TTAACGTACTGATTGGGTGATGAATTAATTAAGAATTATCACCGCTTCTATTCAGC-3’ Amplification of pcDNA3.1(+) IRES 
for pcDNA 3.1-IRES-mazF 3.1VR 5’-GGTACGTATCGGCTTACCATGGTTGTGGCCATATTATCA-3’ 
G-in-F 5′-TTGGACCCTCGTACAGAAGC TAATACG-3′ Amplification of mazF and GFP (for 
preparation of IVT template) G-in-R 5′- T120-CTTCCTA CTCAGGCTTTATTCAAAGACCA-3′ 
IZ-in-F 5’-AACCCACTGCTTACTGGCTTATCGAAATTAATACGAC-3’ Amplification of IRES-mazF and IRES-
GFP (for preparation of IVT) IZ-in-R CCCTCTAGACTCGACTCTAGAAAGTGTCTCATGCCGG-3 
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Table 3.2. The in vitro transcription reaction (Life Technologies, USA) 
Component  Concentration for each reaction 
ATP solution  7.5 mM 
CTP solution  7.5 mM 
GTP solution  2.5 mM 
UTP solution  7.5 mM 
Anti-Reverse Cap Analog 1mM 
10X reaction buffer 1X 
Linear template (PCR product)  0.1-1 μg 
Enzyme  >500 units (Based on the manufacture instructions)  
Cell Culture 
Human embryonic kidney 293 cells (ATCC® CRL-1573) and human MCF7 breast 
(ATCC® HTB-22) adenocarcinoma cells were maintained in Dulbecco’s Modified Eagle’s 
medium (DMEM) with high glucose and 2mM L-glutamine. AGS gastric (ACR-1739) 
adenocarcinoma cell lines were grown in F12K medium, while HT29 colorectal 
adenocarcinoma cell lines (ATCC® HTB-38) were cultured in McCoys 5A medium. All 
the media were supplemented with 10% fetal bovine serum (Atlanta Biologicals, USA) and 
1% penicillin/streptomycin. Cells were maintained in fresh medium every 2 days at 37ºC 
with 5% CO2.  
Transfection 
All cell lines were seeded in concentrations of 5x105 cells per well and 2.5x104 
cells per well in 6-well and 96-well plates, respectively. The cells were incubated overnight 
at standard conditions, and transfection procedures were performed the following day. 
According to the manufacturer’s instructions (ThermoFisher Scientific, USA), 
Lipofectamine™ MessengermAX™ Transfection was diluted and incubated in 
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OPTI-MEM (ThermoFisher Scientific, USA) for 10 minutes, followed by the 
incubation of mRNA and Lipofactamine for 5 minutes at room temperature. 
The Lipofactamine-mRNA complex was added to cells at 80-90% confluency.  
Cell Viability Assay 
The viability of transfected cells was analyzed by trypan blue exclusion. The cells 
were seeded in 6-well plates and transfected with mazF mRNA the following day. The 
transfected cells were trypsinized and counted using a hemocytometer. 
Cell Proliferation Assay 
The toxicity of mazF mRNA on different cell lines was determined using MTT 
assay analysis (Promega, USA) according to the instructions for the CellTiter Non-
Radioactive Cell Proliferation Assay.  
Immunofluorescent Microscopy 
The activation of caspase -3 and -7 was visualized under immunofluorescence 
microscopy by using Image-iT LIVE Red Caspase -3 and -7 Detection Kit (Molecular 
Probes; Invitrogen). Cells were plated at a concentration of 2.5x104  cells per well in 96-
well plates, and the impact of MazF in apoptotic induction was detected after 24 (For MCF7 
and AGS cells) and 48 hours (For HT29 cells) post-transfection.  
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Caspase Activity Assay 
Caspase -3 and -7 activity was measured using Caspase-Glo® 3- and -7 Assay 
(Promega, Madison, USA). In accordance with the manufacturer’s protocol, a luminogenic 
caspase -3 and -7 substrate containing the tetrapeptide sequence DEVD was added to each 
well in white-walled 96-well plates and incubated at room temperature for 1 hour. Each 
sample was analyzed with a plate-reading luminometer.  
Western Blot Analysis 
Western blot assays were conducted with the anti-cleaved PARP monoclonal 
antibodies and anti-actin monoclonal antibodies (Cell Signaling Technology, Inc., USA). 
The transfected cells in 6-well plates were suspended in lysis buffer (20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) (Cell 
signaling technology, Inc., USA) and incubated on ice for 5 minutes. The lysates were 
centrifuged at 14000 X g, at 4ºC for 10 minutes. The proteins present in the lysate were 
separated on a 10% SDS-PAGE gel and then transferred to a PVDF membrane (BioRAD, 
USA) via a semi-dry electroblotting machine. Subsequently, the membranes were blocked 
(TBE, 5% dry milk powder, 0.1% Tween-20) for 1 hour at room temperature and incubated 
with antibodies overnight at 4ºC. Horseradish peroxidase-conjugated secondary antibody 
and chemiluminescence substrate (Cell Signaling Technology, Inc., USA) were used to 
visualize actin and any cleaved PARP.  
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Nascent Protein Synthesis Assay 
The transfected cells were prepared for analysis using the Click-iT Plus OPP 
Protein Synthesis Assay Kit (Alexa Fluor 594 picolyl azide, Invitrogen). Cells were stained 
with 20 uM Click-iT OPP according to the manufacturer’s instructions, with a slight 
modification: cells were fixed using 4% paraformaldehyde for 15 minutes instead of the 
recommended 3.7% formaldehyde. Following staining, samples were imaged using a GE 
IN Cell Analyzer 2500HS. Samples were then analyzed using GE InCarta software (version 
1.5). For analysis, a mask was created using HCS Nuclear Blue Stain. Per the 
manufacturer’s instructions, the only fluorescence signal from Alexa Fluor 594 (red) that 
was detected within the Nuclear Blue mask was recorded as nascent protein synthesis. 
Therefore, only fluorescence intensity in this region was reported. 
Statistical Analysis 
All experiments were conducted in triplicate. Data are shown as the 
mean ± standard deviation. The data were analyzed through the student’s t-test. The 
difference was considered as statistically significant if P< 0.05. 
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Results 
mazF mRNA Structure 
mRNA therapy is an attractive approach for delivering genetic constructs into cells 
to combat or cure a disease. mRNA therapy owes its success to its superior transfection 
and expression efficiency, simplicity, and safety profile [127]. These advantages led us to 
explore whether mRNA delivery could be a suitable tool to transfer mazF mRNA, as a 
ribonuclease, into cancer cells. To this end, a T7-mazF construct (pT7-mazF) was designed 
(Figure 3.1a). To compare the efficacy of cap-dependent and IRES-dependent translation 
of mazF mRNAs for in vitro transcription purposes, we developed a pT7-IRES-mazF 
plasmid (Figure 3.1b). To investigate the impact of the Kozak sequence on mazF mRNA 
translation, pIRES-mazF-II was constructed (Figure 3.1c). GFP mRNAs in cap-dependent 
and IRES-dependent translation manners were synthesized from pcDNA3.3_eGFP and 
pcDNA3.1(+) IRES, respectively (Figure 3.1d and e). Additionally, a number of mRNAs 
lacking one or more important structural elements, such as a cap, an IRES, poly-As, or 
Kozak sequences, were generated and then subjected to transfection. Since mRNA’s 
structural elements and codon compositions play important roles in translational efficiency, 
we investigated whether ACA-less mazF mRNA would be translated effectively in 
mammalian cells.  
Our results indicated that the capped-polyadenylated mazF or IRES polyadenylated 
-mazF could be translated in cells, while omission of any one of these mRNA structural 
 
 63 
elements, i.e. cap/IRES or poly-As, was enough to block MazF expression. As detailed in 
Figure 3.1, the mRNAs lacking cap or poly-As were not translated under these in vitro, 
However, the lack of Kozak did not have any significant impacts on the expression of MazF 
protein. 
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Figure 3.1.a. pcDNA3-3-mazF map 
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Figure 3.1.b. pcDNA 3.1-IRES-mazF 
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Figure 3.1.c. pT7-IRES-mazF map 
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Figure 3.1.d. pcDNA3.3.-eGFP map (Addgene, USA) 
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Figure 3.1.e. pcDNA3.1(+) IRES-GFP (Addgene, USA) 
Figure 3.1. a-e. DNA temples used for in vitro transcription purposes. a) pcDNA3-3-maz was used to 
develop capped mazF mRNA, b) pcDNA 3-1-IRES-mazF designed for generation of IRES-mazF, c) 
mRNA synthesized from pT7-IRES-mazF does not have a Kozak fragment in its sequence, d) and e) 
pCDNA3.3-eGFP and pCDNA3.1(+) IRES-GFP were used to generate cap and IRES-GFP mRNAs, 
respectively. 
In mammalian cells, synthesized RNAs undergo nucleoside modifications that 
distinguish them from exogenous RNA [92]. Kormann et al. suggested that the replacement 
of one of four basic nucleoside triphosphates with a modified nucleotide blocks the 
interaction of mRNA with TLR3, TLR7, TLR8, and RIG-1, which leads to the elimination 
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of the immunogenicity of exogenous mRNA [128]. In comparison to other modified 
nucleotides, the incorporation of pseudouridine into synthesized mRNA has been reported 
to yield a higher level of mRNA translation and increases the safety profile of such RNA 
therapies [129]. Therefore, mazF transcripts containing pseudouridine were also evaluated 
for their translational ability in mammalian cells (Figure 3.2). In order to contribute MazF-
mediated cell death to translation of transfected mazF mRNA, antisense mazF RNAs, 
complementary to the 5’ end of mazF mRNA, were co-transfected into AGS cells. Our 
results indicated that the partially double-stranded mazF mRNAs-antisense hybrid was 
sufficient to block effective translation of mazF mRNA, resulting in reduced cell death 
compared to cells transfected with mazF mRNA alone (Figure 3.2). 
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Figure 3.2. The impact of mRNA structural elements on MazF translation. mazF mRNA containing a cap or IRES and Poly-As were transfected, and 
MazF protein mediated death of AGS cells, while mazF deficient for cap or Poly-As failed to induce cell death. The co-transfection of mazF mRNA and 
its related antisense fragments led to increased AGS cell survival in contrast to transfection of mazF mRNA alone. 
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MazF-Mediated Death in Cancer Cells 
To examine the expression of mazF mRNA and GFP mRNAs in cancer cells, four 
versions of mazF and GFP mRNA were synthesized: capped and Poly-As, capped and 
Poly-A mRNA carrying pseudouridine, cap-independent and Poly-A mazF mRNA, and 
Poly-A cap-independent mRNA with pseudouridine. The mRNAs were then 
dephosphorylated with Antarctic phosphatase to prevent mRNAs from being recognized 
by RIG-1, which is a sensor for viral RNAs. HEK293, MCF7, AGS, and HT29 cells were 
then transfected with these mazF or GFP mRNAs. Monitoring transfected cells by 
fluorescence microscopy showed that cells began to express GFP 6 hours after transfection. 
Cells exclusively translated the capped and polyadenylated GFP mRNA or mRNAs 
possessing an IRES sequence and poly-A tail (Figure 3.3). However, the fluorescence 
intensity of the IRES-dependent GFP was lower than that of capped GFP. GFP supported 
by IRES was expressed only in the AGS cell line, while the expression of IRES-GFP was 
not detectable in HT29, MCF7, and HEK293 cell lines. 
Following the transfection, our results demonstrated that the expression of mazF 
mRNA in cells arrested cell proliferation and led to a progressive cytopathogenic effect 
(CPE) over the course of transfection (Figure 3.4). Significantly, HEK293 and AGS cells 
underwent extreme morphological change 19 hours after transfection, while MCF7 and 
HT29 cells had a severely reduced number of attached cells 24 and 36 hours post 
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transfection, respectively, suggesting that MazF proteins were able to induce death in 
cancer cells. 
  
 
 73 
 
a. MCF7 
 
b. HT29 
 
c. AGS 
 
d. AGS (transfected with IRES-GFP) 
 
e. HEK293 
 
f. Non- transfected cells 
Figure 3.3. a-f. The expression of GFP mRNA in cancer cells 24 hours post transfection; in panels a), b), 
d) and e), cells were transformed with capped GFP-Poly-A mRNAs, while in panel c), AGS was 
transfected with IRES-GFP mRNA.  
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a1. MCF7- control 2a. MCF7- transfected by mazF 
 
b1. HT29- control 
 
b. HT29- transfected with mazF 
 
c1-HEK293- control c2. HEK293- transfected by mazF 
 
d1-AGS- control 
 
 
d2. AGS- transfected by mazF 
 
(Related to Figure 3.4 on the next page). 
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Figure 3.4. a-f. The morphological changes that occured in cancer cells after transfection of cells with mazF 
mRNA 
The viability of MCF7, AGS, and HT29 cells expressing mazF mRNAs was 
determined by trypan blue exclusion. As illustrated in Figure 3.5, when the cells were 
transfected with one of the four types of mRNA mentioned above, the viability of cells was 
drastically reduced. Cell viability was also determined by the MTT assay, and its results 
showed that the expression of MazF protein hampers cell metabolic activity and increases 
the number of dead cells (data not shown). These data confirm that the expression of the 
MazF protein induces death in the examined cancer cell lines.  
 
 
 
e. AGS transfected by antisense RNA 
Fragments+mazF 
 
f. AGS transfected by GFP mRNA 
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a. Transfected MCF7 cells with mazF mRNA 
(Related to Figure 3.5 on page 90) 
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b. Transfected AGS cells with mazF mRNA 
(Related to Figure 3.5 on page 90). 
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c. Transfected HT29 cells with mazF mRNA 
Figure 3.5. a-c. The expression of MazF results in the significant reduction in cell viability in transfected cells. a) MCF7, b) AGS, and c) HT-T9. The 
difference was considered as statistically significant if P< 0.05 ( ). NS: Not Significant 
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MazF-Mediated Apoptosis in Cancer Cells 
During stationary phase, the MazF protein mediates cell death in E. coli cells by 
cleaving cellular mRNAs at ACA sequences [16]. According to the findings of Shimazu et 
al., MazF protein has a similar ribonuclease function in the human HEK293 cell line, which 
stimulates the occurrence of apoptosis. To validate the induction of apoptosis in different 
cancer cells, we examined whether activated caspase -3 and -7 were present in the 
transfected cells. The caspase -3 and -7 detection assay contains aspartic acid-glutamic 
acid-valine-aspartic acid (DEVD), a caspase substrate that has a high affinity for activated 
caspases. Our results showed that the expression of MazF caused apoptosis reactions in 
MCF7, AGS, and HT29 cells and exhibited MazF-mediated apoptosis 12, 18, and 36 hours, 
respectively, post transfection. In comparison to other cell lines, HT29 was less susceptible 
to MazF proteins. Additionally, the activity of caspase was quantified in the various cell 
lines (Figure 3.6 and Figure 3.7). Furthermore, we investigated whether cleaved PARP, a 
marker of cells undergoing apoptosis, was present in the cell lines translating mazF mRNA. 
Except for MCF7, each cell line revealed a detectable level of cleaved-PARP at various 
hours post transfection. While AGS showed the highest level of cleaved-PARP 18 hours 
post transfection (Figure 3.9), HT29 released the cleaved-PARP 48 hours post transfection. 
Altogether, these results demonstrated that MazF could induce apoptosis in cancer cells. 
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a. MCF7 
 
b. AGS 
 
c. HT29 
 
d. Control (Normal cells) 
 
Figure 3.6. a-d. The activation of caspase -3 and -7 in cancer cell lines: a) MCF7, b) AGS, c) HT29, and 
d) Control. Fluorescent cells are the indication of the activation of caspase -3 and -7. 
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a) Detection of caspase -3 and -7 in MCF7 cells transfected with mazF mRNA 
(Related to Figure 3.5 on the next page). 
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b) Detection of caspase – 3 and -7 in AGS cells transfected with mazF mRNA 
 
(Related to Figure 3.57 on page 85). 
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c) Detection of caspase – 3 and -7 in HT29 transfected with mazF mRNA 
Figure 3.7. a-c. The induction of MazF resulted in the activation of caspase in a) MC7, b) AGS, and c) HT29 
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a. cleaved -PARP 
 
b. -actin  
 
Figure 3.8. The presence of cleaved-PARP in transformed cell lysates after 18 hours of induction of MazF 
in AGS. Ladder: Precision Plus protein™ (BioRAD, USA).  
MazF-Mediated Inhibition of Protein Synthesis in Cancer Cells 
 In E. coli, the activation of MazF protein leads to inhibition of protein synthesis 
through digestion of cellular mRNA [16]. Hence, we evaluated the inhibition of protein 
synthesis by MazF in MCF7 and AGS cell lines via quantifying mRNA translation on a 
single-cell basis. In this assay, O-propargyl-puromycin (OPP) was incorporated into de 
novo peptide chains, and the generated chain was labeled by photostable Alexa Fluor® 
dye. Hence, fluorescence signals were used to measure nascent protein synthesis. As 
illustrated in Figure 8, MazF proteins significantly blocked synthesis of new proteins in the 
cells. Thus, our results confirmed the translational interference role of MazF in the 
examined cell lines.  
100 kDa 
75 kDa 
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In E. coli, MazF cleaves mRNA at ACA sequences. GFP mRNA has 21 ACA 
sequences in the codon region. The co-transfection of mazF mRNAs with pcDNA3.3-eGFP 
resulted in the decrease of GFP signal in transfected cells ( 
Figure 3.10). This observation indirectly confirmed that MazF is able to degrade 
mRNAs and eventually block protein synthesis in transfected cells.  
 
a1. MCF7 cells Transfected with mazF mRNA 
 
a2. Control cells (MCF7) 
 
a3. Cells transfected with mazF mRNA 
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(Related to Figure 3.9 on the next page). 
 
b1. Transfected AGS with mazF mRNA 
 
 
b2. Control cells (AGS) 
 
b3. AGS transfected with mazF mRNA 
Figure 3.9. a-b. MazF blocked protein translation in a) MCF7 and b) AGS cells transfected with mazF 
mRNA. The reduction of fluorescence (Red signals) indicated the inhabitation of nascent protein in 
transfected cells. The nucleases were stained by NuclearMask Blue stain (ThermoFisher Scientific, USA). 
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a. HEK293 transfected with pcDNA3.3-
eGFP 
 
b. Co-transfection of cells with mazF 
mRNA and pcDNA3.3-eGFP 
 
Figure 3.10. MazF is able to cleave mRNA at ACA sequences. A few HEK293 co-transfected with GFP 
plasmid and mazF mRNA expressed GFP signals.  
Discussion 
Even with recent advancements in the medical field, cancer remains one of the main 
concerns of recent centuries. Introduction of novel therapies can bestow hope to many 
patients worldwide. As a new treatment, ribonuclease seems to be a promising treatment 
in cancer therapy at the level of transcription and translation. However, within a short 
period of time, it became evident that certain ribonucleases, due to their instability, the lack 
of cytotoxic or cytostatic activity, and the presence of ribonuclease inhibitors (RI) within 
cells, are poor candidates for cancer therapy purposes [130]. MazF is a small and stable 
ribonuclease in bacterial cells that cleaves mRNAs, tRNA, and rRNA at ACA sequences. 
Under normal conditions, MazF binds a small, labile protein, MazE, and remains nontoxic 
in the cells. While under stressful conditions, MazE is degraded, but MazF arrests cell 
proliferation and induces death within bacterial cells [131]. Thus, the mRNA interference 
activity of MazF and the absence of a MazF inhibitor in mammalian cells encouraged us 
to investigate its potential application in cancer therapy. Shimazu et al. showed that MazF 
 
 88 
is able to halt the growth of and induce apoptosis in T-REx-293 cells, a human kidney cell 
line. Given that cancer is a heterogeneous group of diseases with various sensitivities to 
different treatments, we examined the impact of MazF on the growth and viability of three 
cancer cell lines, MCF7, HT29, and AGS, which carry different mutations and exhibit low 
sensitives to traditional cancer treatments.     
In this study, we demonstrated that the delivery of mazF mRNA into cancer cells 
enhances translation of the encoded protein. mRNA is an attractive candidate in non-viral 
gene therapy due to its ability to be active in the cytosol without entering the nucleus. 
However, mRNA lability has always minimized the advantages of mRNA-based therapy. 
In order to address this concern, we studied the necessity of the main structural elements 
of mRNA to boost the translation efficiency of MazF in in vitro cell line conditions. Our 
results demonstrated that the presence of Cap/IRES and poly-A elements enables the 
translation of the encoded protein in cells. We also synthesized and delivered GFP and 
mazF mRNA into HEK293, MCF, AGS, and HT29 cell lines. mazF mRNA deficient for 
caps or Poly-As resulted in no induction of death in transfected cells. These results may 
suggest a synergy between the cap structure and poly-A tail on translation efficiency, a 
finding reported by various researchers [132-135]. This cooperation stems from mRNA 
circulation, where the cap-eIF4E-eIF4G-PABP-poly-A complex hampers the function of 
exonucleolytic nucleases in order to degrade mRNAs [95]. 
The 5′ ends of eukaryotic mRNAs contain a methylated m7GpppN cap structure 
that is crucial for mRNA splicing, stabilization, transport, and translation. In IVT reactions, 
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the cap structure is linked to the synthesized mRNA through an enzymatic reaction. 
However, this capping process caps either the 5′ side or both ends of the mRNA, rendering 
half of the synthesized mRNAs nonfunctional [95]. Recently, several cap analogues have 
been designed to optimize the capping process in in vitro conditions. One example of these 
cap analogs is the anti-reverse-cap analogue (ARCA), which contains a methylated 3’-OH 
group that forces ARCA to localize in the proper orientation [95]. 
Although the cap is a fundamental element in mRNA stability and translation, some 
viral and cellular mRNAs possess internal ribosome entry sites (IRES) that carry out their 
translation in a cap-independent manner. IRES sequences directly recruit ribosomes and 
start translation at either a non-AUG codon or an overlapping +1 frame gene [136]. The 
discovery of IRES has led to an exciting path in cancer therapy. This element enables 
researchers to design bicistronic, tricistronic, or tetracistronic operons encoding two or 
more genes under the control of a single promoter. Here, we recruited the IRES sequence 
from encephalomyocarditis virus (EMCV) RNA to synthesize uncapped mRNAs. We then 
compared the expression of capped and capped-independent mRNA in cell-culture 
systems. As mentioned previously, both IRES-mazF and capped mazF were expressed in 
the examined cell lines in a time-dependent manner. However, it appears that each cell line 
differs in expression of capped and IRES-dependent mRNAs, and AGS cells are more 
likely to express IRES-GFP than other cell lines. This indicates the probability that the type 
of mRNA and cell line has significant influences on the expression of capped and capped-
independent mRNAs. Our results of transfected IVT mRNA in cells concur with that of 
other research groups [126, 137, 138]. Avci-Adali et al. reported that, in spite of the high 
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transfection efficacy, human endothelial cells and BJ human foreskin fibroblasts express 
fewer copies of capped GFP proteins in comparison to HEK293 [126].  
Another problem that overshadows the advantages of the IVT mRNA technique is 
mRNA immunogenicity. Several investigations have indicated that certain innate immune 
receptors such as Toll-like receptors (TLR)3, TLR7, TLR8, and retinoic acid-inducible 
gene I (RIG-I) may be stimulated by exogenous RNA. The incorporation of modified 
nucleosides, e.g. pseudouridine or 2-thiouridine (s2U) in IVT mRNA, and the elimination 
of 5′ triphosphates from synthesized mRNA can suppress the activation of Toll-like 
receptors and RIG-I [126, 139]. Previous research showed that association of 
pseudouridine in mRNA structures significantly enhances the translation efficiency of the 
encoded proteins when compared to mRNAs possessing unmodified uridines [126, 140, 
141]. This difference stems from the diminished activity of protein kinase ribonuclease 
(PKR) in the presence of mRNAs that contain modified nucleotides [139]. It seems that 
pseudouridine has the ability to enhance stability and boost the expression of IVT mRNAs 
in comparison to other modified nucleotides [141]. Our results, however, slightly varied 
from those of previous studies. Our data showed that the presence of modified nucleotides 
in the IRES-GFP structure did not lead to an increased expression of encoded proteins in 
cells. Our data also highlighted the role of each cell line in the expression of IVT mRNAs 
containing either modified or non-modified nucleotides.  
As a part of their defense responses, eukaryotic and prokaryotic cells have the 
capability to degrade mRNA and subsequently suppress protein synthesis. For example, 
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when bacteria are exposed to harsh conditions (e.g. extreme amino acid starvation or 
antibiotic-blocked transcription or translation), they use MazF proteins to cleave mRNAs 
and therefore block protein synthesis [36]. In mammalian cells, some of the host antiviral 
responses that lead to inhibition of protein synthesis and eventually to induction of 
apoptosis in virus-infected cells include the interferon response, RNaseL-mediated 
degradation of 28S and 18S ribosomal RNAs, and the activation of protein kinase-R. 
However, cancer has a high addiction to protein synthesis that can be targeted by 
ribonuclease-based therapy [142]. We analyzed the impact of MazF proteins on inhibition 
of protein synthesis, which results in the induction of apoptosis in MCF7 and AGS cell 
lines. In this study, nascent protein synthesis was determined through measuring the 
incorporation of O-propargyl-puromycin (OPP) into newly synthesized proteins. Our 
observations confirmed that the overexpression of MazF leads to a drastic drop in the levels 
of protein translation in the examined cell lines. These results are consistent with the study 
conducted by Shimazu et al. which demonstrated that the level of protein synthesis was 
reduced in T-REx-293 cells 24 hours post transfection with MazF mRNA. In addition, our 
results suggested the reduction of protein synthesis mediated by MazF was cell line-
dependent.   
In mammals, the inhibition of protein synthesis leads to apoptosis and cell death, 
although the exact mechanisms remain unknown [143]. Here, our data illustrated that MazF 
not only stopped the proliferation of cells but also significantly reduced the number of 
living cells 18 to 24 hours post transfection in tested cell lines. In order to confirm the 
occurrence of apoptosis, the activation of caspase -3 and -7 and the presence of caspase 3’s 
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substrate was evaluated in transfected cells. Our observations suggested that in the presence 
of MazF, the level of caspase -3 and -7 significantly increased, and apoptosis took place in 
the cells. These data confirm the antiproliferative action and apoptotic ability of MazF in 
cancer cells. Interestingly, MazF was able to induce apoptosis in MCF7 cells that are 
supposedly apoptosis-resistant. These cells are deficient for caspase-3 and also are resistant 
to ionizing radiation (IR)-induced apoptosis [144]. Essman et al. demonstrated that the 
exposure of MC7 to methylxanthine caffeine and the staurosporine analogue UCN-01 did 
not lead to the activation of the initiator caspase -9, and the cells then remained resistant to 
apoptosis [144]. Therefore, according to our results, MazF may serve as a suitable 
therapeutic candidate against MCF7. As we have demonstrated, MazF successfully 
induced death in AGS and HT29 cell lines. These cell lines have been reported to possess 
long non-coding RNA GACAT1 (lncGACAT1) and long non-coding RNA (lncRNA) 
Gas5, respectively, that stimulate cell proliferation and invasion [145, 146]. These non-
coding RNAs contain several ACA sites in their sequences that potentially make the non-
coding RNAs more vulnerable to the action of MazF.  
In conclusion, we described the use of MazF, a bacterial ribonuclease, to induce 
apoptosis in three different cell lines. We also investigated the influence of IRES, a cap 
structure,  and the incorporation of modified nucleotides on the expression of the encoded 
protein. Our results showed that although cell lines have a varying preference for 
translation of the delivered mRNAs, the delivered mazF mRNA was expressed, and the 
MazF protein was able to inhibit de novo protein translation. Thus, it seems MazF has a 
great potential to serve as a therapeutic agent for cancer therapies.  
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CHAPTER FOUR  
4. Listeria monocytogenes-Mediated Delivery of mazF mRNA into 
Cancer Cells 
Introduction 
Gene Delivery and Vectors 
Gene therapy is described as the delivery of genetic information to cells intended 
to treat or alleviate a patient’s disease by synthesizing a therapeutic protein or genetically 
engineering the cells [147]. For this purpose, genetic materials including genes, gene 
segments, or oligonucleotides are transferred into patient cells through in vivo or ex vivo 
methods. In vivo practice, cells inside the body are directly targeted by a gene delivery 
system such as intradermal injection or intravesical therapy. While in ex vivo approaches, 
the expelled cells from tumors are genetically modified at a controlled microenvironment 
and then transplanted to the patient [148].  
Deactivation of oncogeneses or replacement of defective tumor suppressor genes 
have always been a challenge in cancer therapy. Delivery of transgenes into target cells has 
opened a new door to change or modify malfunctioning genes or phenotypes of cells 
transiently or permanently. In gene therapy, normal cells, cancerous cells, immune-
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mediated cells, or pluripotent stem cells can be a host for transgenes. Once transferred 
inside cells, the delivered transgenes induce death in cancer cells or correct their cellular 
functions while protecting normal cells from drug-induced toxicities or activating immune 
cells to eliminate cancer cells [148]. However, the success of gene therapy relies on the 
specificity of vectors to deliver DNA or RNA constructs into tumor cells or normal cells. 
In the past, several non-biological (chemical and physical methods of introducing plasmid 
DNA to mammalian cells) and biological (viruses and bacteria) approaches have been 
applied against cancer cells [123, 149-151]. 
The advent of recombinant DNA technology, the advances in the design of gene 
delivery systems, and the accumulation of knowledge on the genetic basis of many diseases 
paved the way for the emergence of gene therapy against cancer. In 1990, the first gene 
therapy trial was conducted against severe combined immunodeficiency disorder in a 
patient. In spite of many disappointments, challenges, and barriers, several successful 
clinical trials and the production of many innovative genetic medicines have strengthened 
the evidence for the effectiveness of gene therapy in treating serious diseases such as cancer 
[2,3].  
Gene therapy approaches halt or prevent a pathological process through gene 
addition, gene correction/alteration, or a gene silencing process [152]. Gene addition is 
applied to introduce a therapeutic protein into deficient cells, while gene 
correction/alteration is used to modulate genomic sequences to correct inoperative genes. 
Gene knockdown inhibits or downregulates gene expression or translation by RNA 
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interference systems or micro RNA (miRNA)-mediated gene systems. Other nucleic-acid- 
based tools such as RNA aptamers, upregulating small RNAs, and non-coding genes for 
protein functional modifications have recently synched to gene therapy attempts [152].  
In spite of spectacular advances in designing vector systems, gene delivery is still 
confronted with numerous obstacles. One of the main barriers is the accessibility of vectors 
to the target sites. Host parameters such as vascular supply and endothelial barriers and 
features of vectors, e.g. size, their ligands, and mechanisms of vector uptakes and toxicity 
of vectors, affect the distribution of vectors in targets. When endosomes and nuclear 
membranes are the most common impediments for success of non-viral vectors, instability 
and the massive size of viral vectors have remained hurdles for viruses to translocate from 
the cytoplasm to the nucleus. The cell division rate can influence the existence of vectors 
in targets. Episomal vectors only survive in quiescent tissues, such as brain, heart or, liver, 
while these vectors will be diminished in rapid turnover cells such as hematopoietic cells. 
Although they survive longer in dividing cells, integrational vectors might stimulate 
mutations in adjoining genes. Additionally, the integrity of vectors and transgene products 
can be hindered by the host immune response [152].  
Transgenes can be exploited for therapeutic and potentially preventive purposes for 
many diseases. However, instability and the non-specific nature of transgenes and low 
delivery efficacy have raised doubts on the feasibility of the direct delivery of transgenes. 
While advances in nucleic acid modifications can increase the half-life of transgenes, the 
low specificity and cellular uptake efficiency remain important challenges in transferring 
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naked transgenes. The advent of gene delivery vehicles (GDV) has overcome some of these 
limitations and also protected the delivered materials from the host immune systems [153]. 
GDV are traditionally categorized into two groups, i.e., non-biological and biological 
vectors. Non-biological vectors are defined as DNA plasmids that can be directly 
transferred to the targets or in association with chemical or physical delivery systems. The 
safety profile and economic advantages, e.g. cost-effectiveness and ease of production, of 
non-biological vectors have enabled them to be potential suitable vectors in gene therapy. 
However, the low delivery efficacy and specificity and perseverance of non-biological 
vectors have cast a shadow over their advantages for several years [154]. Recently, the 
advances in improvement of delivery efficacy have led to growing inclinations to employ 
non-biological vectors in clinical trials. These vectors are generally suitable for delivery of 
oligodeoxynucleotides or related molecules synthesized chemically, plasmid DNA, 
ribozymes, siRNA, and mRNA into a target. Non-biological vectors can be divided 
traditionally into two main groups: physical delivery systems such as a needle, ballistic 
DNA, electroporation, sonoporation, photoporation, magnetofection, and hydroporation; 
and chemical systems, e.g. calcium phosphate, cationic lipids, and lipid nanoemulsions 
[154].  
Biological liposomes, which are able to evade immune systems, are one of the non-
biological vectors extracted from human cells. However, technical limitations such as 
difficulties in harvest time and maintaining the resource cells have obstructed the liposome 
applications in gene therapy [154].  
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Biological vectors contain a range of microorganisms with abilities to infect host 
cells and to escape or be tolerated by immune systems, phagocytic cells, and exosomes 
[153]. The ideal features of GDV biological vectors include possessing appropriate 
capacities for their payload, ability to escape from host immune systems, target specificity, 
and high delivery efficacy. However, each biological vector is deficient in one or some of 
the aforementioned ideal criterions. For example, constraints of packaging size, host range, 
mutagenicity, inflammatory toxicity, and being recognized by immune systems are the 
most common limitations of viral vehicles as the conventional biological GDVs. Advances 
in DNA technology have already resolved some of these limitations. Insertion of a 
heterologous protein on viral vectors leads to the diversity of their host ranges. Genetic 
modifications on viral capsids and usage of tissue-specific promoters and enhancers might 
boost the specificity of viral vehicles and their expression profiles. However, toxicity and 
the stability of gene expression remain the greater challenges in the usage of viral vehicles 
[155]. 
Viral vectors are classified into two groups: integrating vectors, e.g. gamma-
retroviral vectors, and lentiviral vectors, and non-integrating vectors such as adenoviral 
vectors and adeno-associated virus (AAV). Compared to wild types, the modified 
adenoviruses have higher tendencies to transduce dividing and non-dividing cells and 
replicate in target sites. Adenoviruses also offer other advantages, such as the ease of large-
scale production and their abilities to carry drug or pro-drug genes. However, the 
application of adenoviral vehicles has been shadowed by their capabilities to destabilize 
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the carried gene, stimulate chromosomal aberration in host cells, and induce inflammatory 
reactions [155, 156].  
Lentiviruses contain a group of viruses with long incubation periods and persistent 
infections in humans or animals. Lentiviruses have been under various genetic 
modifications to develop integration-deficient lentiviruses, enhance the safety profiles of 
these vectors, transduce both dividing and non-dividing cells, and possess low antivirus 
immunity and low potential for genotoxicity. However, thesis non-pathogen vectors can be 
transformed into a pathogenic virus such as HIV, especially in immunocompromised 
individuals. The integrational nature of these vectors might increase the risk of cancer or 
secondary malignancy [148].  
Current advances in viral vaccines and vehicle designs have resulted in the advent 
of virus-like particles (VLP) as a new class of vector. VLPs contain viral structural 
proteins, while the pathogenic genes are excluded. In contrast to viral vehicles, VLPs can 
be produced in yeast, insect, or mammalian cells and subjugated to harsher purification 
processes. Thus, VLPs are more cost-effective and purer vehicles in comparison to viruses. 
These particles can also be assembled for unusual payloads, such as modified small 
interfering RNAs, with the high efficacy of transduction in vitro [5, 6]. However, the low 
yield of functional VLPs and their complicated disassembly and reassembly processes have 
limited their delivery applications in clinical tests. Initially, VLPs have been created to 
substitute the attenuated viruses in vaccinations. This immunostimulation nature of VLPs 
caused them to not be continuously administrated. The immune response against the VLP 
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can clear the delivered transgenes or inhibit their functions. Thus, further attempts are 
required to resolve the limitations of these newly developed GDVs [153].  
Bacteriophages, as the bacterial pathogens, can be suitable vehicles in gene therapy. 
These viruses are able to survive in a broad range of pH, from 3 to 11, for up to 24 hours 
and against nonenzymic degradation. Unlike viruses, bacteriophages contain an extensive 
packaging capacity, making them suitable candidates for delivery of mammalian plasmids 
or various regions for transgenes. The ease of engineering bacteriophage coat proteins leads 
to the enhancement of the safety profile of this GDV and identifies target proteins or 
peptides on target surfaces. However, the unmodified bacteriophage particles can be easily 
cleared by the reticuloendothelial system (RES) and degraded in the liver, spleen, and lungs 
[153]. Similar to VLPs, the intrinsic immunogenic nature of bacteriophages constrains the 
re-administration of vehicles, resulting in poor transfer of the transgenes into the target 
sites [153].  
In general, the advantages and disadvantages of each vector determine its potential 
applications in cancer treatment. For example, the non-biological vectors, despite their high 
safety profile and low cost, have a poor clinical efficacy in comparison to biological vectors 
[157, 158]. Due to their natural life cycle and pathogenicity, viruses serve as very efficient 
delivery vehicles in gene therapy. However, the use of these vectors in clinical trials is 
hampered by difficulties in production, size restrictions on transgenes in some viral vectors, 
anti-vector immunologic responses, the lack of viral receptors in some cancer cells, and 
induction of inflammatory reactions [150, 158]. 
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Bacteria have unique capabilities that allow them to offer more advantages than 
other vectors. Bacterial vectors can be easily engineered to be tractable and to selectively 
target tumors that could be difficult or even impossible for other kinds of vectors to target 
[51]. In addition, bacteria have chemotactic receptors that can sense external signals from 
the local environment and then propel the bacteria to targets. For example, Salmonella 
typhimurium, which possesses a TAR receptor, is able to detect aspartate secreted by viable 
cancer cells while its ribose/galactose receptor directs the bacteria toward necrosis of 
cancer tumors [46]. Bacterial vectors can carry and transfer toxic molecules into tumor 
regions that are inaccessible to passive therapies e.g. chemotherapy. These vectors can also 
provide clues about the state of the tumor, the success of localization, and the efficacy of 
treatment. When combined, these characteristics help cancer therapists to administer 
treatments at the right time and location [51].  
Today, several strains of bacteria such as Clostridia [159], Bifidobacterium [160], 
Salmonella [161], Listeria [68], Escherichia [162], Caulobacter [163], Proteus [164], and 
Streptococcus [165] have been reported to exclusively accumulate in tumors. As a result, 
many bacterial therapeutic strategies, e.g. bacterial replication in tumors, intracellular 
plasmid transfer (bactofection), native bacterial toxicity, and combinations of other 
therapies and alternative gene therapy (AGT), have been suggested as a treatment against 
cancer [51, 150, 166, 167].  
In AGT, bacteria remain in target tissues and produce the therapeutic polypeptide 
in situ. This feature of AGT makes possible the negative regulation of gene expression 
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through antibiotics or suicide genes. In turn, this negative regulation can lead to increased 
safety in AGT delivery when compared to bactofection [166]. In bactofection, eukaryotic 
host cells are responsible for expression of the desired genes, while in AGT, bacteria are 
responsible for expressing the gene of interest. Thus, while bactofection and AGT share 
some characteristics such as transporting bacteria in the organism, the main difference 
between the two therapies arises in the expression of the therapeutic genes. The overall 
advantages of AGT, e.g. easy and safe delivery, convinced us to apply this approach to 
deliver mazF mRNA into cancer cells [166]. 
In this project, we intended to enhance the safety profiles of the attenuated L. 
monocytogenes strain with deleted internalin A and B (Inl AB)-expressing SPA [72] by 
transferring a plasmid carrying the self-destructing L. monocytogenes lysin gene from 
phage A118 (ply 118), which initiates suicide once inside the cancer cells. 
Experimental Section 
General Microbiology Technique 
Listeria monocytogenes EGDe, an internalin A/B-deficient strain, was cultured in 
Brain Heart Infusion broth (BHI) at 37°C. In order to induce prfA-regulated genes in vitro, 
the culture broth was supplemented with 1% Ameberlite XAD prior to autoclavation [168]. 
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Construction of a T7 Expression System for mazF mRNA 
Overlap Extension PCR Cloning 
The ACA-less mazF was inserted under the control of a T7 promoter in pCNB1 
(Figure 4.1) through overlap extension PCR. For this purpose, mazF and pCNB1 were 
considered as two PCR fragments that should be ligated into a circular DNA. Hence, the 
designed primers for both vector and insert shared an overlap sequence to assemble the 
adjacent fragments. mazF fragments were amplified by using the forward primer (CZF) 
and reverse primer (CZR), and pCNB1 was linearized by applying the forward primer 
(CVF) and reverse primer (CVR). The PCR products were generated by using Q5® High-
Fidelity DNA Polymerase (New England Biolabs Inc., USA), and the amplification 
reactions were assembled according to the company’s manual ( 
Table 4.2 and Table 4.3). To eliminate the plasmid templates, the PCR products were 
digested with DpnI (New England Biolabs Inc., USA). DpnI has the ability to exclusively 
digest E. coli Dam methylase-methylated plasmid DNA, but non-methylated PCR products 
will remain intact. The DpnI digestion reaction was prepared by mixing 5-8 μl of a PCR 
product with 1 μl of 10X CutSmart™ Buffer and 1 μl (20 units) of DpnI. The reaction was 
incubated at 37°C for 30 minutes, followed by heat-inactivation of DpnI at 80°C for 20 
minutes. The digested product was used for the NEBuilder HiFi DNA Assembly protocol 
(Table 4.4). The assembled reaction was incubated at 50°C for 1 hour, and the product was 
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then electroporated into E. coli DH10B competent cells. The transformed colonies were 
purified and used for the purpose of plasmid extraction. 
Table 4.1. List of primers for insertion of mazF fragment in pCNB1 
Primers Sequence Application 
CZF 5’-ATGATAATATGGCCACAACCATGGTAAGCCGATACGT-3’ Amplification of 
mazF gene 
fragment for 
construction of 
pCNB-mazF   
CZR 5’-
CTAGTATGCATGCGGCCGCTTCACCCAATCAGTACGTTAATTTTGGCT-
3’ 
CVF 5’-GGTACGTATCGGCTTACCATGGTTGTGGCCATATTATCA-3’ Amplification of 
pCNB1 for 
construction of 
pCNB-mazF   
CVR 5’-
CTAGTATGCATGCGGCCGCTTCACCCAATCAGTACGTTAATTTTGGCT-
3. 
 
Table 4.2. Q5® High-Fidelity DNA Polymerase PCR reaction assembly (New England Biolabs Inc., USA) 
Component 50 µl reaction Final concentration 
5X Q5 -Reaction Buffer 10 µl 1X 
10 mM dNTPs 1 µl 200 µM 
10 µM Forward Primer 2.5 µl 0.5 µM 
10 µM Reverse Primer 2.5 µl 0.5 µM 
Template DNA variable < 1,000 ng 
Q5 High-Fidelity DNA Polymerase 0.5 µl 0.02 U/µl 
Nuclease-Free Water to 50 µl  
 
Table 4.3. Q5® High-Fidelity DNA Polymerase PCR protocol (New England Biolabs Inc., USA) 
Cycling Temperature Duration Cycles 
Initial Denaturation 98°C 30 Seconds  
Cyclic Denaturation 98°C 10 Seconds  
30 cycles 
Annealing 50-72°C 25 seconds 
Extension 72°C 20-30 seconds/kb 
Final extension 72°C 2 minutes  
 
Table 4.4. HIFI DNA assembly instruction (New England Biolabs Inc., USA). 
Component  20 µl assembly reaction 
Recommended DNA Molar Ratio vector: insert = 1:2 
Total amount of fragments  0.03–0.2 pmols 
NEBuilder HiFi DNA Assembly Master Mix 10 µl 
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Deionized H2O 10-X µl 
 
The extracted plasmid was subjected to sequence verification. Finally, the 
generated plasmid was named pCNB-mazF. 
pCNB-mazF contains a tetracycline resistance gene as a selectable marker. However, L. 
monocytogenes as the final host of this plasmid carries the same antibiotic marker. 
Therefore, the tetracycline resistance gene was substituted with a kanamycin resistance 
gene through overlap extension PCR cloning. For this purpose, a kanamycin gene fragment 
was amplified from pIMAK by using forward (Kan-F) and reverse (Kan-R), and the 
pCNB1-mazF fragment was produced by forward primer (NBZ1-F) and reverse primer 
(NBZ1-R) ( 
Table 4.5). The PCR and HIFI DNA assembly reaction were performed according to the 
above description. The final construct was named pCNB-mz-Kn. As explained before, the 
modified plasmids ultimately were electroporated into E. coli Dh10B. 
Table 4.5. List of primers for insertion of Kan fragments in pCNB1-mazF 
Primers Sequence Application 
Kan-F 5’-GCATTCGTCTCGTTACGCATTATAAA 
CCCAGCGAACCATTTGAGGTGATAGG-3’ 
Amplification of 
kanamycin gene 
fragment Kan -R 5’GCTGACGGTAACCATAATGAGACAGAATTATGATG 
ATCATATGAAACATCAGAGTATGG-3’ 
NZB1-F 5’-CTGGGTTTATGATGTATTCACATTTCACCCTCCAATAATGAGG-3’ Amplification of 
pCNBZ-1 for 
construction of pCNB-
mz-Kn  
NZB1-R 5’-TGTCTCATTATATCGTTAAGGGATCAACTTTGGGAGAG-3’ 
Preparation of Competent Cells from Listeria monocytogenes (Lm) 
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Lm competent cells were prepared by following the protocol previously described 
[169]. Lm strains EGDe were cultured in 50 ml BHI overnight at 37 ºC. The culture was 
then diluted 1:100 in 500 ml of BHI supplemented with 500 mM of sucrose. At this point, 
the optical density at 600 nm (OD600) was in the 0.01 to 0.02 range. The diluted culture 
was re-incubated at 37ºC and 250 rpm until OD600 reached 0.2 to 0.25. Consequently, the 
culture was cured with 10 μg/ml of freshly prepared ampicillin and incubated for another 
2 hours to double the cell population. The culture was then placed on ice for 10 minutes, 
followed by centrifugation at 5,000 ×g for 10 min at 4°C. The cell pellet was then washed 
by ice-cold sucrose-glycerol wash buffer (SGWB) (10% glycerol, 500 mM sucrose; pH 
adjusted to 7 with 100 mM NaOH; filtersterilized) three times. Subsequently, 10 μg/ml of 
filter-sterilized lysozyme (40,000 to 45,000 U per mg; hen egg white; crystallized three 
times; Sigma) was added to the cells and incubated at 37°C for 20 min. The Cells were 
pelleted at 3,000 ×g for 10 min at 4°C and washed by SGWB. The final pellets were 
dissolved in the same buffer and dispensed into 50 μl centrifuge tubes. The competent cells 
were stored at −80°C [169].  
Electroporation of Lm cells 
The electrotransformation of Lm was performed by following the protocols previously 
described [169]. A 50-μl aliquot of electrocompetent cells was incubated with 1μg of 
plasmids and placed on ice for 5 minutes. The contents were pipetted to a chilled 1-mm 
electroporation cuvette (Bio-Rad) and electroporated at 10 kV/cm, 400 Ω, 25 μF, and 7 
minutes time constant. Immediately, 1ml of room temperature BHI+500 mM sucrose was 
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added to the cuvette. The cells were incubated at 30°C for 1.5 h and cultured on BHI agar 
possessing antibiotics [169]. 
Functionalization of Bacterial Cells with Anti-HER Antibodies 
The Lm functionalization was performed by following the protocols previously 
described [168], with several modifications in preparation and concentration of cells. Lm 
cells were cultured in 20 ml BHI overnight at 37ºC. The culture was then centrifuged at 
5000 ×g for 10 minutes at 4°C. The pellet was washed twice and re-suspended in PBS 
(pH=7). The optical density at 600 nm (OD600) of bacteria and cell numbers were measured 
by using a BioRAD spectrophotometer. Bacterial cells were diluted in PBS for a final 
concentration of 109 cells in 100 μl PBS, and the contents were inoculated with 4-5 μg of 
antibody for 1 hour at 23°C under vigorous shaking (500 rpm). Afterward, 900 μl PBS was 
added to the bacterial cells, and the contents were centrifuged at 16000 ×g for 2 minutes. 
The supernatant was discarded, and the bacterial cells were resuspended in 1 ml PBS. 
In this project, Human ErbB2/Her2 Alexa Fluor® 488-conjugated Antibody (R&D 
systems, USA) and Anti-HER2 (Trastuzumab) Humanized Antibody (Bio Vision, USA) 
were used to functionalize Lm cells. Mouse IgG2 Alexa Fluor® 488-conjugated isotype 
control (R&D system, USA) was used as the negative control in the experiments.  
 To confirm the presence of SPA, the bacterial cells coated with Human 
ErbB2/Her2 Alexa Fluor® 488-conjugated Antibody (R&D systems, USA) were 
visualized under immunofluorescent microscopy.  
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Eukaryotic Cell Culture 
Human gland/breast SKBR3 (ATCC® HTB-30™) adenocarcinoma and mouse 
gland T41 carcinoma (provided by Dr. Rice’s lab, Clemson University) were cultured in 
DMEM/F12 medium (ThermoFischer Scientific, USA) and maintained at cultural 
conditions. The media were supplemented with 15% FCS. Cells were passaged at 80-90% 
confluency at 1:2 to 1:6 ratios. T41 cells were cultured in McCoy’s medium containing 
10% FCS and then placed at 37°C under 5% CO2 atmosphere. 
Immunofluorescence Staining 
The cell staining procedure was performed based on R&D system’s suggested 
protocol with few optimizations in the buffer amounts and incubation time. At least 16 
hours prior to infection, cells were seeded in an 8-well chamber slide at 8x104 cells per 
well. When cells reached 60-70% confluency, wells were washed with wash buffer. The 
cells were incubated with 200 µL Donkey serum, the blocking buffer, for 45-60 minutes at 
room temperature to block non-specific interactions with antibodies. The blocking buffer 
was then discarded, and the cells were incubated with 5 µg of Alexa Fluor® 488-
conjugated Antibody (R&D systems) at room temperature for 1 hour. Cells were 
consequently washed twice in 200 µl of wash buffer and visualized under the fluorescence 
microscope. 
The infection of cancer cells with Lm was performed as previously described with 
some modifications [168]. With at least 16 hours of preincubation, SKBR3 and 4T1 cells 
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were seeded at 3x105 cells/well in 12-well plates. First, each well was washed with 1ml 
serum-free medium followed by the addition of bacteria in the same medium. The infection 
step was performed for 1 hour at culture condition. Furthermore, the medium containing 
bacteria was substituted with 1 ml fresh culture medium supplemented with 100 µg/ml 
gentamicin, and cells were incubated with the antibiotic for 1 hour at 37°C.  
To evaluate the number of internalized bacteria at the early invasive stage, 
eukaryotic cells were washed five times with PBS and then lysed with 0.1% triton X-100. 
The lysed cells were collected from each well and used to prepare serial dilutions. Each 
dilution was plated in triplicate on BHI agar plates.  
To determine the delivery of mazF mRNA to cells by Lm, DEME/F12 containing 
100 µg/ml gentamicin was replaced by the same medium containing 10 µg/ml gentamicin. 
The cells were then maintained at 37°C under 5% CO2 for 5 days.  
Delivery of mazF mRNAs into HER-Positive Cells by Lm Cells 
As discussed in Chapter 5, MazF proteins induce cell death in eukaryotic cells. 
Hence, the viability assay and the presence of activated caspases were used as the indirect 
evidence of delivery of mazF mRNA into cancer cells. Eukaryotic cells and the Lm cells 
were prepared as described above. Consequent to 1hour post infection, cells from each well 
were trypsinized and dispensed into 96-well plates at 2.5x104 cells/ml. To eliminate non-
internalized bacteria, 10 µg/ml gentamycin was added into each well. The viability of 
eukaryotic cells was analyzed using MTT assay (Promega, USA) in accordance with the 
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manufacture’s protocol. For this assay, the medium was removed from each well, and the 
cells were washed with PBS once. The next step was the addition of 100 µl of MTT 
solution, followed by incubating the plate at 37°C under 5% CO2 for 2-4 hours. The 
viability of cells was determined based on the absorption of the reagent at 490 nm. The 
caspase activity was evaluated by caspase -3 and -7 assay (Promega, USA) according to 
the manufacturer’s instructions.  
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Results 
Construction of a T7 Transcription System for mazF mRNA in                         
L. monocytogenes 
The ability of cancer cells to develop adaptation against various molecular 
treatments such as DNA has remained the biggest obstacle in cancer therapy. However, 
transient delivery of mRNAs has been a promising approach to treat cancer with a low 
chance of resistance. It has been shown that L. monocytogenes, as a vector, has a great 
potential to deliver therapeutic mRNAs into cellular cytosols that stems from the L. 
monocytogenes’ ability to escape from the vacuoles and enter the cytosol where the 
therapeutic mRNAs can be released from vectors and expressed in the cells [63]. Schoen 
et al. designed a T7 expression plasmid system for GFP mRNAs delivery by L. 
monocytogenes in Caco-2 cells [63]. This system contains two plasmids: pCSA1 and 
pCSB1. In this research, pCSB1 was genetically engineered to generate mazF mRNA and 
used to transfer mRNAs to SKBR-3, a breast cancer cell line overexpressing HER. The 
constructs are explained in detail below. 
Plasmid pCSA1: Plasmid pCSA1 carries the T7 RNA polymerase gene (polT7) and the 
lysin gene from phage A118 (ply 118) under the control of a listerial promoter, actA 
promoter (PactA). For maintenance and expression purposes, this plasmid is equipped with 
two sets of replication origins from Gram-positive bacteria (repD and repE) and Gram- 
negative bacteria (oriE1). In addition, the erythromycin resistance gene and the gene for 
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the tryptophanyl-tRNA synthetase (trpS) in the plasmid secure the presence of the plasmid 
in cells [63] (Figure 4.1) . 
 
Figure 4.1. pCSA1 map. pCSA1 carries the T7 polymerase gene and suicide gene 
Plasmid pCSB-mazF-kan: This plasmid is supplied with the origin of replications 
for Gram-positive bacteria (repU) from plasmid pBC16 and for Gram-negative bacteria 
(colE1). This plasmid carries a mutated variant of the bacteriophage T7 promoter f10 
(PT7), followed by a transcriptional terminator (TT7). Since mRNAs generated by bacteria 
are cap- and poly-A -less, the internal ribosomal entry site of the encephalomyocarditis 
virus (IRES EMCV) was placed downstream of T7 promoter [63].  
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In this research, an ACA-less mazF fragment from pBApo (Takara Bio., USA) was 
placed downstream of the IRES on pCSB1 vector through the overlapping PCR technique. 
For this purpose, two sets of primers were designed to amplify the ACA-less mazF 
fragment and pCSB1 with appropriate overlaps. The construct was assembled by NEB 
DNA Polymerases ligating the insert and the vector together. Since the L. monocytogenes 
strain used in this study is already resistant to tetracycline, this antibiotic marker was 
replaced by a kanamycin gene through overlapping PCR as explained above (Figure 4.2). 
The genetic modifications of pCNB-mz-Kn were conducted in E. coli DH10 B host, and 
the final construct and pCSA1 were electroporated into L. monocytogenes. 
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Figure 4.2. pCNB-mz-kn, carries mazF gene under the control of T7 promoter 
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Interaction of Protein A with Anti-HER Antibodies for Bacterial Coating  
To generate and deliver mazF mRNA into cancer cells, an attenuated L. 
monocytogenes lacking internalin A and B was recruited. This strain was engineered to 
express cell wall-anchored S. aureus protein A (SPA). The functionalization of bacteria 
occurs through binding of the Fc fragment of antibodies to protein A anchored on L. 
monocytogenes cell walls [168]. As described by Hesig et al., the SPA gene is placed under 
the control of listeriolysin (hly) promoter (Phly). This gene contains the sequence of all five 
Fc binding domains and the LPXTG motif for sortase-dependent anchoring of the SPA 
protein to peptidoglycan. The genotype of this attenuated strain is ΔtrpS, 
aroA,inlA/B,int::Phly-spa × pFlo-trpS and termed Lm-spa+. The Lm-spa- strain has the 
identical genotype (ΔtrpS, aroA,inlA/B,int::Phly-spa × pFlo-trpS) to Lm-spa+ [168], 
except that it does not carry the SPA gene, and this strain was used as the negative control 
in this research.  
The functionalized SPA-mediated Lm-spa+ cells with antibodies were evaluated 
by immunofluorescence microscopy. For this purpose, 1x109 CFU/ml of Lm-spa+ or Lm-
spa- cells were incubated with 4 μg of human ErbB2/HER2 Alexa Fluor 488-conjugated 
antibody for 1 hour at 23C under vigorous shaking. Subsequently, the bacterial cells were 
washed with PBS, and unbonded antibodies were removed. As shown in Figure 4.3, Lm-
spa+ strains generated strong fluorescence signals, while Lm-spa- was not detectable under 
the immunofluorescence microscopy. Therefore, the comparison of Lm-spa+ and Lm-spa- 
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strains implies that Lm-spa+ produce SPA on their cells, and also the bacterial cells can be 
efficiently functionalized with antibodies. 
 
a. Lm-spa+     b. Lm-spa- 
Figure 4.3. The functionalized Lm-spa+ and Lm-spa- with human ErbB2/HER2 Alexa Fluor 488-
conjugated antibody. a) Lm-spa+, and b) Lm-spa- 
Immunolabeling of SKBR3 Cells with Anti-HER 2 Antibodies 
The overexpression of human epidermal growth factor receptor 2 (HER2) is one of 
the important biomarkers in several aggressive human cancers, such as stomach, ovary, 
uterine serous endometrial carcinoma, colon, bladder, lung, uterine cervix, head and neck, 
and esophagus. This receptor has been reported to be overexpressed in 15-30% of invasive 
breast cancers. SKBR3 is a breast cancer cell line overexpressing HER2 that is derived 
from mammary gland/breast and metastatic site (ATCC website). To analyze this 
morphological feature of SKBR3 cells, 8x104 cells were seeded in a chamber slide 24 hours 
prior to the immunolabeling process. The cells were incubated with human ErbB2/Her2 
Alexa Fluor 488-conjugated Antibody for one hour at cultural condition. Subsequent to 
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removing unbound antibodies, the cells were visualized under the immunofluorescence 
microscopy (Figure 4.4). As the results showed, SKBR3 cells overexpressed HER2 
receptors with high affinity to the ErbB2/Her2 antibody.  
 
a. SKBR3 labeled with ErbB2/HER2 
Alexa Fluor® 488-conjugated Antibody 
 
b. SKBR3 labeled with Mouse IgG2 
Alexa Fluor® 488-conjugated isotype control 
Figure 4.4. Immunofluorescence staining SKBR3 cells with an anti-HER antibody 
 
Internalization of Anti-HER Functionalized Lm Cells into Eukaryotic Cells 
in Vitro  
Invasion and internalization of L. monocytogenes into non-phagocytic mammalian 
cells are mediated by two surface proteins known as InlA and InlB. The deletion of inlAB 
has been reported to drastically attenuate listerial entry into the non-phagocytic hosts. Lm-
spa+ is an attenuated L. monocytogenes strain that is inlAB deficient. However, it has been 
shown that the internalization of this strain can be restored through antibody-mediated cell 
targeting approaches [170]. When this attenuated strain enters the cells, it shows an 
 
 117 
identical behavior to the wildtype to escape the vacuole and replicate in the cytosol [168]. 
In this study, Lm-spa+ was recruited to deliver mazF mRNA exclusively into cancer cells. 
For improving the efficiency of this delivery system, antibody-mediated targeting was 
optimized and discussed below.  
The Impact of Bacterial Density on Antibody-Mediated Internalization 
The impact of bacterial density on antibody-mediated targeting was analyzed by 
inoculation of SKBR3 cells with different bacterial concentrations in vitro. For this 
purpose, 3x105 cells/well were seeded in 12-well plates for 48 hours. Consequently, the 
cells were infected with the functionalized Lm-spa+ at 10, 50, 100, and 200 MOI 
(Multiplicity of Infection), i.e., the bacteria to SKBR3 ratio, for 1 hour. Non-coated Lm-
spa+ was used as the negative control to confirm that the internalization of bacterial cells 
was indeed mediated by anti-HER antibodies. To remove the exterior bacterial cells, the 
infected cells were washed 5 times with PBS and then subjected to a lysing process. The 
lysate was plated on BHI plates and the CFU/ml was calculated for each MOI (Figure 4.5). 
As exhibited in Figure 5, the increment of bacterial density leads to an increase in the 
bacterial internalization in an antibody-independent manner. According to the CFU/ml 
value, the infection of cells with an MOI of 100 had the highest internalization compared 
to the non-coated bacteria. The antibody-meditated internalization rate of bacteria was 
calculated by dividing the amount of coated by the amount of non-coated bacteria, as 
previously described by Heisig [171]. Our results indicated that applying an MOI of 400 
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led to a drastically reduced infection rate. Thus, an MOI of 100 was applied for subsequent 
experiments.
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a) CFU/ml value  
 
b) Relative to non-coated bacteria value 
Figure 4.5. Infection of SKBR3 cells with various concentrations of functionalized bacteria. The difference 
was considered as statistically significant if P< 0.05 ( ). NS: Not Significant.  
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To validate the specificity of antibody-mediated of targeting cells, the Lm-spa+ 
cells coated with Human ErbB2/Her2 Alexa Fluor® 488-conjugated Antibody (R&D 
system, USA) was used to infect SKBR3 cells. Lm-spa+ cells coated with Mouse IgG2 
Alexa Fluor® 488-conjugated isotype (R&D system, USA) was used as a negative control. 
Subsequent to infection of SKBR3 cells with coated bacteria cells, cancer cells were lysed 
in Triton 10X and plated in BHI medium. As shown in Figure 4.6, the density of 
internalized bacteria in SKBR3 was almost two logs higher in comparison to the negative 
control. However, it was observed that the bacteria coated with Human ErbB2/HER2 
Alexa Fluor® 488-conjugated antibody were able to enter 4T1 cells. Therefore, in 
subsequent experiments, bacteria were only coated with Anti-HER2 (Trastuzumab) 
Humanized Antibody (Bio Vision, USA). 
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Figure 4.6. The infection of SKBR3 with Lm cells coated with Human ErbB2/HER2 Alexa Fluor® 488-
conjugated. Bacterial cells with Mouse IgG2 were used as the negative control. 
The Lm-spa+ cells coated with Anti-HER2 (Trastuzumab) Humanized Antibody 
were utilized to infect 4T1, the mouse mammary gland cells, and SKBR3, the breast cancer 
cells, in vitro. In contrast to SKBR3, 4T1 cells are known as HER negative cells and were 
used as the negative control in these experiments. The cell lines were inoculated with 100 
MOI Lm-spa+ for 1 hour post infection. The CFUs/ml of the internalized bacteria are 
depicted in Figure 4.7.  
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Figure 4.7. The infection of HER positive and negative cell lines with Lm-spa
+
 in vitro.  
According to Figure 4.7, the internalization of Lm-spa+ into cells follows antibody-
dependent manners. In contrast to 4T1 cells, the internalization of bacteria increased 
approximately 1000-fold in SKBR3 cells.  
These results are consistent with Heisig’s findings, which indicates that the 
internalization of Lm-spa+ depends on the functionalization of bacterial cells with 
antibodies that correspond to specific receptors on host cells (Heisig, 2009).  
Toxicity of the Bacterial Vectors in SKBR3 Cells 
In the current project, Lm-spa+ was employed to specifically deliver mazF mRNA 
into cancer cells. Lm-spa+ was equipped with a suicide gene which destroys the bacterial 
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cells in the host cytosols. As discussed in previous sections, the MazF protein has a great 
potential to induce death in transfected cells. To contribute the induced cell death 
exclusively to the translation of the delivered mazF mRNA, the influence of the vector 
harbouring pCSA1 on cell viability was investigated in vitro (Figure 4.8). According to our 
results, the Lm-spa+ strain as the vector does not show a significant impact on cell viability. 
 
Figure 4.8. The influence of coated bacteria on cell viability. The difference was considered as statistically 
significant if P< 0.05 ( ). NS: Not Significant.  
 
Bacterial-Mediated Delivery of mazF mRNA into SKBR3 
Induction of cell death in SKBR3 by mazF mRNA 
MazF protein, a bacterial ribonuclease, has a capability to cleave mRNAs at ACA 
sequences. Degradation of mRNAs followed by inhibition of protein synthesis triggers a 
lethal process in cells. In prior sections, the toxic effect of mazF mRNA on different cell 
lines, i.e., MCF7, AGS, HT29, and HEK298 was shown. To validate the bacterial protein 
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activity, SKBR3 cells were transfected with mazF mRNA, and induction of cell death was 
analyzed (Figure 4.9). Similar to other cell lines, SKBR3 was susceptible to MazF protein 
expression, leading to reduced viability of the transfected cells.  
 
 
 
Figure 4.9. The induction of death in SKBR3 cells by mazF mRNA. The difference was considered as 
statistically significant if P< 0.05 ( ). NS: Not Significant.  
 
Lm-spa+-mediated delivery of mazF mRNA into SKBR3 
The emergence of bacterial therapy has opened a new window to fighting cancer. 
Exploitation of bacteria to hone in on the tumors, application of bacterial toxins as cancer 
0
0.5
1
1.5
2
2.5
Control Negative control mazF mRNA
A
b
so
rb
an
ce
  
at
 4
9
0
 n
m
 
 125 
treatments, and the ability of bacteria to deliver a gene into tumors are examples of bacterial 
therapeutic approaches in the cancer field. The unique capability of L. monocytogenes to 
enter the host’s cytosols has made this bacterium a suitable candidate for delivery of 
therapeutic mRNAs into cells. In this investigation, Lm cells were transformed with a T7 
transcription system for mazF mRNA delivery. The transformed bacteria were utilized to 
infect SKBR3 for 1 hour. The infected cells were treated with gentamicin for another hour 
and reseeded in 96-well plates. The expression of MazF in cells was measured through cell 
viability and caspase activities. If mazF mRNA is synthesized and delivered into cancer 
cells, the viability of the cells is expected to drop, while the caspase activity would increase.   
The viability of SKBR3 and 4T1 cells infected by L. monocytogenes harboring 
mazF fragment was depicted in Figure 4.10. The Lm-spa+ strain was used as the negative 
control. Our results showed that the infection of cells with the functionalized Lm-spa+ 
carrying mazF solely decreased the viability of transfected cells, while no significant 
cytotoxic effects in 4T1 were recorded.  
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Figure 4.10. The impact of mazF delivered into SKBR3 and T4 cells. The difference was considered as 
statistically significant if P< 0.05 ( ). NS: Not Significant. 
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As demonstrated in 
 
Figure 4.11, the activity of caspase was monitored for 48 hours post infection. The 
activity of caspase -3 and -7 in SKBR3 cells infected with functionalized Lm-spa+ was 
higher in comparison to other controls, and this activity increased 48 hours post infection. 
These results indicated that attenuated L. monocytogenes expressing protein A can be 
effectively functionalized with a target-specific antibody and employed for mRNA 
delivery purposes. In this investigation, bacteria-mediated delivery of mazF mRNA was 
developed for the first time. 
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Figure 4.11. Detection of caspase -3 and -7 activity in cells infected with Lm-spa
+
 and Lm-spa
-
 
Discussion 
Gene delivery has been a promising route to treat or alleviate severe diseases such 
as cancer and HIV [62]. Over the past few decades, the accumulation of knowledge and 
advances in molecular technology have led to the development of various vectors for gene 
delivery purposes. However, the application of the designed viral and non-viral vectors has 
been constrained by several limitations, such as the lack of specificities and the toxic 
impacts of vectors on host cells. Recently, the utilization of bacteria, due to their natural 
abilities to identify and colonize tumors, for gene delivery purposes has been a focus in the 
cancer field. Invasion of tumors, bacterial vaccines, bacterial toxins with anticancer 
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activities, and gene delivery vectors are examples of strategies developed in the application 
of bacteria against cancer [53].  
L. monocytogenes is a versatile vector in gene delivery. The ability of this bacterium 
to deliver DNA plasmid into macrophage cell lines was reported by Dietrich et al [70]. 
However, this bacterial delivery system has faced several challenges, such as the low 
expression efficacy in non-dividing cells due to the need for plasmid translocation to the 
cell nucleus. Integration of plasmid DNA into the host genome was another drawback of 
this system, as reported by Dietrich et al [70]. To overcome these challenges, an L. 
monocytogenes-mediated RNA delivery system was designed by Schoen et al., in which 
GFP mRNAs were generated and transferred into phagocytic cells by L. monocytogenes 
[63]. Recently, Heisig et al. described an attenuated L. monocytogenes that expresses the 
S. aureus protein A on the cell walls. The attenuation of the bacteria stems from the deletion 
of internalin A and B, the cell wall proteins that play important roles in invasion and 
internalization of host cells. As reported previously, the anchored SPAs on the cell wall of 
L. monocytogenes have the affinity to bind to the Fc part of antibodies, and the bacterial 
internalization occurs through the interaction of antibodies with the corresponding 
receptors (or other ligands) exposed on the surface of target cells [168]. In this research, 
we utilized this attenuated vector to deliver mazF mRNA into cancer cells in an antibody-
dependent manner. In order to increase the safety profile of the attenuated bacteria, we 
equipped the vector with a suicide gene to degrade the bacteria and release the therapeutic 
products once the bacteria are inside the host cytosol. In this research, this attenuated L. 
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monocytogenes was utilized to deliver a therapeutic mRNA into cancer cells for the first 
time. 
MazF is a bacterial toxin that can degrade mRNAs at ACA sequences and block 
protein synthesis in bacterial and mammalian cells [143, 172]. As shown in Chapter 3, 
MazF has the capability to trigger apoptosis in MCF7 cells, which are naturally resistant to 
apoptosis, and induce cell death in two types of aggressive cancer cell lines, AGS and 
HT29. The invasion and aggressiveness of these cell lines were reported to be related to 
long non-coding RNAs (lnRNAs) containing several ACA codons in their sequences. 
These lnRNAs might be potential targets for the MazF protein. Therefore, according to our 
results, MazF can be confirmed as a potential and novel treatment against cancer. However, 
the MazF protein is a non-specific ribonuclease, and the application of MazF in cancer 
therapy demands the development of a delivery system with high specificity for cancer 
cells.  
In this study, we developed a bacterial delivery system for the MazF protein to 
exclusively deliver mazF mRNA into cancer cells. To this end, a T7 delivery system 
containing two plasmids, pCSA1 and pCNB-mz-kan, was developed to generate mazF 
mRNA inside bacterial cells. In this system, pCSA1 carries T7 polymerase and the lysin 
gene from phage A118 (ply 118), placed under the control of a listerial promoter, actA 
promoter (PactA). In pCNB-mz-kn, the mazF fragment was inserted downstream of the 
IRES, the internal ribosomal entry site of the encephalomyocarditis virus (IRESEMCV). 
Since mazF mRNAs are cap-less and polyA-less mRNAs, the IRES can secure the mRNA 
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integrity and enhance the translation of mazF mRNA in targeted cells. Because mazF was 
inserted as the ribosome-binding-site-less-fragment, mazF mRNA was not translated in 
bacterial cells. This T7 binary plasmid system was electroporated into an attenuated L. 
monocytogenes that was InlA- and InlB- deficient and expressed SPA anchored to the cell 
wall (Lm-spa+). Consequently, the bacterial vector was functionalized by Anti-HER2 
(Trastuzumab) humanized antibody and employed to infect the breast cancer SKBR3 line 
in vitro. The Anti-HER2 antibody enables the bacterial vector to exclusively target cells 
overexpressing the cell surface receptors HER2/neu. 
Lm-spa+ was designed to express anchored SPA on its cell walls. In order to 
validate this feature of Lm-spa+, the bacterial cells were incubated with human 
ErbB2/HER2 Alexa Fluor 488-conjugated antibody. The interaction of the antibody with 
SPA was investigated under immunofluorescence microscopy. The comparison of Lm-
spa+ with Lm-spa-,which does not express protein A, implies that the interaction of the 
applied antibodies with bacterial cells depends on the presence of protein A on bacteria 
cell walls. This result was in agreement with the findings of Heisig [171].   
The specificity of antibody-receptor interaction was investigated by 
immunostaining SKBR3 overexpressing HER2 with ErbB2/HER2 Alexa Fluor 488-
conjugated Antibody and the antibody isotype as the negative control. Our results validated 
that the overexpression of HER2 receptors on SKBR3 cell surfaces resulted in a high 
affinity to ErbB2/HER2 antibodies. 
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The antibody-mediated internalization of attenuated Lm-spa+ was examined 
through the infection of SKBR3 (HER2-positive) and 4T1 (HER2-negative) cells with Lm-
spa+. Our results showed that bacteria entered the cells in an antibody-dependent manner, 
and the internalization of functionalized bacteria in SKBR3 was 3 logarithmic magnitudes 
higher than in 4T1. The internalization of the coated bacteria was also 2 logarithmic 
magnitudes higher than non-coated bacteria. These results imply that the internalization of 
this bacterial strain depends on the presence of protein A on bacterial cell walls and the 
interaction of the linked antibody to SPA with corresponding receptors on cell surfaces. In 
this experiment, the expression of SPA was induced by the supplement of the bacterial 
medium with 1% XAD. Our observation showed that bacteria growing in medium lacking 
XAD failed to express SPA. However, Heisig reported that internalization of bacteria 
without artificially-activated prfA by XAD was significantly reduced [171].  
The density of bacteria is another important element that influences the specificity 
of bacterial internalization in cells. To optimize the antibody-mediated cell entry, SKBR3 
cells were infected with different concentrations of bacterial cells. Our observations 
indicated that increasing the bacteria MOI from 100 to 400 led to antibody-independent 
entry in cells. The incubation of cells with bacteria for 2 hours or more also caused 
antibody-independent internalization (data not shown). However, Heisig suggested that a 
two hour-incubation enhances bacterial internalization [171]. 
In this research, Lm-spa+ was employed to deliver mazF mRNA into SKBR3 cells. 
In order to contribute the MazF-mediated cell death exclusively to translation of the 
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delivered mazF mRNA, the influence of the vector harboring pCSA1 on cell viability was 
investigated in vitro. As shown in Figure 4.8, the vector does not have a significant 
cytotoxicity to SKBR3 cells.  
The ability of Lm-spa+ to carry the T7 transcription delivery system for mazF mRNA was 
validated by inoculating SKBR3 cells with Lm-spa+ equipped with the mazF fragment. 
Our results showed that the vector can exclusively deliver mazF mRNAs into targeted cells. 
As we reported in Chapter 3, MazF can induce apoptosis in cancer cells. The activity of 
caspase is one of the markers of apoptosis in eukaryote cells. As shown in 
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Figure 4.11, the infected cells with functionalized bacteria exhibit higher caspase inactivity 
48 hours post transfections. This vector was previously utilized for the delivery of plasmids 
encoding prodrug-converting enzymes into 4T1- HER2 cells. As a proof of concept, it was 
reported to have only 25% cytotoxicity in transfected cells. Therefore, further 
optimizations for prodrug delivery purposes were suggested by Heisig [171]. Lm-spa+was 
previously used for delivery of plasmids encoding prodrug-converting enzymes into 4T1- 
HER2 cells, the delivery rate was observed to be low, and only 25% cytotoxicity in 
transfected cells was reported [171]. Heisig et al. investigated the internalization of Lm-
spa+ into xenograft mouse tumors. Their results showed that in contrast to in vitro 
experiments, the internalization of bacteria depended on crosslinking of the antibody to 
SPA on the surface of live bacteria. After crosslinking, the bacterial count in the tumors 
was significantly increased in comparison to non-coated bacteria [168]. 
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CHAPTER FIVE 
5. Conclusion  
Cancer remains the second leading cause of mortality and morbidity worldwide. 
Besides the side effects and limitations of traditional therapies, its natural abilities to 
develop adaptation against medical treatments have made cancer one of the main concerns 
of recent centuries. Therefore, the introduction of novel therapies with high safety profiles 
is strongly demanded. Recently, ribonucleases with anticancer activities have opened a 
new avenue to treat cancer [79]. Ribonucleases can inhibit protein synthesis at transcription 
and translation stages. Thus, development of resistance to these small proteins seems to be 
challenging for cancer cells. In recent years, many ribonucleases with anticancer activities 
have been identified in both eukaryotic and prokaryotic cells. However, within a short 
period, it became evident that due to their instability, the lack of cytotoxic or cytostatic 
activity, and the presence of ribonuclease inhibitors within cells, some specific 
ribonucleases are weak candidates for cancer therapy applications [130]. Therefore, finding 
stable ribonucleases with anticancer activity could be a promising treatment against this 
lethal disease.  
MazF is a small, 12kDa, and stable ribonuclease in bacterial cells that digests 
mRNAs, tRNA, and rRNA at ACA sequences. Under normal conditions, MazE, a bacterial 
antitoxin, binds to two MazF proteins and neutralizes their lethal functions. Under harsh 
conditions, MazE is degraded by ATP-dependent proteases, while the released MazF 
arrests cell proliferation and induces death within bacterial cells [131]. It has been reported 
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that the expression of the mazEF locus is inhibited during stressful conditions [76]. One of 
the reasons for this inhibition might stem from the ability of the MazF protein to cleave its 
mRNAs at ACA sequences. To avoid the degradation of mazF mRNAs in cells, we used 
an ACA-less mazF fragment for our experiments in this research. To validate that ACA-
less mazF will be expressed in the cells and the products have the same abilities and 
functions as the wild type, a pBAD-mazF construct was designed and electroporated into 
bacterial cells. In this construct, ACA-less mazF was inserted under the control of a 
stringent and inducible promoter, PBAD. Our results exhibited that following the induction 
of the PBAD promoter with arabinose, the viability of bacterial cells reduced drastically. 
Over the 6 hours post induction, the surviving populations showed a 6-log reduction in 
comparison to the control strain. The surviving cells also generated small colonies. These 
results suggested that ACA-less mazF can be overexpressed, and the products can remain 
lethal in bacterial cells. 
Ribonucleases, antibiotics, bacterial toxins, and viruses block protein synthesis 
leading to the onset of apoptosis in mammalian cells [143]. Shimazu et al. showed that 
MazF could halt the growth of T-REx-293 cells, a human kidney cell line, and induce 
apoptosis. Although the exact mechanism remains unknown, it seems that the MazF-
mediated apoptosis depends on the presence of BAK in cells [143]. The injection of mazF 
plasmid DNA into tumors developed by T-REx-293 was unable to stop the progression of 
tumors in 4 out of 8 mice. Further investigation showed that MazF proteins were absent in 
tumors shortly after the injections. The lack of continuous expression of MazF in tumors, 
degradation, and the incidence of mutations in mazF gene might be the potential reasons 
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for the failure of MazF proteins to halt tumor growth and progression [172]. To address 
these challenges, we utilized ACA-mazF fragments that generate MazF resistance mRNAs. 
In addition, the DNA delivery system does not seem to be a suitable approach to transfer 
the mazF gene in tumors. Also, the occurrences of mutations in the mazF sequence led to 
the deactivation of MazF in tumors. Therefore, we developed an mRNA delivery system 
to transfer ACA-less mazF mRNA exclusively into cancer cells.   
Since cancer is a heterogeneous group of diseases with various sensitivities to 
different treatments, we first examined the impact of MazF proteins on the growth and 
viability of three different cancer cell lines, i.e., MCF7, HT29, and AGS. These cell lines 
were transfected with ACA-less mazF mRNAs, and the cells were evaluated for MazF-
mediated cell death [145, 146].  
mRNA is an attractive candidate as a non-viral treatment in gene therapy. Unlike 
DNA, mRNA is translated independently from the nucleus. However, in comparison to 
DNA, RNA is less stable in cells. In this study, we analyzed the role of the main structural 
elements of mRNAs in their stability and the translation efficiency in vitro. Our results 
demonstrated that ACA-less mazF mRNA can be translated in both cap- and IRES-
dependent manners. We also synthesized GFP mRNA for IRES- or cap- dependent 
translation as the controls for the experiments. Our results showed that capped GFP 
mRNAs were translated in all cell lines, while IRES-GFP mRNA was only expressed in 
AGS cells. Further investigations showed that mazF and GFP mRNA without the caps or 
poly-As were not expressed in all transfected cell lines. Therefore, the protection of the 5′ 
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ends of mRNAs by either a cap or IRES sequence is associated with the stability and 
expression of mRNAs in transfected cells. It has been reported that the incorporation of 
modified nucleotides such as pseudouridine in IVT the mRNA structure can enhance 
stability and boost the expression of the mRNAs in cells in comparison to other modified 
nucleotides [141]. Our observations suggested that cap/IRES-dependency, a poly-A tail, 
and modified/unmodified nucleotides played important roles in the efficient expression of 
MazF proteins in transfected cell lines but is cell line-dependent. 
In mammalian cells, the inhibition of protein synthesis triggers apoptosis and 
eventually induces death [143]. In this research, we analyzed the impact of MazF proteins 
on the inhibition of protein synthesis, induction of apoptosis, and death in MC7, AGS and 
HT 29 cells. The synthesis of nascent proteins was measured in transfected cells with mazF 
mRNAs. As explained in detail in Chapter 3, the expression of MazF led to significant 
inhibition of protein translation in the examined cell lines. In addition, our data showed 
that MazF proteins can induce death in the transfected cancer cell lines (Figure 3.5). In 
order to confirm MazF-mediated apoptosis, the activation of caspase -3 and -7 (Figure 3.6) 
and the presence of PARP as a biomarker of apoptosis were examined (Figure 3.8). Our 
observations suggested that in the presence of MazF, the levels of caspase -3 and - 7 
significantly increased, and apoptosis took place in the cells. These results confirm the 
antiproliferative action and apoptotic ability of MazF in cancer cells. However, MazF is a 
nonspecific ribonuclease that can induce death in both normal and tumor cells. Thus, the 
application of MazF is dependent on efficient expression and delivery of MazF into tumors. 
As described in Chapter 4, we developed and utilized a bacterial delivery system to 
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exclusively deliver mazF mRNAs into cancer cells. For this purpose, a T7 delivery system 
containing two plasmids, pCSA1 and pCNB-mz-kan, was developed to produce mazF 
mRNAs inside the bacterial cells and deliver the mRNAs into cancer cells. To deliver the 
T7 system, an attenuated L. monocytogenes that was InlA- and InlB- deficient and 
expressed SPA anchored to the cell wall (Lm-spa+) was utilized to infect cancer cells. This 
bacterial strain, due to displaying SPA on the cell walls, can be functionalized with cancer-
specific antibodies. As discussed in Chapter 4 in detail, we functionalized the bacterial 
vectors with anti-HER antibodies to transfer mazF mRNAs into SKBR3 cells that 
overexpress HER receptors on their cell surfaces. Our results showed that consequent to 
the infection of cells by functionalized bacterial vectors, caspase activities elevated in 
SKBR3 cells 48 hours post-transfection. One advantage of this modular approach is that 
the bacterial delivery system could be functionalized with different antibodies to target a 
specific cancer or a group of cancer types. 
In this research, for the first time, mazF mRNA was delivered into cancer cells 
through an expression and delivery system. However, further experiments in vitro and in 
vivo are required to verify and further improve the exclusive abilities of this system to 
deliver therapeutic molecules into specific cancer cells. As a proof of concept, we 
demonstrated that mazF mRNA can be translated in cancer cells in an IRES-dependent 
translation manner. Here, mazF was placed downstream of an attenuated phage IRES. 
Since various IRES sequences have been found in mammalian mRNAs [173], the 
application of non-attenuated and mammalian IRES might enhance the translation. 
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Several bacteria such as Salmonella have cancer-specific promoters in their genome 
[174]. Utilization of such promoters in the development of Lm vectors could further 
increase the specificity of this system. Due to the limited number of proven cancer-specific 
antibodies, these systems might not apply to all cancer types. Thus, using such promoters 
might overcome this limitation of the Lm delivery systems.  
In bacterial cells, several mRNAs are reported to be resistant to MazF functions 
[37]. Application of MazF against cancer cells and identification of MazF targets in cancer 
cells might advance the current knowledge about mammalian mRNAs and particularly 
pathogenic mRNA involved in tumor progression. 
 
 
 
 
 
 
  
 
 141 
6. References 
 
1. Ngoi, S.M., A.C. Chien, and C.G. Lee, Exploiting internal ribosome 
entry sites in gene therapy vector design. Curr Gene Ther, 2004. 
4: p. 15-31. 
2. Nagy, J.A., et al., Heterogeneity of the tumor vasculature. Seminars in 
Thrombosis and Hemostasis, 2010. 36: p. 321-331. 
3. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: The next 
generation. Cell, 2011. 144: p. 646-674. 
4. Adams, J.M. and S. Cory, The Bcl-2 apoptotic switch in cancer 
development and therapy. Oncogene, 2007. 26: p. 1324-1337. 
5. Tonini, T., F. Rossi, and P.P. Claudio, Molecular basis of angiogenesis 
and cancer. Oncogene, 2003. 22: p. 6549-6556. 
6. Kaphingst, K.A., S. Persky, and C. Lachance, NIH Public Access. 
2010. 14: p. 384-399. 
7. Ouyang, L., et al., Programmed cell death pathways in cancer: A 
review of apoptosis, autophagy and programmed necrosis. Cell 
Proliferation, 2012. 45: p. 487-498. 
8. Kroemer, G., et al., Classification of cell death 2009. Cell death and 
differentiation, 2009. 16: p. 3-11. 
9. Elmore, S., Apoptosis: A review of programmed cell death. 
Toxicologic Pathology, 2007. 35(4): p. 495-516. 
10.Elmore, S., Apoptosis: A review of programmed cell death. 
Toxicologic Pathology, 2007. 35: p. 495-516. 
11. Herr, I. and K.M. Debatin, Cellular stress response and apoptosis in 
cancer therapy. Blood, 2001. 98(9): p. 2603-14. 
12. Van Loo, E., et al., Surgical excision versus Mohs' micrographic 
surgery for basal cell carcinoma of the face: A randomised 
clinical trial with 10 year follow-up. Eur J Cancer, 2014. 50(17): 
p. 3011-20. 
13. Schimmer, A.D., et al., Small-molecule antagonists of apoptosis 
suppressor XIAP exhibit broad antitumor activity. Cancer Cell, 
2004. 5(1): p. 25-35. 
14. Enari, M., et al., A caspase-activated DNase that degrades DNA 
during apoptosis, and its inhibitor ICAD. Nature, 1998. 391: p. 
43. 
 
 142 
15. Hata, A.N., J.A. Engelman, and A.C. Faber, The BCL2 family: key 
mediators of the apoptotic response to targeted anticancer 
therapeutics. Cancer discovery, 2015. 5: p. 475-487. 
16. Lowe, S.W. and A.W. Lin, Apoptosis in cancer. Carcinogenesis, 
2000. 21(3): p. 485-495. 
17. Cotter, T.G., Apoptosis and cancer: the genesis of a research field. 
Nat Rev Cancer, 2009. 9(7): p. 501-507. 
18. Ouyang, L., et al., Programmed cell death pathways in cancer: a 
review of apoptosis, autophagy and programmed necrosis. Cell 
Proliferation, 2012. 45(6): p. 487-498. 
19. Letai, A., et al., Antiapoptotic BCL-2 is required for maintenance of 
a model leukemia. Cancer Cell, 2004. 6: p. 241-249. 
20. Letai, A., et al., Antiapoptotic BCL-2 is required for maintenance of 
a model leukemia. Cancer Cell, 2004. 6(3): p. 241-9. 
21. Cheung, H.H., E.C. LaCasse, and R.G. Korneluk, X-linked inhibitor 
of apoptosis antagonism: strategies in cancer treatment. Clin 
Cancer Res, 2006. 12(11 Pt 1): p. 3238-42. 
22. Hata, A.N., J.A. Engelman, and A.C. Faber, The BCL2 family: key 
mediators of the apoptotic response to targeted anticancer 
therapeutics. Cancer Discov, 2015. 5(5): p. 475-87. 
23. Engelberg-Kulka, H., et al., Bacterial programmed cell death and 
multicellular behavior in bacteria. PLoS Genet, 2006. 2(10). 
24. Lobato-Márquez, D., R. Díaz-Orejas, and F. García-del Portillo, 
Toxin-antitoxins and bacterial virulence. FEMS Microbiology 
Reviews, 2016. 40(5): p. 592-609. 
25. Yamaguchi, Y., J.H. Park, and M. Inouye, Toxin-antitoxin systems 
in bacteria and archaea. Annu Rev Genet, 2011. 45: p. 61-79. 
26. Unterholzner, S.J., B. Poppenberger, and W. Rozhon, Toxin-
antitoxin systems: Biology, identification, and application. Mob 
Genet Elements, 2013. 5(3): p. e26219. 
27. Masuda, H., et al., YeeU. Enhances the bundling of cytoskeletal 
polymers of MreB and FtsZ, antagonizing the CbtA (YeeV) 
toxicity in Escherichia coli. Molecular Microbiology, 2012. 84: 
p. 979–989. 
28. Wang, X., et al., A new type V toxin-antitoxin system where mRNA 
for toxin GhoT is cleaved by antitoxin GhoS. Nat Chem Biol, 
2012. 8(10): p. 855-61. 
 
 143 
29. Engelberg-Kulka, H., R. Hazan, and S. Amitai, MazEF: a 
chromosomal toxin-antitoxin module that triggers programmed 
cell death in bacteria. J Cell Sci, 2005. 118(Pt 19): p. 4327-32. 
30. Gerdes, K. and E. Maisonneuve, Bacterial persistence and toxin-
antitoxin loci. Annu Rev Microbiol, 2012. 66: p. 103-23. 
31. Nariya, H. and M. Inouye, MazF, an mRNA interferase, mediates 
programmed cell death during multicellular Myxococcus 
development. Cell, 2008. 132(1): p. 55-66. 
32. Park, J.H., Y. Yamaguchi, and M. Inouye, Bacillus subtilis MazF-bs 
(EndoA) is a UACAU-specific mRNA interferase. FEBS Lett, 
2011. 585(15): p. 2526-32. 
33. Kolodkin-Gal, I. and H. Engelberg-Kulka, Induction of Escherichia 
coli chromosomal mazEF by stressful conditions causes an 
irreversible loss of viability. Journal of Bacteriology, 2006. 
188(9): p. 3420-3423. 
34. Engelberg-Kulka, H., et al., Bacterial programmed cell death and 
multicellular behavior in bacteria. PLoS Genet, 2006. 2(10): p. 
e135. 
35. Bertram, R. and C.F. Schuster, Post-transcriptional regulation of gene 
expression in bacterial pathogens by toxin-antitoxin systems. 
Front Cell Infect Microbiol, 2014. 4(6). 
36. Zhang, Y., et al., MazF cleaves cellular mRNAs specifically at ACA 
to block protein synthesis in Escherichia coli. Mol Cell, 2003. 
12(4): p. 913-23. 
37. Zhang, Y., et al., Insights into the mRNA cleavage mechanism by 
MazF, an mRNA interferase. J Biol Chem, 2005. 280(5): p. 
3143-50. 
38. Schneider, W.M., et al., Independently inducible system of gene 
expression for condensed single protein production (cSPP) 
suitable for high efficiency isotope enrichment. J Struct Funct 
Genomics, 2009. 10(3): p. 219-25. 
39. Shimazu, T., et al., NBK/BIK antagonizes MCL-1 and BCL-X(L) 
and activates BAK-mediated apoptosis in response to protein 
synthesis inhibition. Genes Dev. 2007 Apr 15;21(8):929-41. 
doi:10.1101/gad.1522007. 
40. Chono, H., et al., Acquisition of HIV-1 resistance in T lymphocytes 
using an ACA-specific E. coli mRNA interferase. Hum Gene 
Ther, 2011. 22(1): p. 35-43. 
 
 144 
41. Shapira, A., et al., Removal of Hepatitis C Virus-Infected Cells by a 
Zymogenized Bacterial Toxin. PLoS ONE, 2012. 7(2). 
42. Kucerova, P. and M. Cervinkova, Spontaneous regression of tumour 
and the role of microbial infection – possibilities for cancer 
treatment. Anti-Cancer Drugs, 2016. 27(4): p. 269-277. 
43. Zheng, Y.-q., et al., Applications of bacillus Calmette-Guerin and 
recombinant bacillus Calmette-Guerin in vaccine development 
and tumor immunotherapy. Expert review of vaccines, 2015. 
14(9): p. 1255-1275. 
44. Morrissey, D., G.C. O'Sullivan, and M. Tangney, Tumour targeting 
with systemically administered bacteria. Current Gene Therapy, 
2010. 10(1): p. 3-14. 
45. Hoffman, R.M., The preclinical discovery of bacterial therapy for the 
treatment of metastatic cancer with unique advantages. Expert 
Opin Drug Discov, 2012. 7(1): p. 73-83. 
46. Kasinskas, R.W. and N.S. Forbes, Salmonella typhimurium lacking 
ribose chemoreceptors localize in tumor quiescence and induce 
apoptosis. Cancer Res, 2007. 67(7): p. 3201-9. 
47. Dietrich, G., et al., Gram-positive and Gram-negative bacteria as 
carrier systems for DNA vaccines. Vaccine, 2001. 19(17–19): p. 
2506-2512. 
48. Yu, Y.A., et al., Visualization of tumors and metastases in live 
animals with bacteria and vaccinia virus encoding light-emitting 
proteins. Nat Biotechnol, 2004. 22(3): p. 313-20. 
49. Gardlik, R., et al., Gene therapy for cancer: bacteria-mediated anti-
angiogenesis therapy. Gene Ther, 2011. 18(5): p. 425-31. 
50. Theys, J., et al., Tumor-specific gene delivery using genetically 
engineered bacteria. Curr Gene Ther, 2003. 3(3): p. 207-21. 
51. Forbes, N.S., Engineering the perfect (bacterial) cancer therapy. Nat 
Rev Cancer, 2010. 10(11): p. 785-794. 
52. Wall, D.M., C.V. Srikanth, and B.A. McCormick, Targeting tumors 
with Salmonella typhimurium- potential for therapy. Oncotarget, 
2010. 1(8): p. 721-8. 
53. Lee, C.-H., Engineering bacteria toward tumor targeting for cancer 
treatment: current state and perspectives. Applied Microbiology 
and Biotechnology, 2012. 93(2): p. 517-523. 
54. Patyar, S., et al., Bacteria in cancer therapy: a novel experimental 
strategy. J Biomed Sci, 2010. 17(1): p. 1423-0127. 
 
 145 
55. Seow, S.W., et al., Lactobacillus rhamnosus GG induces tumor 
regression in mice bearing orthotopic bladder tumors. Cancer 
Sci, 2010. 101(3): p. 751-8. 
56. Patyar, S., A. Prakash, and B. Medhi, Bacteria as a therapeutic 
approach in cancer therapy, in bacteria and cancer, A.A. Khan, 
Editor. 2012, Springer: Springer Dordrecht Heidelberg London 
New York. p. 185-208. 
57. Arrach, N., et al., Salmonella promoters preferentially activated 
inside tumors. Cancer Res, 2008. 68(12): p. 4827-32. 
58. Leschner, S. and S. Weiss, Salmonella-allies in the fight against 
cancer. J Mol Med, 2010. 88(8): p. 763-73. 
59. Vassaux, G., et al., Bacterial gene therapy strategies. J Pathol, 2006. 
208(2): p. 290-8. 
60. Stritzker, J., et al., Prodrug converting enzyme gene delivery by L. 
monocytogenes. BMC Cancer, 2008. 8(94): p. 1471-2407. 
61. Baban, C.K., et al., Bacteria as vectors for gene therapy of cancer. 
Bioengineered bugs, 2010. 1(6): p. 385-394. 
62. Palffy, R., et al., Bacteria in gene therapy: bactofection versus 
alternative gene therapy. Gene Ther, 2005. 13(2): p. 101-105. 
63. Schoen, C., et al., Bacterial delivery of functional messenger RNA to 
mammalian cells. Cell Microbiol, 2005. 7(5): p. 709-24. 
64. Cossart, P., J. Pizarro-Cerda, and M. Lecuit, Invasion of mammalian 
cells by Listeria monocytogenes: functional mimicry to subvert 
cellular functions. Trends Cell Biol, 2003. 13(1): p. 23-31. 
65. Ireton, K., Entry of the bacterial pathogen Listeria monocytogenes 
into mammalian cells. Cell Microbiol, 2007. 9(6): p. 1365-75. 
66. Bonazzi, M., M. Lecuit, and P. Cossart, Listeria monocytogenes 
internalin and e-cadherin: From Bench to Bedside. Cold Spring 
Harb Perspect Biol. 2009 Oct; 1(4): a 003087. doi: 10.1101/ 
cshperspect.a003087. 
67. Travier, L. and M. Lecuit, Listeria monocytogenes ActA: a new 
function for a ‘classic’ virulence factor. Current Opinion in 
Microbiology, 2014. 17(0): p. 53-60. 
68. Tangney, M. and C.G. Gahan, Listeria monocytogenes as a vector for 
anti-cancer therapies. Curr Gene Ther, 2010. 10(1): p. 46-55. 
69. Yang, Y., et al., Attenuated Listeria monocytogenes as a cancer 
vaccine vector for the delivery of CD24, a biomarker for hepatic 
cancer stem cells. Cell Mol Immunol, 2014. 11(2): p. 184-96. 
 
 146 
70. Dietrich, G., et al., Delivery of antigen-encoding plasmid DNA into 
the cytosol of macrophages by attenuated suicide Listeria 
monocytogenes. Nat Biotechnol, 1998. 16(2): p. 181-5. 
71. Tangney, M., J.P. van Pijkeren, and C.G. Gahan, The use of Listeria 
monocytogenes as a DNA delivery vector for cancer gene 
therapy. Bioeng Bugs, 2010. 1(4): p. 284-7. 
72. Heisig, M., et al., Specific antibody-receptor interactions trigger 
InlAB-independent uptake of Listeria monocytogenes into tumor 
cell lines. BMC Microbiology, 2011. 11(163). 
73. Hazan, R., B. Sat, and H. Engelberg-Kulka, Escherichia coli mazEF-
mediated cell death is triggered by various stressful conditions. 
Journal of Bacteriology, 2004. 186(11): p. 3663-3669. 
74. Erental, A., I. Sharon, and H. Engelberg-Kulka, Two programmed 
cell death systems in Escherichia coli: an apoptotic-like death is 
inhibited by the mazEF-mediated death pathway. PLoS Biol, 
2012. 10(3): p. e1001281. 
75. Amitai, S., Y. Yassin, and H. Engelberg-Kulka, MazF-mediated cell 
death in Escherichia coli: a point of no return. J Bacteriol. 2004 
Dec;186(24):8295-300.doi:10.1128/JB.186.24.8295-8300.2004. 
76. Amitai, S., Y. Yassin, and H. Engelberg-Kulka, MazF-mediated cell 
death in Escherichia coli: a point of no return. J Bacteriol, 2004. 
186(24): p. 8295-300. 
77. Beebe, S.J., N.M. Sain, and W. Ren, Induction of cell death 
Mechanisms and Apoptosis by nanosecond Pulsed Electric 
Fields (nsPEFs). Cells, 2013. 2(1): p. 136-162. 
78. Makarov, A.A. and O.N. Ilinskaya, Cytotoxic ribonucleases: 
molecular weapons and their targets. FEBS Letters, 2003. 
540(1): p. 15-20. 
79. Fang, E.F. and T.B. Ng, Ribonucleases of different origins with a 
wide spectrum of medicinal applications. Biochimica et 
Biophysica Acta (BBA) - Reviews on Cancer, 2011. 1815(1): p. 
65-74. 
80. Schein, C.H., From housekeeper to microsurgeon: the diagnostic and 
therapeutic potential of ribonucleases. Nat Biotechnol, 1997. 
15(6): p. 529-36. 
81. De Lorenzo, C., et al., Intracellular route and mechanism of action of 
ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. 
FEBS Letters, 2007. 581(2): p. 296-300. 
 
 147 
82. Patricia, S., et al., A recombinant human RNASET2 glycoprotein 
with antitumorigenic and antiangiogenic characteristics. Cancer, 
2006. 107(12): p. 2760-2769. 
83. Green, P.J., The Ribonucleases of higher plants. Annual Review of 
Plant Physiology and Plant Molecular Biology, 1994. 45(1): p. 
421-445. 
84. Banovic, B., et al., Basic RNases of wild almond (Prunus webbii): 
cloning and characterization of six new S-RNase and one "non-
S RNase" genes. J Plant Physiol, 2009. 166(4): p. 395-402. 
85. Xing, D., et al., Identification of a plant-specific Zn2+-sensitive 
ribonuclease activity. Planta, 2009. 230(4): p. 819-25. 
86. Ardelt, W., B. Ardelt, and Z. Darzynkiewicz, Ribonucleases as 
potential modalities in anticancer therapy. Eur J Pharmacol, 
2009. 625(1-3): p. 181-9. 
87. Lee, I., Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, 
manipulates tumour physiological parameters as a selective killer 
and a potential enhancer for chemotherapy and radiation in 
cancer therapy. Expert Opin Biol Ther, 2008. 8(6): p. 813-27. 
88. Zelenikhin, P.V., et al., Induction of Apoptosis in tumor cells by 
binase. Molecular Biology, 2005. 39(3): p. 404-409. 
89. Sevcik, J., et al., X-ray structure of two crystalline forms of a 
Streptomycete ribonuclease with cytotoxic activity. J Biol Chem, 
2002. 277(49): p. 47325-30. 
90. Sergeeva, O.V., V.E. Koteliansky, and T.S. Zatsepin, mRNA-based 
therapeutics - advances and perspectives. Biochemistry (Mosc), 
2016. 81(7): p. 709-22. 
91. Wolff, J.A., et al., Direct gene transfer into mouse muscle in vivo. 
Science, 1990. 247(4949 Pt 1): p. 1465-8. 
92. Sahin, U., K. Kariko, and O. Tureci, mRNA-based therapeutics 
[mdash] developing a new class of drugs. Nat Rev Drug Discov, 
2014. 13(10): p. 759-780. 
93. Jirikowski, G.F., et al., Reversal of diabetes insipidus in Brattleboro 
rats: intrahypothalamic injection of vasopressin mRNA. Science, 
1992. 255(5047): p. 996-8. 
94. Martinon, F., et al., Induction of virus-specific cytotoxic T 
lymphocytes in vivo by liposome-entrapped mRNA. Eur J 
Immunol, 1993. 23(7): p. 1719-22. 
 
 148 
95. Tavernier, G., et al., mRNA as gene therapeutic: how to control 
protein expression. J Control Release, 2011. 150(3): p. 238-47. 
96. Franks, T.M. and J. Lykke-Andersen, The control of mRNA 
decapping and P-body formation. Mol Cell, 2008. 32(5): p. 605-
15. 
97. Stoneley, M. and A.E. Willis, Cellular internal ribosome entry 
segments: structures, trans-acting factors and regulation of gene 
expression. Oncogene, 2004. 23(18): p. 3200-7. 
98. Kuhn, A.N., et al., Phosphorothioate cap analogs increase stability 
and translational efficiency of RNA vaccines in immature 
dendritic cells and induce superior immune responses in vivo. 
Gene Ther, 2010. 17(8): p. 961-71. 
99. Kieft, J.S., Viral IRES RNA structures and ribosome interactions. 
Trends in biochemical sciences, 2008. 33(6): p. 274-283. 
100. Jackson, R.J., The current status of vertebrate cellular mRNA 
IRESs. Cold Spring Harb Perspect Biol, 2013. 5(2). 
101. Jan, E., et al., Initiator Met-tRNA-independent translation mediated 
by an internal ribosome entry site element in cricket paralysis 
virus-like insect viruses. Cold Spring Harb Symp Quant Biol, 
2001. 66: p. 285-92. 
102. Rijnbrand, R., et al., Internal entry of ribosomes is directed by the 
5' noncoding region of classical swine fever virus and is 
dependent on the presence of an RNA pseudoknot upstream of 
the initiation codon. J Virol, 1997. 71(1): p. 451-7. 
103. Jang, S.K., et al., A segment of the 5' nontranslated region of 
encephalomyocarditis virus RNA directs internal entry of 
ribosomes during in vitro translation. J Virol, 1988. 62(8): p. 
2636-43. 
104. Kuhn, R., N. Luz, and E. Beck, Functional analysis of the internal 
translation initiation site of foot-and-mouth disease virus. J 
Virol, 1990. 64(10): p. 4625-31. 
105. Pilipenko, E.V., et al., Starting window, a distinct element in the 
cap-independent internal initiation of translation on picornaviral 
RNA. J Mol Biol, 1994. 241(3): p. 398-414. 
106. Baird, S.D., et al., Searching for IRES. RNA, 2006. 12(10): p. 1755-
85. 
 
 149 
107. Pelletier, J. and N. Sonenberg, Internal initiation of translation of 
eukaryotic mRNA directed by a sequence derived from 
poliovirus RNA. Nature, 1988. 334: p. 320. 
108. Ngoi, S.M., A.C. Chien, and C.G. Lee, Exploiting internal ribosome 
entry sites in gene therapy vector design. Curr Gene Ther, 2004. 
4(1): p. 15-31. 
109. Morgan, R.A., et al., Retroviral vectors containing putative internal 
ribosome entry sites: development of a polycistronic gene 
transfer system and applications to human gene therapy. Nucleic 
Acids Res, 1992. 20(6): p. 1293-9. 
110. De Felipe, P. and M. Izquierdo, Tricistronic and tetracistronic 
retroviral vectors for gene transfer. Hum Gene Ther, 2000. 
11(13): p. 1921-31. 
111. Harries, M., et al., Comparison of bicistronic retroviral vectors 
containing internal ribosome entry sites (IRES) using expression 
of human interleukin-12 (IL-12) as a readout. J Gene Med, 2000. 
2(4): p. 243-9. 
112. Barzon, L., et al., Transcriptionally targeted retroviral vector for 
combined suicide and immunomodulating gene therapy of 
thyroid cancer. J Clin Endocrinol Metab, 2002. 87(11): p. 5304-
11. 
113. Wen, X.Y., et al., Tricistronic viral vectors co-expressing 
interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy 
of cancer: preclinical studies in myeloma. Cancer Gene Ther, 
2001. 8(5): p. 361-70. 
114. Takebe, N., et al., Generation of dual resistance to 4-
hydroperoxycyclophosphamide and methotrexate by retroviral 
transfer of the human aldehyde dehydrogenase class 1 gene and 
a mutated dihydrofolate reductase gene. Mol Ther, 2001. 3(1): p. 
88-96. 
115. Jalkanen, A.L., S.J. Coleman, and J. Wilusz, Determinants and 
implications of mRNA Poly(A) Tail Size - Does this protein 
make my tail look big? Semin Cell Dev Biol, 2014. 0: p. 24-32. 
116. Mignone, F., et al., Untranslated regions of mRNAs. Genome 
Biology, 2002. 3(3): p. reviews0004.1-reviews0004.10. 
117. Cannarozzi, G., et al., A Role for codon order in translation 
dynamics. Cell, 2010. 141(2): p. 355-367. 
 
 150 
118. Van Gulck, E.R., et al., Efficient stimulation of HIV-1-specific T 
cells using dendritic cells electroporated with mRNA encoding 
autologous HIV-1 Gag and Env proteins. Blood, 2006. 107(5): 
p. 1818-27. 
119. Boczkowski, D., et al., Dendritic cells pulsed with RNA are potent 
antigen-presenting cells in vitro and in vivo. J Exp Med, 1996. 
184(2): p. 465-72. 
120. Van Gulck, E., et al., mRNA-based dendritic cell vaccination 
induces potent antiviral T-cell responses in HIV-1-infected 
patients. Aids, 2012. 26(4): p. F1-12. 
121. Allard, S.D., et al., A phase I/IIa immunotherapy trial of HIV-1-
infected patients with Tat, Rev and Nef expressing dendritic cells 
followed by treatment interruption. Clinical Immunology, 2012. 
142(3): p. 252-268. 
122. Fleeton, M.N., et al., Self-replicative RNA vaccines elicit protection 
against influenza A virus, respiratory syncytial virus, and a 
tickborne encephalitis virus. J Infect Dis, 2001. 183(9): p. 1395-
8. 
123. Anraku, I., et al., Kunjin virus replicon vaccine vectors induce 
protective CD8+ T-cell immunity. J Virol, 2002. 76(8): p. 3791-
9. 
124. Zangi, L., et al., Modified mRNA directs the fate of heart progenitor 
cells and induces vascular regeneration after myocardial 
infarction. Nature Biotechnology, 2013. 31: p. 898. 
125. Takahashi, K., et al., Induction of pluripotent stem cells from adult 
human fibroblasts by defined factors. Cell, 2007. 131(5): p. 861-
72. 
126. Avci-Adali, M., et al., Optimized conditions for successful 
transfection of human endothelial cells with in vitro synthesized 
and modified mRNA for induction of protein expression. J Biol 
Eng, 2014. 8: p. 8. 
127. Kariko, K., et al., Incorporation of pseudouridine into mRNA yields 
superior nonimmunogenic vector with increased translational 
capacity and biological stability. Mol Ther, 2008. 16(11): p. 
1833-40. 
128. Avci-Adali, M., et al., Optimized conditions for successful 
transfection of human endothelial cells with in vitro synthesized 
 
 151 
and modified mRNA for induction of protein expression. Journal 
of Biological Engineering, 2014. 8(1): p. 8. 
129. Kariko, K., et al., Incorporation of pseudouridine into mRNA yields 
superior nonimmunogenic vector with increased translational 
capacity and biological stability. Mol Ther, 2008. 16. 
130. Ardelt, W., B. Ardelt, and Z. Darzynkiewicz, Ribonucleases as 
potential modalities in anticancer therapy. European journal of 
pharmacology, 2009. 625(1-3): p. 181-189. 
131. Wang, N.R. and P.J. Hergenrother, A Continuous Fluorometric 
Assay for the Assessment of MazF Ribonuclease Activity. 
Analytical biochemistry, 2007. 371(2): p. 173-183. 
132. Preiss, T., M. Muckenthaler, and M.W. Hentze, Poly(A)-tail-
promoted translation in yeast: implications for translational 
control. RNA, 1998. 4(11): p. 1321-1331. 
133. Gallie, D.R., The cap and poly(A) tail function synergistically to 
regulate mRNA translational efficiency. Genes & Dev, 1991. 5: 
p. 2108-2116. 
134. Mockey, M., et al., mRNA transfection of dendritic cells: 
Synergistic effect of ARCA mRNA capping with Poly(A) chains 
in cis and in trans for a high protein expression level. 
Biochemical and Biophysical Research Communications, 2006. 
340(4): p. 1062-1068. 
135. Michel, Y.M., et al., Cap-Poly(A) synergy in mammalian cell-free 
extracts investigation of the requirements for poly(a)-mediated 
stimulation of translation initiation. The Journal of Biological 
Chemistry, 2000. 275: p. 32268-32276. 
136. Wang, Q.S. and E. Jan, Switch from Cap- to factorless IRES-
dependent 0 and +1 Frame translation during cellular stress and 
dicistrovirus infection. PLoS ONE, 2014. 9(8): p. e103601. 
137. Xi, S., et al., IRES-mediated protein translation overcomes 
suppression by the p14ARF tumor suppressor protein. Journal of 
Cancer, 2017. 8(6): p. 1082-1088. 
138. Avci-Adali, M., et al., In vitro synthesis of modified mRNA for 
induction of protein expression in human cells. Journal of 
Visualized Experiments : JoVE, 2014(93): p. 51943. 
139. Anderson, B.R., et al., Incorporation of pseudouridine into mRNA 
enhances translation by diminishing PKR activation. Nucleic 
Acids Research, 2010. 38(17): p. 5884-5892. 
 
 152 
140. Hornung, V., et al., 5'-Triphosphate RNA is the ligand for RIG-I. 
Science, 2006. 314(5801): p. 994-7. 
141. Karikó, K., et al., Suppression of RNA recognition by toll-like 
receptors: the impact of nucleoside modification and the 
evolutionary origin of RNA. Immunity, 2005. 23(2): p. 165-175. 
142. Martineau, Y., D. Müller, and S. Pyronnet, Targeting protein 
synthesis in cancer cells. Oncoscience, 2014. 1(7): p. 484-485. 
143. Shimazu, T., et al., NBK/BIK antagonizes MCL-1 and BCL-X(L) 
and activates BAK-mediated apoptosis in response to protein 
synthesis inhibition. Genes Dev, 2007. 21(8): p. 929-41. 
144. Essmann, F., et al., Apoptosis resistance of MCF-7 breast carcinoma 
cells to ionizing radiation is independent of p53 and cell cycle 
control but caused by the lack of caspase-3 and a caffeine-
inhibitable event. Cancer Research, 2004. 64(19): p. 7065-7072. 
145. Wang, D., et al., Long non-coding RNA GACAT1promotes 
proliferation and invasion of gastric cancercells by targeting 
miR-378. Int J Clin Exp Pathol 2017. 10(6): p. 6364-6374. 
146. Li, J., et al., Effect of long non-coding RNA Gas5 on proliferation, 
migration, invasion and apoptosis of colorectal cancer HT-29 
cell line. cancer cell int., 2018. 18. 
147. Hardee, C.L., et al., Advances in non-viral dna vectors for gene 
therapy. genes (basel), 2017. 8(2). 
148. Amer, M.H., Gene therapy for cancer: present status and future 
perspective. Mol Cell Ther, 2014. 2. 
149. Ponder, K.P., Vectors of gene therapy, in an introduction to 
molecular medicine and gene therapy, T.F. Kresina, Editor. 
2001, Wiley-Liss, Inc. p. 420. 
150. Baban, C.K., et al., Bacteria as vectors for gene therapy of cancer. 
Bioengineered Bugs, 2010. 1(6): p. 385-394. 
151. Hacein-Bey-Abina, S., et al., Efficacy of gene therapy for X-linked 
severe combined immunodeficiency. N Engl J Med, 2010. 363. 
152. Kay, M.A., State-of-the-art gene-based therapies: the road ahead. 
Nat Rev Genet, 2011. 12(5): p. 316-28. 
153. Seow, Y. and M.J. Wood, Biological gene delivery vehicles: beyond 
viral vectors. Mol Ther, 2009. 17(5): p. 767-77. 
154. Ramamoorth, M. and A. Narvekar, Non viral vectors in gene 
therapy- an overview. J Clin Diagn Res, 2015. 9(1): p. Ge01-
6. 
 
 153 
155. Sheridan, C., Gene therapy finds its niche. Nat Biotechnol, 2011. 
29(2): p. 121-8. 
156. Nayerossadat, N., T. Maedeh, and P.A. Ali, Viral and nonviral 
delivery systems for gene delivery. Advanced Biomedical 
Research, 2012. 1: p. 27. 
157. Alton, E.W., et al., Non-invasive liposome-mediated gene delivery 
can correct the ion transport defect in cystic fibrosis mutant 
mice. Nat Genet, 1993. 5(2): p. 135-42. 
158. Grillot-Courvalin, C., S. Goussard, and P. Courvalin, Bacteria as 
gene delivery vectors for mammalian cells. Curr Opin 
Biotechnol, 1999. 10(5): p. 477-81. 
159. Minton, N.P., Clostridia in cancer therapy. Nat Rev Microbiol, 
2003. 1(3): p. 237-42. 
160. Fujimori, M., J. Amano, and S. Taniguchi, The genus 
Bifidobacterium for cancer gene therapy. Curr Opin Drug 
Discov Devel, 2002. 5(2): p. 200-3. 
161. Moreno, M., et al., Salmonella as live trojan horse for vaccine 
development and cancer gene therapy. Curr Gene Ther, 2010. 
10(1): p. 56-76. 
162. Yu, Y.A., et al., Visualization of tumors and metastases in live 
animals with bacteria and vaccinia virus encoding light-
emitting proteins. Nat Biotech, 2004. 22(3): p. 313-320. 
163. Bhatnagar, P.K., et al., Anti-tumor effects of the bacterium 
Caulobacter crescentus in murine tumor models. Cancer Biol 
Ther, 2006. 5(5): p. 485-91. 
164. Arakawa, M., et al., Oncolytic effect of Proteus mirabilis upon 
tumor-bearing animals. II. Effect on transplantable mouse and 
rat tumors. Gan, 1968. 59(2): p. 117-22. 
165. Maletzki, C., et al., Pancreatic cancer regression by intratumoural 
injection of live Streptococcus pyogenes in a syngeneic mouse 
model. Gut, 2008. 57(4): p. 483-91. 
166. Palffy, R., et al., Bacteria in gene therapy: bactofection versus 
alternative gene therapy. Gene Ther, 2006. 13(2): p. 101-5. 
167. Bernardes, N., A.M. Chakrabarty, and A.M. Fialho, Engineering of 
bacterial strains and their products for cancer therapy. Appl 
Microbiol Biotechnol, 2013. 97(12): p. 5189-99. 
 
 154 
168. Heisig, M., et al., Specific antibody-receptor interactions trigger 
InlAB-independent uptake of Listeria monocytogenes into 
tumor cell lines. BMC Microbiology, 2011. 11: p. 163. 
169. Monk, I.R., C.G.M. Gahan, and C. Hill, Tools for functional 
postgenomic analysis of Listeria monocytogenes. Applied and 
Environmental Microbiology, 2008. 74(13): p. 3921-3934. 
170. Bierne, H., et al., Internalins: a complex family of leucine-rich 
repeat-containing proteins in Listeria monocytogenes. 
Microbes Infect, 2007. 9(10): p. 1156-66. 
171. Heisig, M., Development of novel Listeria monocytogenes strains 
as therapeutic agents for targeted tumor therapy, in Section 
Infection and Immunity. 2009, Julius Maximilian University 
Würzburg. p. 134. 
172. Shimazu, T., et al., Regression of solid tumors by induction of 
MazF, a bacterial mRNA endoribonuclease J Mol Microbiol 
Biotechnol 2014. 24: p. 228–233. 
173. Koh, E.Y.C., et al., an Internal Ribosome Entry Site (IRES) mutant 
library for tuning expression level of multiple genes in 
mammalian cells. PLOS ONE, 2013. 8(12): p. e82100. 
174. Leschner, S., et al., Identification of tumor-specific Salmonella 
typhimurium promoters and their regulatory logic. Nucleic 
Acids Research, 2012. 40(7): p. 2984-2994. 
 
 155 
Appendix 
Rights and Permissions 
 
PRINGER NATURE LICENSE 
TERMS AND CONDITIONS 
Jun 29, 2018 
 
 
 
This Agreement between Maryam Saffarian ("You") and Springer Nature ("Springer 
Nature") consists of your license details and the terms and conditions provided by 
Springer Nature and Copyright Clearance Center. 
License Number 
4378331251507 
License date 
Jun 29, 2018 
Licensed Content Publisher 
Springer Nature 
Licensed Content Publication 
Nature Reviews Cancer 
Licensed Content Title 
Engineering the perfect (bacterial) cancer therapy 
Licensed Content Author 
Neil S. Forbes 
Licensed Content Date 
Oct 14, 2010 
Licensed Content Volume 
10 
Licensed Content Issue 
11 
Type of Use 
Thesis/Dissertation 
Requestor type 
academic/university or research institute 
Format 
print and electronic 
Portion 
 
 156 
figures/tables/illustrations 
Number of figures/tables/illustrations 
1 
High-res required 
no 
Will you be translating? 
no 
Circulation/distribution 
<501 
Author of this Springer Nature content 
no 
Title 
BACTERIA-MEDIATED DELIVERY OF MAZF MRNA INTO CANCER CELLS 
FOR INDUCTION OF APOPTOSIS 
Instructor name 
Tzeng 
Institution name 
Clemson University 
Expected presentation date 
Jul 2018 
Portions 
Figure 1 
Bacteria are the optimal robot factory cancer therapies 
Requestor Location 
Maryam Saffarian 
149 Life Sciences Facility 
190 Collings Street 
 
CLEMSON, SC 29634 
United States 
Attn: Maryam Saffarian 
Billing Type 
Invoice 
Billing Address 
Maryam Saffarian 
149 Life Sciences Facility 
190 Collings Street 
 
 
 157 
CLEMSON, SC 29634 
United States 
Attn: Maryam Saffarian 
Total 
0.00 USD 
Terms and Conditions 
Springer Nature Terms and Conditions for RightsLink Permissions 
Springer Customer Service Centre GmbH (the Licensor) hereby grants you a non-
exclusive, world-wide licence to reproduce the material and for the purpose and 
requirements specified in the attached copy of your order form, and for no other use, 
subject to the conditions below: 
1. The Licensor warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to the Licensor and does not carry the copyright of another 
entity (as credited in the published version). 
 
If the credit line on any part of the material you have requested indicates that it 
was reprinted or adapted with permission from another source, then you should 
also seek permission from that source to reuse the material. 
2. Where print only permission has been granted for a fee, separate permission must 
be obtained for any additional electronic re-use.  
3. Permission granted free of charge for material in print is also usually granted for 
any electronic version of that work, provided that the material is incidental to your 
work as a whole and that the electronic version is essentially equivalent to, or 
substitutes for, the print version. 
4. A licence for 'post on a website' is valid for 12 months from the licence date. This 
licence does not cover use of full text articles on websites. 
5. Where 'reuse in a dissertation/thesis' has been selected the following terms 
apply: Print rights for up to 100 copies, electronic rights for use only on a 
personal website or institutional repository as defined by the Sherpa guideline 
(www.sherpa.ac.uk/romeo/). 
6. Permission granted for books and journals is granted for the lifetime of the first 
edition and does not apply to second and subsequent editions (except where the 
first edition permission was granted free of charge or for signatories to the STM 
 
 158 
Permissions Guidelines http://www.stm-assoc.org/copyright-legal-
affairs/permissions/permissions-guidelines/), and does not apply for editions in 
other languages unless additional translation rights have been granted separately 
in the licence. 
7. Rights for additional components such as custom editions and derivatives require 
additional permission and may be subject to an additional fee. Please apply to 
Journalpermissions@springernature.com/bookpermissions@springernature.com 
for these rights. 
8. The Licensor's permission must be acknowledged next to the licensed material in 
print. In electronic form, this acknowledgement must be visible at the same time 
as the figures/tables/illustrations or abstract, and must be hyperlinked to the 
journal/book's homepage. Our required acknowledgement format is in the 
Appendix below. 
9. Use of the material for incidental promotional use, minor editing privileges (this 
does not include cropping, adapting, omitting material or any other changes that 
affect the meaning, intention or moral rights of the author) and copies for the 
disabled are permitted under this licence. 
10. Minor adaptations of single figures (changes of format, colour and style) do not 
require the Licensor's approval. However, the adaptation should be credited as 
shown in Appendix below. 
 
Appendix — Acknowledgements: 
For Journal Content: 
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g. 
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE 
CITATION(Article name, Author(s) Name), [COPYRIGHT] (year of 
publication) 
For Advance Online Publication papers: 
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g. 
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE 
CITATION(Article name, Author(s) Name), [COPYRIGHT] (year of 
publication), advance online publication, day month year (doi: 
10.1038/sj.[JOURNAL ACRONYM].) 
 
 159 
For Adaptations/Translations: 
Adapted/Translated by permission from [the Licensor]: [Journal Publisher (e.g. 
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE 
CITATION(Article name, Author(s) Name), [COPYRIGHT] (year of 
publication) 
Note: For any republication from the British Journal of Cancer, the 
following credit line style applies: 
Reprinted/adapted/translated by permission from [the Licensor]: on behalf of 
Cancer Research UK: : [Journal Publisher (e.g. Nature/Springer/Palgrave)] 
[JOURNAL NAME] [REFERENCE CITATION (Article name, Author(s) 
Name), [COPYRIGHT] (year of publication) 
For Advance Online Publication papers: 
Reprinted by permission from The [the Licensor]: on behalf of Cancer Research 
UK: [Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME] 
[REFERENCE CITATION (Article name, Author(s) Name), [COPYRIGHT] 
(year of publication), advance online publication, day month year (doi: 
10.1038/sj.[JOURNAL ACRONYM]) 
For Book content: 
Reprinted/adapted by permission from [the Licensor]: [Book Publisher (e.g. 
Palgrave Macmillan, Springer etc) [Book Title] by [Book author(s)] 
[COPYRIGHT] (year of publication) 
Other Conditions: 
 
Version  1.0 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777. 
 
 
 
 
 
 
 
 
 
 
 160 
 
SPRINGER NATURE LICENSE 
TERMS AND CONDITIONS 
Jun 30, 2018 
 
 
 
This Agreement between Maryam Saffarian ("You") and Springer Nature ("Springer 
Nature") consists of your license details and the terms and conditions provided by Springer 
Nature and Copyright Clearance Center. 
License Number 4378851409350 
License date Jun 30, 2018 
Licensed Content 
Publisher 
Springer Nature 
Licensed Content 
Publication 
Applied Microbiology and Biotechnology 
Licensed Content Title Engineering bacteria toward tumor targeting for cancer 
treatment: current state and perspectives 
Licensed Content Author Che-Hsin Lee 
Licensed Content Date Jan 1, 2011 
Licensed Content 
Volume 
93 
Licensed Content Issue 2 
Type of Use Thesis/Dissertation 
Requestor type academic/university or research institute 
Format print and electronic 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
 
 161 
Will you be translating? no 
Circulation/distribution <501 
Author of this Springer 
Nature content 
no 
Title BACTERIA-MEDIATED DELIVERY OF MAZF MRNA 
INTO CANCER CELLS FOR INDUCTION OF APOPTOSIS 
 
Instructor name Tzeng  
Institution name Clemson University  
Expected presentation 
date 
Jul 2018  
Portions Fig. 1 
Schematic representing the advantage offered by bacteria as an 
antitumor agent. Bacteria offer several advantages like (1) 
tumor-targeting potential, (2) mobility, (3) transgene capacity, 
and (4) cheap 
 
Requestor Location Maryam Saffarian 
149 Life Sciences Facility 
190 Collings Street 
 
CLEMSON, SC 29634 
United States 
Attn: Maryam Saffarian 
 
Billing Type Invoice  
Billing Address Maryam Saffarian 
149 Life Sciences Facility 
190 Collings Street 
 
CLEMSON, SC 29634 
United States 
Attn: Maryam Saffarian 
 
Total 0.00 USD  
Terms and Conditions  
 
 162 
Springer Nature Terms and Conditions for RightsLink Permissions 
Springer Customer Service Centre GmbH (the Licensor) hereby grants you a non-
exclusive, world-wide licence to reproduce the material and for the purpose and 
requirements specified in the attached copy of your order form, and for no other use, 
subject to the conditions below: 
1. The Licensor warrants that it has, to the best of its knowledge, the rights to license 
reuse of this material. However, you should ensure that the material you are 
requesting is original to the Licensor and does not carry the copyright of another 
entity (as credited in the published version). 
 
If the credit line on any part of the material you have requested indicates that it was 
reprinted or adapted with permission from another source, then you should also 
seek permission from that source to reuse the material. 
2. Where print only permission has been granted for a fee, separate permission must 
be obtained for any additional electronic re-use.  
3. Permission granted free of charge for material in print is also usually granted for 
any electronic version of that work, provided that the material is incidental to your 
work as a whole and that the electronic version is essentially equivalent to, or 
substitutes for, the print version. 
4. A licence for 'post on a website' is valid for 12 months from the licence date. This 
licence does not cover use of full text articles on websites. 
5. Where 'reuse in a dissertation/thesis' has been selected the following terms apply: 
Print rights for up to 100 copies, electronic rights for use only on a personal website 
or institutional repository as defined by the Sherpa guideline 
(www.sherpa.ac.uk/romeo/). 
6. Permission granted for books and journals is granted for the lifetime of the first 
edition and does not apply to second and subsequent editions (except where the first 
edition permission was granted free of charge or for signatories to the STM 
Permissions Guidelines http://www.stm-assoc.org/copyright-legal-
affairs/permissions/permissions-guidelines/), and does not apply for editions in 
other languages unless additional translation rights have been granted separately in 
the licence. 
 
 
 163 
7. Rights for additional components such as custom editions and derivatives require 
additional permission and may be subject to an additional fee. Please apply to 
Journalpermissions@springernature.com/bookpermissions@springernature.com for 
these rights. 
8. The Licensor's permission must be acknowledged next to the licensed material in 
print. In electronic form, this acknowledgement must be visible at the same time as 
the figures/tables/illustrations or abstract, and must be hyperlinked to the 
journal/book's homepage. Our required acknowledgement format is in the Appendix 
below. 
9. Use of the material for incidental promotional use, minor editing privileges (this 
does not include cropping, adapting, omitting material or any other changes that 
affect the meaning, intention or moral rights of the author) and copies for the 
disabled are permitted under this licence. 
10. Minor adaptations of single figures (changes of format, colour and style) do not 
require the Licensor's approval. However, the adaptation should be credited as 
shown in Appendix below. 
 
Appendix — Acknowledgements: 
For Journal Content: 
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g. 
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE 
CITATION (Article name, Author(s) Name), [COPYRIGHT] (year of 
publication) 
For Advance Online Publication papers: 
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g. 
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE 
CITATION (Article name, Author(s) Name), [COPYRIGHT] (year of 
publication), advance online publication, day month year (doi: 
10.1038/sj.[JOURNAL ACRONYM].) 
For Adaptations/Translations: 
Adapted/Translated by permission from [the Licensor]: [Journal Publisher (e.g. 
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE 
CITATION (Article name, Author(s) Name), [COPYRIGHT] (year of 
publication) 
 
 164 
Note: For any republication from the British Journal of Cancer, the following 
credit line style applies: 
Reprinted/adapted/translated by permission from [the Licensor]: on behalf of 
Cancer Research UK: : [Journal Publisher (e.g. Nature/Springer/Palgrave)] 
[JOURNAL NAME] [REFERENCE CITATION(Article name, Author(s) 
Name), [COPYRIGHT] (year of publication) 
For Advance Online Publication papers: 
Reprinted by permission from The [the Licensor]: on behalf of Cancer Research 
UK: [Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME] 
[REFERENCE CITATION (Article name, Author(s) Name), [COPYRIGHT] 
(year of publication), advance online publication, day month year (doi: 
10.1038/sj.[JOURNAL ACRONYM]) 
For Book content: 
Reprinted/adapted by permission from [the Licensor]: [Book Publisher (e.g. 
Palgrave Macmillan, Springer etc) [Book Title] by [Book author(s)] 
[COPYRIGHT] (year of publication) 
Other Conditions: 
 
Version  1.0 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777. 
 
 
 
 
 
 
